Note: Descriptions are shown in the official language in which they were submitted.
C-Terminal Hsp90 Inhibitors
FIELD OF THE INVENTION
[0003] The present invention is directed to novel C-terminal heat
shock protein
90 (Hsp 90) inhibitors with cytoprotective activity against sensory neuron
glucotoxicity.
DESCRIPTION OF RELATED ART
[0004] Approximately 26 million Americans are afflicted with either
Type 1 or
Type 2 diabetes. Despite the use of insulin and oral anti-diabetic medications
to help
maintain euglycemia, about 60-70% of these individuals develop diabetic
peripheral
neuropathy (DPN). Veves, A.; Baekonja, M.; Malik, R. A., Painful diabetic
neuropathy:Epidemiology, natural history, early diagnosis, and treatment
options. Pain
Med. 2008, 9, 660-674.
[0005] To date, approaches toward the treatment of DPN have centered
on
pathways/targets directly limited to hyperglycemia (i.e., polyol & hexosamine
pathways, advanced glyeation end products (AGEs), enhanced oxidative stress,
PKC
activation). Tomlinson, D. R.; Gardiner, N. J., Glucose neurotoxicity. Nat Rev
Neurosci
2008, 9 (1), 36-45.
[0006] Unfortunately, the contribution of these targets/pathways to
the
progression of DPN differs between individuals and does not occur with
biochemical
1
CA 2866814 2019-06-20
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
uniformity, and consequently, these approaches have resulted in little success
for the
management of DPN. As an alternative approach, we have explored the
pharmacologic
modulation of molecular chaperones to promote a broad cytoprotective response
that
may enhance a patient's ability to tolerate hyperglycemic insults and improve
the
symptoms of DPN.
[0007] Molecular chaperones, such as heat shock proteins 90 and 70
(Hsp90,
Hsp70), are essential for folding nascent polypeptides into their biologically
active
structures and for the refolding of aggregated and denatured proteins that
occur upon
cellular stress. Mayer, M. P.; Bukau, B., Hsp70 chaperones: cellular functions
and
molecular mechanism. Cell Mol Life Sci 2005, 62 (6), 670-84; Peterson, L. B.;
Blagg,
B. S., To fold or not to fold: modulation and consequences of Hsp90
inhibition. Future
Med Chem 2009, 1 (2), 267-283.
[0008] Numerous conditions that cause cell stress can also induce the
"heat
shock response" (HSR); the transcriptional upregulation of antioxidant genes
and
chaperones such as Hsp70. Importantly, small molecule inhibition of 11sp90 is
sufficient to induce the HSR. KU-32 (FIG.1) is a small molecule Hsp90 C-
terminal
inhibitor that is based on novobiocin, a naturally occurring antimicrobial
agent that
inhibits DNA gyrase. KU-32 is disclosed in U.S. Pat. No. 7,622,451 to Blagg et
al. and
U.S. Pat. No. 7,960,353 to Blagg. Although the etiology of DPN is unrelated to
the
accumulation of one specific mis-folded or aggregated protein, hyperglycemia
can
increase oxidative stress and the oxidative modification of amino acids
(Obrosova, I.
G., Diabetes and the peripheral nerve. Biochirn Biophys Acta 2009, 10, 931-
940;
Akude, E.; Zherebitskaya, E.; Roy Chowdhury, S. K.; Girling, K.; Fernyhough,
P., 4-
Hydroxy-2-Nonenal Induces Mitochondrial Dysfunction and Aberrant Axonal
Outgrowth in Adult Sensory Neurons that Mimics Features of Diabetic
Neuropathy.
Neurotox Res 2009, /, 28-38) that impair protein folding, (Muchowski, P. J.;
Wacker, J.
L., Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci
2005,
6 (1), 11-22) decrease mitochondrial protein import (Baseler, W. A.;
Dabkowski, E. R.;
Williamson, C. L.; Croston, T. L.; Thapa, D.; Powell, M. J.; Razunguzwa, T.
T.;
Hollander, J. M., Proteomic alterations of distinct mitochondrial
subpopulations in the
type 1 diabetic heart: contribution of protein import dysfunction. Am J
Physiol Regul
Integr Comp Physiol 2011, 300 (2), R186-200) and promote mitochondrial
dysfunction.
Tomlinson et al., 2008 Id.; Obrosova et al., 2009 Id.
2
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
[0009] Even in the absence of a single, disease-specific protein
aggregate, it has
been shown that pharmacologic induction of cytoprotective molecular chaperones
can
improve myelinated and unmyelinated fiber function in cellular models of
glucotoxic
stress and animal models of DPN. Urban, M. J.; Li, C.; Yu, C.; Lu, Y.; Krise,
J. M.;
McIntosh, M. P.; Rajewski, R. A.; Blagg, B. S. J.; Dobrowsky, R. T.,
Inhibiting Heat
Shock Protein 90 Reverses Sensory Hypoalgesia in Diabetic Mice. ASN Neuro
2010, 2,
e00040 DOI :189-199.
[0010] Mechanistically, KU-32 was ineffective at preventing neuregulin-
induced demyelination of myelinated cultures of sensory neurons prepared from
Hsp70.1 and 70.3 double knockout mice, indicating that Hsp70 is necessary for
the
neuroprotective activity manifested by KU-32. Similarly, weekly treatment with
KU-
32 restored normal sensory and motor nerve function in diabetic wild type
mice, but
was unable to reverse multiple clinical indices of DPN in the diabetic Hsp70
knockout
mice. Urban et al., 2010 Id. Collectively, these studies provide the
biological and
clinical rationale to support the modulation of molecular chaperones as a
viable
approach toward the treatment of DPN.
[0011] An enviable aspect of KU-32 is that it induces Hsp70 at
concentrations
well below those needed to inhibit Hsp90's protein folding ability. Urban et
al., 2010
Id. Thus, KU-32 possesses a rather broad therapeutic window that dissociates
cytoprotective properties from potentially cytotoxic effects resulting from
the
degradation of Hsp90-dependent client proteins. Peterson et al., 2009 Id. This
lab
previously demonstrated that molecules containing a benzamide, as found in
novobiocin, exhibit anti-proliferative activities, whereas molecules
containing an
acetamide (e.g., KU-32) manifest neuroprotective properties. However, these
prior
studies sought to evaluate structure¨activity relationships for novobiocin
analogues as
anti-cancer agents, (Burlison, J. A.; Avila, C.; Vielhauer, G.; Lubbers, D.
J.;
Holzbeierlein, J.; Blagg, B. S., Development of novobiocin analogues that
manifest
anti-proliferative activity against several cancer cell lines. J Org Chem
2008, 73 (6),
2130-7; Donnelly, A. C.; Mays, J. R.; Burlison, J. A.; Nelson, J. T.;
Vielhauer, G.;
Holzbeierlein, J.; Blagg, B. S. J., The Design, Synthesis, and Evaluation of
Coumarin
Ring Derivatives of the Novobiocin Scaffold that Exhibit Antiproliferative
Activity. J.
Org. Chem. 2008, 73 (22), 8901-8920) rather than exploring chemical attributes
that
enhance the neuroprotective properties of novobiocin-based analogs. Therefore,
diversification of the KU-32 scaffold was explored to identify novel compounds
which
3
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
lack the coumarin ring system yet surprisingly enhance the neuroprotective
properties
manifested by Hsp90 C-terminal inhibitors.
BRIEF SUMMARY OF THE INVENTION
[0012] The present invention is directed to novel compounds useful as
Hsp90
inhibitors, and in particular as neuroprotective agents. In particular, the
present
invention is directed to the therapeutic use of such compounds in the
treatment and/or
prevention of diabetic peripheral neuropathy or other neurodegenerative
disorders in a
subject in need thereof.
[0013] In one embodiment, the disclosure provides a compound or
pharmaceutically acceptable salt according to Formula (I):
R24
R23
Xi N R'COR"
v
^2
X
R22
R8 \IC\ õ,
X3 Ri rt3
R4
Zi R2
R5 (CH)n R7
(I)
R6
wherein
[0014] R1 is hydrogen, hydroxy, halo, trifluoroalkyl, alkyl, alkenyl,
alkynyl,
carbocyclic, heterocyclic, aryl, aralkyl, carboxyl, amido, amino, alkoxy,
halo,
trifluoromethyl, sulfanyl, sulfenyl, sulfonyl, or ether;
[0015] R2 is hydrogen, halo, hydroxy, trifluoromethyl, alkoxy, alkyl,
alkenyl,
alkynyl, carbocyclic, alkylcarbocyclic, alkylheterocyclic, heterocyclic, or
¨R9-0R1 ,
wherein R9 is a covalent bond or alkyl, and RI is hydrogen, alkyl, C-amido or
acyl; or
R2 together with R3 and the atoms to which they are attached form a
carbocyclic ring
with 5 to 7 ring members or a heterocyclic ring having 4 to 8 ring members
with at least
one heteroatom selected from oxygen or nitrogen;
[0016] R3 is hydrogen, hydroxy, halo, trifluoroalkyl, alkyl, alkoxy,
sulfanyl, or
O-R12, wherein RH is a covalent bond or alkyl, and R12 is alkyl, C-amido or
acyl;
4
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
or R3 together with R2 and the atoms to which they are attached form a
carbocyclic ring
with 5 to 7 ring members or a heterocyclic ring having 4 to 8 ring members
with at least
one heteroatom selected from oxygen or nitrogen;
[0017] R4 is hydrogen, hydroxy, alkyl, arylalkoxy, carboxyl, ¨R13-0-R14,
or ¨
R13-R15; and wherein R13 is a covalent bond or alkyl, and R14 is hydrogen, C-
amido or
acyl, and R15 is N-amido, -POR16R17 -SO2R18, or sulfonamido, and wherein R16,
R17,
R18are independently alkoxy;
[0018] R5 is hydrogen, hydroxy, alkyl, arylalkoxy, alkenyl, alkynyl,
aryl, or
aralkyl;
[0019] R6 is hydrogen, hydroxy, sulfanyl, alkyl, alkenyl, alkynyl, aryl,
arylalkyl, alkoxy, aryloxy, arylalkoxy or a heterocyclic ring having 4 to 8
ring members
with at least one heteroatom selected from oxygen or nitrogen;
[0020] R7 is hydrogen, hydroxyl, arylalkoxy, alkyl, acyl, carboxyl or
absent;
[0021] R8 is hydrogen, hydroxyl, or arylalkoxy;
[0022] R22 is hydrogen, hydroxy, amino, amido, cyano, alkoxy, halogen,
trifluoroalkyl, alkyl, alkenyl, alkynyl, ester, nitro, carboxyl, aralkyl,
aryl, carbocyclic,
heterocyclic, trifluoromethyl, sulfonyl, sulfanyl, sulfenyl, ether, R25-0R26,
or R25-
NR26; where R25 is a covalent bond or alkyl and R26 is a hydrogen, alkyl, C-
amido, or
acyl;
[0023] R23 is hydrogen, hydroxy, amino, amido, cyano, alkoxy, halogen,
trifluoroalkyl, alkyl, alkenyl, alkynyl, ester, nitro, carboxyl, aralkyl,
aryl, carbocyclic,
heterocyclic, trifluoromethyl, sulfonyl, sulfanyl, sulfenyl, ether, R27-0R28,
or R27 ¨
NR28; where R27 is a covalent bond or alkyl and R28 is a hydrogen, alkyl, C-
amido, or
acyl; or R23 together with R24 and the atoms to which they are attached form a
carbocyclic ring with 5 to 7 ring members or a heterocyclic ring having 4 to 8
members
with at least one heteroatom selected from oxygen or nitrogen;
[0024] R24 is hydrogen, hydroxy, amino, amido, cyano, alkoxy, halogen,
trifluoroalkyl, alkyl, alkenyl, alkynyl, ester, nitro, carboxyl, aralkyl,
aryl, carbocyclic,
heterocyclic, trifluoromethyl, sulfonyl, sulfanyl, sulfenyl, ether, R29-0R30,
or R29 ¨
NR313; where R29 is a covalent bond or alkyl and R3 is a hydrogen, alkyl, C-
amido, or
acyl; or R24 together with R23 and the atoms to which they are attached form a
carbocyclic ring with 5 to 7 ring members or a heterocyclic ring having 4 to 8
members
with at least one heteroatom selected from oxygen or nitrogen;
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
[0025] X1 is ¨CHR19¨ , or -CR19=, and wherein R19 is selected from
hydrogen,
halo, alkyl, alkenyl, or alkynyl; or X1 together with X2 form a carbocyclic
ring having 3
to 7 ring members; or wherein X1-X2 is¨C=C-;
[0026] X2 is ¨CHR20¨ , or =CR20-, and wherein R2 is selected from
hydrogen,
halo, alkyl, alkenyl, or alkynyl; or X2 together with Xi form a carbocyclic
ring having 3
to 7 ring members; or wherein Xi-X2 is ¨C=C-;
[0027] X3 is 0, or CH2;
[0028] X is c,_ R21¨, or =N¨, wherein R21 is hydrogen, halo,
trifluoromethyl,
alkyl, alkenyl, alkynyl, alkoxy, or hydroxy;
[0029] R' is H, or alkyl;
[0030] R" is alkyl, alkoxy, haloalkyl, alkylcycloalkyl or
alkylamidoalkyl;
[0031] Y is =CR3¨ or =N¨;
[0032] Z is CH, or Z ¨Zi is ¨C=C-;
[0033] Z1 is CH, 0, S, N, or Z-Zi is ¨C=C-; and
[0034] n is 0, 1, 2, or 3.
[0035] In some embodiments, the disclosure provides a compound or salt
according to Formula (I) wherein X1 is ¨CHR19¨ , and R19 is hydrogen or alkyl;
or X1
together with X2 form a carbocyclic ring having 3 to 7 ring members; and X2 is
¨
CHR20¨ , and wherein R2 is hydrogen or alkyl; or X2 together with Xi form a
carbocyclic ring having 3 to 7 ring members.
[0036] In some embodiments, the disclosure provides a compound or salt
according to Formula (I) wherein Xi is CH2, and X2 is CH2.
[0037] In some embodiments, the disclosure provides a compound or salt
according to Formula (I) wherein R' is H and R" is CH3.
[0038] In a further aspect, the disclosure provides a compound or salt
according
to Formula (I) wherein R4 and R5 are independently methyl or hydrogen.
[0039] In another aspect, the disclosure provides a compound or salt
according
to Formula (I) wherein R6 is selected from hydrogen, hydroxy, methoxy,
sulfanyl, or
alkyl.
[0040] In another aspect, the disclosure provides a compound or salt
according
to Formula (I) wherein R7 and R8 are hydroxy.
[0041] In another aspect, the disclosure provides compounds of Foimula
(II):
6
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
M e04 N HAc
0
(II)
Ns"
H 0
OH
R1
R2
wherein
[0042] R1 is hydrogen, halo, hydroxy, trifluoroalkyl, alkoxy, or
sulfanyl;
[0043] R2 is hydrogen, halo, hydroxy, trifluoroalkyl, alkoxy, sulfanyl,
or alkyl,
or R2 together with R3 and the atoms to which they are attached form a
carbocyclic ring
with 5 to 7 ring members or a heterocyclic ring having 4 to 8 ring members
with at least
one heteroatom selected from oxygen or nitrogen;
[0044] R3 is hydrogen, halo, hydroxy, trifluoroalkyl, alkoxy, sulfanyl,
alkyl; or
R3 together with R2 and the atoms to which they are attached form a
carbocyclic ring
with 5 to 7 ring members or a heterocyclic ring having 4 to 8 ring members
with at least
one heteroatom selected from oxygen or nitrogen;
[0045] X is =CR21¨, or =N¨, wherein R21 is hydrogen, halo, or
trifluoromethyl;
and
[0046] Y is =CR3¨ or =N¨.
[0047] In another aspect, the disclosure provides a compound or salt
according
to Formula (II) wherein R1 is hydrogen, halo, alkoxy, or sulfanyl;R2 is
hydrogen,
hydroxy, halo, trifluoroalkyl, alkoxy, or sulfanyl;R3 is hydrogen, hydroxy,
halo,
trifluoroalkyl, alkoxy, or sulfanyl; X is =CR21¨, wherein R21 is hydrogen,
halo, or
trifluoromethyl; and Y is =CR3¨ .
[0048] In specific aspects, the disclosure provides compounds useful for
treating or preventing a neurodegenerative disorder selected from N-(2-(5-
(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-
[1,1'-bipheny1]-2-ypethyDacetamide (11a); N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-
methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3'-fluoro-[1,11-bipheny1]-2-
ypethypacetamide (11b); N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-yl)oxy)-4'-fluoro-[1,1'-bipheny1]-2-
yl)ethyl)acetamide
(11c); N-(2-(2'-chloro-5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
7
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
dimethyltetrahydro-2H-pyran-2-yl)oxy)-[1,1'-bipheny1]-2-yflethypacetamide
(11d); N-
(2-(3'-chloro-5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-
pyran-2-yl)oxy)-[1,11-bipheny1]-2-ypethypacetamide (1 1 e); N-(2-(5-
(((3R,4S,5R)-3,4-
dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-ypoxy)-3'-
(trifluoromethyl)-
[1,1'-biphenyl]-2-ypethypacetamide (11f); N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-
methoxy-6,6-dimethyltetrahydro-211-pyran-2-yl)oxy)-4'-(trifluoromethy1)41,1'-
biphenyl]-2-y1)ethyl)acetamide (11g); N-(2-(5 -(((3R,45,5R)-3 ,4-dihydroxy-5-
methoxy-
6,6-dimethyltetrahydro-2H-pyran-2-ypoxy)-2'-(methylthio)41,1'-biphenyl] -2-
ypethypacetamide (11h); N-(2-(5 -(((3R,4 S,5R)-3 ,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-yl)oxy)-2'-methoxy- [1,1'-biphenyl] -2-
ypethypacetamide (111); N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5 -methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-yl)oxy)-3 '-methoxy- [l,1'-biphenyl] -2-
ypethypacetamide (11j); N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-yl)oxy)-3'-methyl-[1,11-bipheny1]-2-
yl)ethyl)acetamide
(11k); N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-
pyran-2-yl)oxy)-3'-(morpholinomethyl)-[1,1'-biphenyl]-2-ypethypacetamide
(111); N-
(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-
yl)oxy)-4'-hydroxy-[1,1'-bipheny1]-2-ypethypacetamide (11m); N-(2-(5-
(((3R,4S,5R)-
3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-4'-hydroxy-
[1,1 '-biphenyl] -2-yl)ethypacetamide (11m): N-(2-(benzo[d][1,3]dioxo1-5-y1)-4-
(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-
yl)oxy)phenethyl)acetamide (11n): N-(4-(R3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-y0oxy)-2-(pyridin-3-yl)phenethypacetamide (11o);
N-
(4-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-211-pyran-2-
yl)oxy)-2-(pyridin-4-yl)phenethypacetamide (1 1p); N-(4'-(((3R,4S,5R)-3 ,4-
dihydroxy-
-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3"-fluoro-1,2,3,6-
tetrahydro-
[1,1':2',1"-terpheny1]-2-yDacetamide (20a); N-(4'-(((3R,4S,5R)-3,4-dihydroxy-5-
methoxy-6,6-dimethyltetrahydro-2H-pyran-2-ypoxy)-3"-(trifluoromethyl)-1,2,3,6-
tetrahydro-[1,1':2',1"-terphenyl]-2-y1)acetamide (20b); N-(2-(54(4-
(benzyloxy)cyclohexypoxy)-3'-fluoro-[1,1'-biphenyl]-2-ypethypacetamide (24); N-
(2-
(5-((4-(benzyloxy)cyclohex-2-en-l-yDoxy)-31-fluoro-[1,1'-biphenyl] -2-
ypethypacetamide (36); N-(2-(544-(benzyloxy)-2,3-dihydroxycyclohexypoxy)-3'-
fluoro-[1,1'-biphenyl]-2-ypethypacetamide (37); N-(2-(54(4-(tert-
butyl)cyclohexypoxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)acetamide (39); N-(2-
(3'-
8
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
fluoro-5((4-(piperidin-4-ypcyclohexypoxy)41,1'-biphenyl]-2-yDethyDacetamide
(40);
N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-21-1-pyran-
2-
yeoxy)-3'-fluoro-6-hydroxy-[1,11-biphenyl]-2-ypethypacetamide (41); N-(2-(5-
(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-
3'-
fluoro-3-methoxy-[1,11-bipheny1]-2-ypethyl)acetamide (42); and N-(2-(5-
(((3R,4S,5R)-
3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-ypoxy)-3'-fluoro-4-
methyl-[1,1'-bipheny1]-2-ypethypacetamide (43).
[0049] In a specific aspect, the compound is selected from: N-(2-(5-
(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-y0oxy)-
31-
fluoro-[1,1'-bipheny1]-2-ypethypacetamide (11b); N-(2-(5-(((3R,4S,5R)-3,4-
dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-ypoxy)-4'-fluoro-[1,1'-
biphenyl] -2-ypethypacetamide (11c); N-(2-(2'-chloro-5-(((3R,4S,5R)-3,4-
dihydroxy-5-
methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-[1,1'-bipheny1]-2-
ypethyl)acetamide (11d); N-(2-(3 '-chloro-5-(((3R,4S,5R)-3 ,4-dihydroxy-5-
methoxy-
6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-[ 1, 11-biphenyl] -2-
ypethyl)acetamide (1 le);
N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-
yl)oxy)-3'-(trifluoromethy1)41,1'-bipheny11-2-ypethyDacetamide (110; or
(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-ypoxy)-
4'-
(trifluoromethy1)41,1'-biphenyl]-2-ypethyDacetamide (11g).
[0050] In another specific aspect, the compound is selected from N-(2-(5-
(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-
3'-
fluoro-[1,1'-bipheny1]-2-yl)ethyl)acetamide (1 lb); N-(2-(3'-chloro-5-
(((3R,4S,5R)-3,4-
dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-[1,1'-bipheny1]-
2-
yl)ethypacetamide (1 1 e); or N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-yl)oxy)-3'-(trifluoromethyl)-[1,1'-biphenyl]-2-
yDethypacetamide (1 10.
[0051] In some embodiments, the disclosure provides a pharmaceutical
composition comprising a therapeutically effective amount of a compound or
pharmaceutically acceptable salt of a compound of Formula (I) wherein the
substituents
are as defined above for RI, R2, R3, R4, R5, R6, R7, R8, R22, R23, R24, Z, Zi,
Xi, X2, X3,
R', R", X, Y and n in combination with a pharmaceutically acceptable carrier.
9
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
R24
R23 õ.õNR'COR"
X2
X
0
R22
v R3rs.3
R4 R R2
R5 (CH)n R7
(I)
R6
[0052] In some embodiments, the disclosure provides a compound of
Formula
(I) wherein X3 is 0. In some embodiments, the disclosure provides a compound
of
Formula (I) wherein X3 is CH2. In some embodiments, the disclosure provides a
compound of Formula (I) wherein one of RI, R2 and R3 is not H. In some
embodiments, the disclosure provides a compound of Formula (I) wherein one of
RI,
R2 and R3 is halo. In some embodiments, the disclosure provides a compound of
Formula (I) wherein one of R22, R23 and R24 is not H. In some embodiments, the
disclosure provides a compound of Formula (I) wherein one of R22, R23 and R24
is
hydroxyl, alkoxy or alkyl. In some embodiments, the disclosure provides a
compound
of Formula (I) wherein X1 is -CH¨, and X2 is =CH-. In some embodiments, the
disclosure provides a compound of Formula (I) wherein X1 and X2 are both CH2.
In
some embodiments, the disclosure provides a compound of Formula (I) wherein Z-
Z1 is
¨C=C-. In some embodiments, the disclosure provides a compound of Formula (I)
wherein R4 and R5 are independently alkyl. In some embodiments, the disclosure
provides a compound of Formula (I) wherein R6 is alkoxy, aralkoxy or alkyl. In
some
embodiments, n = I.
[0053] In some embodiments, Zi is 0 and R7 is absent. In some
embodiments,
Zi is S and R7 is absent. In some embodiments, Z1 is N and R7 is alkyl,
hydrogen or
carboxyl.
[0054] In some embodiments, the compound of Formula (I) is selected from
a
compound of Formula (Ia) wherein the substituents are as defined above for RI,
R2, R3,
R4, R5, R6, R7, Rg, X1, X2, R', R", X, Y and n.
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
Xi, .,.NR'COR"
X2
0
X
R8
0 R3
R4
R2
R- (CH)n
(Ia.)
R6
[0055] In some embodiments, the compound of Formula (I) is selected from
a
compound of Formula (Ia) wherein the substituents are as defined above for RI,
R2, R3,
R4, R55 R6, R7, R85 XI, X2, R', R", X, Y and n.
[0056] In other embodiments, the disclosure provides a method for
treating or
preventing a neurodegenerative disorder in a subject in need thereof
comprising
administering to the subject a therapeutically effective amount of a compound
or
pharmaceutically acceptable salt of a compound of Formula (I), wherein the
substituents are defined above.
[0057] In other embodiments, the disclosure provides for use of a
compound of
Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture
of a
composition for treating a neurodegenerative disorder in a subject in need
thereof;
wherein the composition is to be administered in an amount effective to
alleviate or
prevent symptoms of neuronal glucotoxicity. In a specific embodiment, the
neuronal
glucotoxicity is sensory neuron glucotoxicity.
[0058] In another specific embodiment, the neurodegenerative disorder is
diabetic peripheral neuropathy.
[0059] In still another embodiment, the compounds of the present
invention
exhibit neuroprotective effects by upregulation of Hsp70.
BRIEF DESCRIPTION OF THE DRAWINGS
[0060] FIG. 1 shows chemical structures of novobiocin and KU-32.
[0061] FIG. 2A shows a molecular model of KU-32 docked to Hsp90 C-
terminal binding site.
[0062] FIG. 2B shows a molecular model of a novologue (structure shown
in
FIG. 2D) docked to Hsp90 C-terminal binding site.
11
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
[0063] FIG. 2C shows an overlay of KU-32 and a novologue (structure
shown
in FIG. 2D) docked to 11sp90 C-terminal binding site.
[0064] FIG. 2D shows the chemical structure of a novologue and its
attributes.
[0065] FIG. 3 shows the determination of EC50 of select novologues KU-
32,
llf, 111, lib, lln, llh, and lb. DRG sensory neurons were incubated in the
absence
or presence of 0.1-1000 nM of the indicated novologue overnight and then
subjected to
4 hrs of hyperglycemia. Cell viability was measured as described in Example 2
and the
data expressed as percent of normoglycemic controls. Under hyperglycemic
conditions
and in the absence of any novologues, cell viability was 20% 7.
[0066] FIG. 4 shows determination of EC50 of select novologues KU-32,
llf,
111, lib, 11n, 11h, and llo from FIG 3. The EC50 was determined using the
ECanything
function of GraphPad Prism 5.0 and the mean SEM (n=3-8) is shown. #, p< 0.05
versus KU-32.
[0067] FIG. 5 shows immunoblot analysis of induction of Hsp70 by select
novologues KU-32, lln and 11 b. DRG sensory neurons were incubated in the
presence of DMSO (Cntrl) or 10-1000 riM of the indicated novologue overnight
and
then subjected to 4 hrs of hyperglycemia. The neurons were harvested and Hsp70
and
13-actin levels were determined by immunoblot analysis. Band intensity was
quantified
using Image J, Hsp70 expression was noimalized to the level of 13-actin.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENT
[0068] Molecular terms, when used in this application, have their common
meaning unless otherwise specified. It should be noted that the alphabetical
letters used
in the formulas of the present invention should be interpreted as the
functional groups,
moieties, or substituents as defined herein. Unless otherwise defined, the
symbols will
have their ordinary and customary meaning to those skilled in the art.
[0069] The term "acyl" refers to ¨COR wherein R used in this definition
is
hydrogen, alkyl, alkenyl, alkynyl, carbocyclic, heterocylic, aryl, or aralkyl.
Most
preferably, R is hydrogen, alkyl, aryl, or aralkyl.
[0070] The term "amido" indicates either a C-amido group such as
¨CONR'R"
or an N-amido group such as ¨NR'COR" wherein R' and R" as used in this
definition
are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, carbocyclic,
heterocylic,
12
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
aryl, or aralkyl. A "sulfoamido" group includes the ¨NR'-S02-R". Most
preferably, R'
and R" are hydrogen, alkyl, aryl, or aralkyl.
[0071] The term "amino" signifies a primary, secondary or tertiary amino
group
of the formula ¨NR'R" wherein R' and R" as used in this definition are
independently
hydrogen, alkyl, alkyenyl, alkynyl, aralkyl, carbocyclic, heterocyclic,
aralkyl, or other
amino (in the case of hydrazide) or R' and R" together with the nitrogen atom
to which
they are attached, form a ring having 4 to 8 atoms. Thus, the term "amino," as
used
herein, includes unsubstituted, mono substituted (e.g., monoalkylamino or
monoarylamino), and disubstituted (e.g., dialkylamino or aralkylamino) amino
groups.
Amino groups include ¨NH2, methylamino, ethylamino, dimethylamino,
diethylamino, methyl-ethylamino, pyrrolidin-l-yl, or piperidino, morpholino,
etc.
Other exemplary "amino" groups forming a ring include pyrrolyl, imidazolyl,
pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl,
pyridazinyl,
indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolizinyl. The ring
containing the
amino group may be optionally substituted with another amino, alkyl, alkenyl,
alkynyl,
halo, or hydroxyl group.
[0072] The term "alkyl" refers to a branched or unbranched saturated
hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, n-propyl,
isopropyl,
n-butyl, isobutyl, t-butyl, octyl, decyl, tetradecyl, hexadecyl, eicosyl,
tetracosyl, and the
like. Preferred "alkyl" groups herein contain 1 to 12 carbon atoms. Most
preferred are
"lower alkyl" which refer to an alkyl group of one to six, more preferably one
to four,
carbon atoms. The alkyl group may be optionally substituted with an amino,
alkyl,
cycloalkyl, halo, or hydroxyl group.
[0073] The term "alkoxy" denotes oxy-containing groups substituted with
an
alkyl, or cycloalkyl group. Examples include, without limitation, methoxy,
ethoxy,
tert-butoxy, and cyclohexyloxy. Most preferred are "lower alkoxy" groups
having one
to six carbon atoms. Examples of such groups include methoxy, ethoxy, propoxy,
butoxy, isopropoxy, and tert-butoxy groups.
[0074] The terms "alkenyl" and "alkynyl" refer to unsaturated aliphatic
groups
analogous in length and possible substitution to the alkyls described above,
but that
contain at least one double bond or triple bond respectively.
[0075] The term "aryl" means a carbocyclic aromatic system containing
one,
two, or three rings wherein such rings may be attached together in a pendant
manner or
may be fused. The term "fused" means that a second ring is present (i.e.,
attached or
13
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
formed) by having two adjacent atoms in common (i.e., shared) with the first
ring. The
term "fused" is equivalent to the term "condensed." The term "aryl" embraces
aromatic
groups such as phenyl, naphthyl, tetrahydronaphthyl, indane, and biphenyl. The
aryl
group may optionally be substituted with an amino, alkyl, halo, hydroxyl,
carbocyclic,
heterocyclic, or another aryl group.
[0076] The term "aralkyl" embraces aryl-substituted alkyl moieties.
Preferable
aralkyl groups are "lower aralkyl" groups having aryl groups attached to alkyl
groups
having one to six carbon atoms. Examples of such groups include benzyl,
diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl. The terms
benzyl
and phenylmethyl are interchangeable.
[0077] The tem! "aryloxy" embraces aryl groups, as defined above,
attached to
an oxygen atom. The aryloxy groups may optionally be substituted with a halo,
hydroxyl, or alkyl group. Examples of such groups include phenoxy, 4-chloro-3-
ethylphenoxy, 4-chloro-3-methylphenoxy, 3-chloro-4-ethylphenoxy, 3,4-
dichlorophenoxy, 4-methylphenoxy, 3-trifluoromethoxyphenoxy, 3-
trifluoromethylphenoxy, 4-fluorophenoxy, 3,4-dimethylphenoxy, 5-bromo-2-
fluorophenoxy, 4-bromo-3-fluorophenoxy, 4-fluoro-3-methylphenoxy, 5,6,7,8-
tetrahydronaphthyloxy, 3-isopropylphenoxy, 3-cyclopropylphenoxy, 3-
ethylphenoxy,
4-tert-butylphenoxy, 3-pentafluoroethylphenoxy, and 3-(1,1,2,2-
tetrafluoroethoxy)phenoxy.
[0078] The term "arylalkoxy" embraces oxy-containing aralkyl groups
attached
through an oxygen atom to other groups. "Lower arylalkoxy" groups are those
phenyl
groups attached to lower alkoxy group as described above. Examples of such
groups
include benzyloxy, 1-phenylethoxy, 3-trifluoromethoxybenzyloxy, 3-
trifluoromethylbenzyloxy, 3,5-difluorobenyloxy, 3-bromobenzyloxy, 4-
propylbenzyloxy, 2-fluoro-3-trifluoromethylbenzyloxy, and 2-phenylethoxy.
[0079] The term "carboxyl" refers to ¨R1C(=0)0R", wherein R' and R" as
used
in this definition are independently hydrogen, alkyl, alkenyl, alkynyl,
carbocyclic,
heterocylic, aryl, or aralkyl or R' can additionally be a covalent bond.
"Carboxyl"
includes both carboxylic acids, and carboxylic acid esters. The term
"carboxylic acid"
refers to a carboxyl group in which R" is hydrogen. Such acids include foimic,
acetic,
propionic, butyric, valeric acid, 2-methyl propionic acid, oxirane-carboxylic
acid, and
cyclopropane carboxylic acid. The term "carboxylic acid ester" or "ester"
refers to a
14
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
carboxyl group in which R" is alkyl, alkenyl, alkynyl, carbocyclic,
heterocylic, aryl, or
aralkyl.
[0080] The term "carbocyclic" refers to a group that contains one or
more
covalently closed ring structures, and that the atoms forming the backbone of
the ring
are all carbon atoms. The ring structure may be saturated or unsaturated. The
term
thus distinguishes carbocyclic from heterocyclic rings in which the ring
backbone
contains at least one non-carbon atom. The term carbocylic encompasses
cycloalkyl
ring systems.
[0081] The terms "cycloalkane" or "cyclic alkane" or "cycloalkyl" refer
to a
carbocyclic group in which the ring is a cyclic aliphatic hydrocarbon, for
example, a
cyclic alkyl group preferably with 3 to 12 ring carbons. "Cycloalkyl"
includes, by way
of example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or
cyclooctyl, and the like. The cycloalkyl group may be optionally substituted
with an
amino, alkyl, halo, or hydroxyl group.
[0082] The term "ether" refers to the group ¨R'-0-R" wherein R' and R"
as
used in this definition are independently hydrogen, alkyl, alkenyl, alkynyl,
carbocyclic,
heterocylic, aryl, or aralkyl, and R' can additionally be a covalent bond
attached to a
carbon.
[0083] The terms "halo" or "halogen" refer to fluoro, chloro, bromo, or
iodo,
usually regarding halo substitution for a hydrogen atom in an organic
compound.
[0084] The term "heterocyclic", "het", or "heterocycle" means an
optionally
substituted, saturated or unsaturated, aromatic or non-aromatic cyclic
hydrocarbon
group with 4 to about 12 carbon atoms, preferably about 5 to about 6, wherein
1 to
about 4 carbon atoms are replaced by nitrogen, oxygen or sulfur. Exemplary
heterocyclic which are aromatic include groups piperidinyl, pyridinyl,
furanyl,
benzofizanyl, isobenzofuranyl, pyrrolyl, thienyl, 1,2,3-triazolyl, 1,2,4-
triazolyl, indolyl,
imidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, oxazolyl, triazinyl, and
tetrazolyl.
Exemplary heterocycles include benzimidazole, dihydrothiophene, dioxin,
dioxane,
dioxolane, dithiane, dithiazine, dithiazole, dithiolane, furan, indole, 3-H
indazole, 3-H-
indole, imidazole, indolizine, isoindole, isothiazole, isoxazole, morpholine,
oxazole,
oxadiazole, oxathiazole, oxathiazolidine, oxazine, oxadiazine, piperazine,
piperidine,
purine, pyran, pyrazine, pyrazole, pyridine, pyrimidine, pyrimidine,
pyridazine, pyrrole,
pyrrolidine, tetrahydrofuran, tetrazine, thiadiazine, thiadiazole,
thiatriazole, thiazine,
thiazole, thiomorpholine, thiophene, thiopyran, triazine, and triazole. The
heterocycle
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
may be optionally substituted with an amino, alkyl, alkenyl, alkynyl, halo,
hydroxyl,
carbocyclic, thio, other heterocyclic, or aryl group. Exemplary heterocyclic
groups
include 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1-
pyrrolyl, 2-pyrrolyl,
3-pyrrolyl, 1-indolyl, 2-indolyl, 3-indolyl, 1-pyridyl, 2-pyridyl, 3-pyridyl,
4-pyridyl, 1-
imidazolyl, 2-imidazolyl, 3-imidazolyl, 4-imidazolyl, 1-pyrazolyl, 2
pyrazolyl, 3-
pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 1-pyrazinyl, 2-pyrazinyl, 1-pyrimidinyl,
2-
pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 1-pridazinyl, 2-pyridazinyl, 3-
pyridazinyl,
4-pyridizinyl, 1-indolizinyl, 2-indolizinyl, 3-indolizinyl, 4-indolizinyl, 5-
indolizinyl, 6-
indolizinyl, 7-indolizinyl, 8-indolizinyl, 1-isoindolyl, 2-isoindolyl, 3-
isoindolyl, 4-
isoindolyl, 5-isoindolyl.
[0085] The term "hydroxy" or "hydroxyl" refers to the substituent -OH.
[0086] The term "oxo" shall refer to the substituent =0.
[0087] The term "nitro" means -NO2.
[0088] The term "sulfanyl" refers to -SR' where R' as used in this
definition is
hydrogen, alkyl, alkenyl, alkynyl, carbocyclic, heterocylic, aryl, or aralkyl.
[0089] The term "sulfenyl" refers to -SOR' where R' as used is this
definition is
hydrogen, alkyl, alkenyl, alkynyl, carbocyclic, heterocylic, aryl, or aralkyl.
[0090] The term "sulfonyl" refers to -SOR' where R' as used in this
definition is
hydrogen, alkyl, alkenyl, alkynyl, carbocyclic, heterocylic, aryl, or aralkyl.
[0091] "Optional" or "optionally" means that the subsequently described
event
or circumstance may or may not occur, and that the description includes
instances
where said event or circumstance occurs and instances in which it does not.
"Optionally" is inclusive of embodiments in which the described conditions is
present
and embodiments in which the described condition is not present. For example,
"optionally substituted phenyl" means that the phenyl may or may not be
substituted,
and that the description includes both unsubstituted phenyl and phenyl wherein
there is
substitution. "Optionally" is inclusive of embodiments in which the described
conditions is present and embodiments in which the described condition is not
present.
[0092] The compounds of the present invention can exist in tautomeric,
geometric, or stereoisomeric forms. The present invention contemplates all
such
compounds, including cis- and trans-geometric isomers, E- and Z-geometric
isomers,
R- and S- enantiomers, diastereomers, d-isomers, 1-isomers, the racemic
mixtures
thereof and other mixtures thereof, as falling within the scope of the
invention.
16
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
[0093] Also included in the family of compounds of the present invention
are
the pharmaceutically acceptable salts, esters, and prodrugs thereof. The term
"pharmaceutically-acceptable salts" embraces salts commonly used to form
alkali metal
salts and to form addition salts of free acids or free bases. The nature of
the salt is not
critical, provided that it is pharmaceutically acceptable. Suitable
pharmaceutically
acceptable acid addition salts of compounds of the present invention be
prepared from
inorganic acid or from an organic acid. Examples of such inorganic acids are
hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and
phosphoric acid.
Appropriate organic acids may be selected from aliphatic, cycloaliphatic,
aromatic,
araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids,
examples of
which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic,
malic, tartaric,
citric, ascorbic, glucoronic, maleic, fumaric, pyruvic, aspartic, glutamic,
benzoic,
anthranilic, mesylic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic,
embonic
(pamoic), methanesulfonic, ethylsulfonic, benzenesulfonic, sulfanilic,
stearic,
cyclohexylaminosulfonic, algenic, galacturonic acid. Suitable pharmaceutically-
acceptable base addition salts of compounds of the present invention include
metallic
salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and
zinc
or organic salts made from N,N'-dibenzylethyleneldiamine, choline,
chloroprocaine,
diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procain.
All
of these salts may be prepared by conventional means from the corresponding
compounds of by reacting, for example, the appropriate acid or base with the
compounds of the present invention.
[0094] As used herein, the term "pharmaceutically acceptable ester"
refers to
esters which hydrolyze in vivo and include, but are not limited to, those that
break
down readily in the human body to leave the parent compound or a salt thereof.
Suitable ester groups include, for example, those derived from
pharmaceutically
acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic,
cycloalkanoic and
alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has
not more
than 6 carbon atoms. Examples of particular esters include formates, acetates,
propionates, butyrates, acrylates, and ethylsuccinates.
[0095] The term "pharmaceutically acceptable prodrugs" as used herein
refers
to those prodrugs of the compounds of the present invention which are, within
the
scope of sound medical judgment, suitable for use in contact with the tissues
of humans
and lower animals without undue toxicity, irritation, allergic response and
the like,
17
commensurate with a reasonable risk/benefit ratio, and effective for their
intended use,
where possible, of the compounds of the invention. The term "prodrug" refers
to
compounds that are rapidly transformed in vivo to yield the parent compound of
the
above formulae, for example, by hydrolysis in blood. A thorough discussion is
provided in T. Higuchi and V. Stella, Prodrugs as Novel delivery Systems, Vol.
14 of
the A.C.S. Symposium Series and in Edward B. Roche, ed., Bioreversible
Carriers in
Drug Design, American Pharmaceutical Association and Pergamon Press, (1987).
[0096) The term "neuroprotection" embraces inhibition of progressive
deterioration of neurons that leads to cell death.
[0097] The term "neurodegenerative disorder" embraces a disorder in
which
progressive loss of neurons occurs either in the peripheral nervous system or
in the
central nervous system. In one embodiment, the condition treated and/or
prevented by
the compounds, compositions and methods of the disclosure is a
neurodegenerative
disorder. Without being bound by theory, it is believed that the compounds and
compositions of the present disclosure provide neuroprotective effects of the
Hsp90
inhibitor(s) during the treatment of the neurodegenerative disorder by
inhibiting the
progressive deterioration of neurons that leads to cell death.
[0098] In one aspect, the neurodegenerative disorder is sensory
neuron
glucotoxicity resultant from, e.g., hyperglycemia associated with a diabetic
condition,
and resultant in, e.g., diabetic peripheral neuropathy.
[0099] Examples of neurodegenerative disorders include, but are not
limited to
chronic neurodegenerative diseases such as diabetic peripheral neuropathy
(including
third nerve palsy, mononeuropathy, mononeuropathy multiplex, diabetic
amyotrophy,
autonomic neuropathy and thoracoabdominal neuropathy), Alzheimer's disease,
age-
related memory loss, senility, age-related dementia, Pick's disease, diffuse
Lewy body
disease, progressive supranuclear palsy (Steel-Richardson syndrome),
multisystem
degeneration (Shy-Drager syndrome), motor neuron diseases including
amyotrophic
lateral sclerosis ("ALS"), degenerative ataxias, cortical basal degeneration,
ALS-
Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis,
Huntington's disease, Parkinson's disease, multiple sclerosis ("MS"),
synucleinopathies,
primary progressive aphasia, striatonigral degeneration, Machado-Joseph
disease/spinocerebellar ataxia type 3 and olivopontocerebellar degenerations,
Gilles De
La Tourette's disease, bulbar and pseudobulbar palsy, spinal and spinobulbar
muscular
18
CA 2866814 2019-06-20
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
atrophy (Kennedy's disease), primary lateral sclerosis, familial spastic
paraplegia,
Wernicke-Korsakoffs related dementia (alcohol induced dementia), Werdnig-
Hoffmann disease, Kugelberg-Welander disease, Tay-Sach's disease, Sandhoff
disease,
familial spastic disease, Wohifart-Kugelberg-Welander disease, spastic
paraparesis,
progressive multifocal leukoencephalopathy, and prion diseases (including
Creutzfeldt-
Jakob, Gerstmarm-Straussler-Scheinker disease, Kuru and fatal familial
insomnia).
Other conditions also included within the methods of the present invention
include age-
related dementia and other dementias, and conditions with memory loss
including
vascular dementia, diffuse white matter disease (Binswanger's disease),
dementia of
endocrine or metabolic origin, dementia of head trauma and diffuse brain
damage,
dementia pugilistica, and frontal lobe dementia. Also other neurodegenerative
disorders resulting from cerebral ischemia or infarction including embolic
occlusion
and thrombotic occlusion as well as intracranial hemorrhage of any type
(including, but
not limited to, epidural, subdural, subarachnoid, and intracerebral), and
intracranial and
intravertebral lesions (including, but not limited to, contusion, penetration,
shear,
compression, and laceration). Thus, the term also encompasses acute
neurodegenerative disorders such as those involving stroke, traumatic brain
injury,
schizophrenia, peripheral nerve damage, hypoglycemia, spinal cord injury,
epilepsy,
and anoxia and hypoxia.
[00100] In some embodiments, the neurodegenerative disorder is
amyloidosis.
Amyloidosis is observed in Alzheimer's Disease, hereditary cerebral
angiopathy,
nonneuropathic hereditary amyloid, Down's syndrome, macroglobulinemia,
secondary
familial Mediterranean fever, Muckle-Wells syndrome, multiple myeloma,
pancreatic-
and cardiac-related amyloidosis, chronic hemodialysis arthropathy, and Finnish
and
Iowa amyloidosis. In preferred embodiments, the neurodegenerative disorder
treated
and/or prevented using the methods and compositions of the disclosure is
diabetic
peripheral neuropathy.
[00101] The phrase "pharmaceutically acceptable" is employed herein to
refer to
those compounds, materials, compositions, and/or dosage forms which are,
within the
scope of sound medical judgment, suitable for use in contact with the tissues
of human
beings and animals without excessive toxicity, irritation, allergic response,
or other
problem or complication, commensurate with a reasonable benefit/risk ratio.
[00102] The phrase "pharmaceutically-acceptable carrier" as used herein
means a
pharmaceutically-acceptable material, composition or vehicle, such as a liquid
or solid
19
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
filler, diluent, excipient, solvent or encapsulating material, involved in
carrying or
transporting the analogue or derivative from one organ, or portion of the
body, to
another organ, or portion of the body. Each carrier must be "acceptable" in
the sense of
being compatible with the other ingredients of the formulation and not
injurious to the
patient. Some examples of materials which may serve as pharmaceutically-
acceptable
carriers include: (1) sugars, such as lactose, glucose and sucrose; (2)
starches, such as
corn starch and potato starch; (3) cellulose, and its derivatives, such as
sodium
carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered
tragacanth;
(5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and
suppository
waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame
oil, olive oil,
corn oil and soybean oil; (10) glycols, such as propylene glycol; (11)
polyols, such as
glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as
ethyl oleate
and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium
hydroxide and
aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic
saline;
(18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions;
and (21)
other non-toxic compatible substances employed in pharmaceutical formulations.
[00103] The "patient" or "subject" to be treated with the compounds of
the
present invention can be any animal, e.g., dogs, cats, mice, monkeys, rats,
rabbits,
horses, cows, guinea pigs, sheep, and is preferably a mammal, such as a
domesticated
animal or a livestock animal. In another aspect, the patient is a human.
[00104] The term "inhibit" or "inhibiting" refers to a statistically
significant and
measurable reduction in neurotoxicity, preferably as measured by one or more
of the
assays discussed herein, preferably a reduction of at least about 10% versus
control,
more preferably a reduction of about 50% or more, still more preferably a
reduction of
about 60%, 70%, 80%, 90%, or more.
[00105] The term "preventing" as used herein means that the compounds of
the
present invention are useful when administered to a patient who has not been
diagnosed
as possibly having the disorder or disease at the time of administration, but
who would
normally be expected to develop the disorder or disease or be at increased
risk for the
disorder or disease. The compounds of the invention will slow the development
of the
disorder or disease symptoms, delay the onset of the disorder or disease, or
prevent the
individual from developing the disorder or disease at all. Preventing also
includes
administration of the compounds of the invention to those individuals thought
to be
predisposed to the disorder or disease due to age, familial history, genetic
or
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
chromosomal abnormalities, and/or due to the presence of one or more
biological
markers for the disorder or disease.
[00106] The term "treating," as used herein generally means that the
compounds
of the invention can be used in humans or animals with at least a tentative
diagnosis of
the disorder or disease. The compounds of the invention will delay or slow the
progression of the disorder or disease thereby giving the individual a more
useful life
span. The term "treatment" embraces at least an amelioration of the symptoms
associated with the disorder or disease in the patient is achieved, where
amelioration is
used in a broad sense to refer to at least a reduction in the magnitude of a
parameter,
e.g. symptom, associated with the condition being treated. As such,
"treatment" also
includes situations where the diseased condition or disorder, or at least
symptoms
associated therewith, are completely inhibited, e.g. prevented from happening,
or
stopped, e.g. terminated, such that the patient no longer suffers from the
condition or
disorder, or at least the symptoms that characterize the condition or
disorder.
[00107] A "therapeutically effective amount" is an amount of a compound
of the
present invention or a combination of two or more such compounds, which
inhibits,
totally or partially, the progression of the condition or alleviates, at least
partially, one
or more symptoms of the condition. A therapeutically effective amount can also
be an
amount that is prophylactically effective. The amount that is therapeutically
effective
will depend upon the patient's size and gender, the condition to be treated,
the severity
of the condition and the result sought. For a given patient and condition, a
therapeutically effective amount can be determined by methods known to those
of skill
in the art.
[00108] KU-32 is a first-generation novologue (a novobiocin-based, C-
terminal,
heat shock protein 90 (Hsp90) inhibitor) that decreases glucose-induced death
of
primary sensory neurons and reverses numerous clinical indices of diabetic
peripheral
neuropathy in mice. The structures of KU-32 and Novobiocin are shown in FIG.
1. The
disclosure provides a new series of C-terminal Hsp90 inhibitors designed to
optimize
hydrogen bonding and hydrophobic interactions in an attempt to enhance
neuroprotective activity. A series of substituted phenylboronic acids was used
in a
synthetic route to replace the coumarin lactone of KU-32 with an aryl moiety,
such as a
biphenyl moiety. Electronegative atoms placed at the meta-position of the B-
ring were
identified that exhibit improved cytoprotective activity, which while not
wishing to be
bound by theory, is believed to result from favorable interactions with Lys539
in the
21
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
Hsp90 C-terminal binding pocket. Consistent with these results, a meta-3-
fluorophenyl
substituted novologue (11b) surprisingly exhibited a 14-fold lower ED50
compared to
KU-32 for protection against glucose-induced toxicity of primary sensory
neurons.
[00109] Recently, molecular modeling studies were performed by this lab
and
azide-containing novobiocin derivatives as photoaffinity probes were used to
elucidate,
for the first time, the 11sp90 C-terminal binding site. Mans, R. L.; Dixit,
A.; Peterson,
L. B.; Sun, L.; Voruganti, S.; Kalyanaraman, P.; Hartson, S. D.; Verkhivker,
G. M.;
Blagg, B. S., Elucidation of the Hsp90 C-Terminal Inhibitor Binding Site. ACS
Chem
Biol 2011. As shown in FIG. 2 (A-C), KU-32 docks to this region and appears to
exhibit binding interactions with both the protein backbone and the amino acid
side
chains similar to those manifested by novobiocin. Interestingly, the coumarin
lactone
of KU-32 appears too distant from Lys539 to provide complementary interactions
with
this residue. In addition, the 3-amido side chain appears to project into a
large
hydrophobic pocket that could accommodate more flexible linkers. As a
consequence
of these observations, the novologue scaffold (FIG. 2D) was designed to
project the B-
ring into the pocket where Lys539 resides and to serve as a lead compound for
further
diversification. Without being bound to theory, it is possible that the
flexible ethyl
amide projecting from the A-ring could accommodate a number of orientations
that
could better occupy the large hydrophobic pocket that remains vacant in the
presence of
KU-32.
[00110] Based on the novologue design, construction of a parallel library
was
designed to validate this scaffold for use as a neuroprotective agent. The
library was
designed so that the 3'-carbamate on noviose was omitted; based upon prior
studies that
showed this group to be detrimental to Hsp90 inhibitory activity. Burlison, J.
A.;
Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B. S. J., Novobiocin:
Redesigning a
DNA Gyrase Inhibitor for Selective Inhibition of Hsp90. Journal of the
American
Chemical Society 2006, 128 (48), 15529-15536.
[00111] In contrast, additional hydrophobic and hydrogen bonding
interactions
are provided by the incorporation of functionalities onto the 3-aryl
substituent (B-ring),
which was designed to provide complementary interactions with Lys539. The 4-
ethyl
acetamide is included to occupy the binding pocket about the coumarin ring
system. In
one aspect, consistent with data obtained from prior studies, the 7-noviosyl
linkage is
maintained as well the requisite 2',3'-diol. The disclosure provides the
parallel
22
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
synthesis of rationally designed novologues as Hsp90 C-terminal inhibitors and
assessment of their neuroprotective activities.
[00112] Retrosynthetically, a library of novologues was designed for
construction via four components (Scheme 1); a resorcinolic benzaldehyde (1),
a
variety of commercially available boronic acids (2a¨p), noviose (3), and the
acetamide
side chain (Scheme 1). Prior work from this laboratory demonstrated that the
trichloroacetimidate of noviose carbonate undergoes rapid coupling with
phenols to
give the desired a-anomer in high yield.
Henry reaction
noviose
coupling
\L /'
o
Me0-.74
HO
OH Suzuki
coupling
CHO
OH +
Me0W4
0 HO OH
3 1
0
(H0)213,,,,,7õ,
2a-p
[00113] Scheme 1. Retrosynthetic analysis for the construction of
novologue.
[00114] The boronic acids chosen for this study contain both electronic
and
steric moieties that could aid in elucidation of structure¨activity
relationships and
provide crucial interactions with Lys539 and the surrounding pocket. Towards
this
goal, phenylboronic acids (Scheme 2) containing electronegative atoms at the
meta-
and para-positions were explored. In addition, hydrogen bond acceptors were
included
at these locations to provide potential hydrogen bonding interactions with the
protonated form of Lys539. To serve as controls, hydrophobic groups (2j, 2k)
and a
tertiary amine (21) were included in this series.
23
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
(I-10)2B (Ho)2B 401 0-00,2B (H0)28 õI
2a 2b 2c F CI 2d
(H0)2B 401 (H0)2B (H0)2B (H0)2B 40
2e 2f 2g CF3 mes
2h
Cl CF3
(H0)2B (H0)26 is (H0)26 (H0)2B 401
Me0 2j 2k
21 21
OMe
(H0)213 (H0)26 401
I I
OH
2m 2no
2o 2p
[00115] Scheme 2. Boronic acids selected for incorporation into novologue
X
scaffold.
[00116] The synthesis of ethyl acetamide side chain containing novologues
ha¨
p, began with commercially available 2,4-dihydroxybenzaldehyde, 1. The 4-
phenol of
resorcinolic benzaldehyde 1 was protected as the corresponding benzyl ether 4,
(Lee,
M.; Gubernator, N. G.; Sulzer, D.; Sames, D., Development of pH-Responsive
Fluorescent False Neurotransmitters. Journal of the American Chemical Society
2010,
132 (26), 8828-8830) and the 2-phenol converted to triflate 5 using
trifluoromethanesulfonic anhydride and triethylamine (Scheme 3). Compound 5
was
subsequently coupled with commercially available aryl boronic acids (2a¨p)
under
standard Suzuki conditions to give biaryl ring systems 6a¨p in good yields.
Grasa, G.
A.; Viciu, M. S.; Huang, J.; Zhang, C.; Trudell, M. L.; Nolan, S. P.,
Suzuki¨Miyaura
Cross-Coupling Reactions Mediated by Palladium/Imidazolium Salt Systems.
Organometallics 2002, 21 (14), 2866-2873; Olson, J. P.; Gichinga, M. G.;
Butala, E.;
Navarro, H. A.; Gilmour, B. P.; Carroll, F. I., Synthesis and evaluation of
1,2,4-
methyltriazines as mGluR5 antagonists. Organic & Biomolecular Chemistry 2011,
9
(11), 4276-4286.
[00117] Benzaldehydes 6a¨p were converted to the corresponding
nitrostyrenes
(7a¨p), following a Henry reaction with nitromethane and ammonium acetate.
Fuganti,
C.; Sacchetti, A., Biocatalytic enantioselective approach to 3-ary1-2-
nitropropanols:
Synthesis of enantioenriched (R)-5-methoxy-3-aminochroman, a key precursor to
the
antidepressant drug Robalzotan. Journal of Molecular Catalysis B: Enzymatic
2010, 66
(3-4), 276-284; Wood, K.; Black, D. S.; Kumar, N., Ring closing metathesis
strategies
24
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
towards functionalised 1,7-annulated 4,6-dimethoxyindoles. Tetrahedron 2011,
67 (22),
4093-4102.
[00118] Reduction of the nitro and olefin functionalities with lithium
aluminum
hydride was followed by acylation of the resulting amines to afford acetamides
8a¨p in
good yields. The benzyl ether of compounds 8a¨p was cleaved under
hydrogenolysis
conditions to afford phenols 9a¨p, which were coupled with the
tricloroacetimidate of
noviose carbonate 1014 in the presence of a catalytic amount of boron
trifluoride
etherate. Burlison, J. A.; Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B.
S. J.,
Novobiocin: Redesigning a DNA Gyrase Inhibitor for Selective Inhibition of
Hsp90.
Journal of the American Chemical Society 2006, 128 (48), 15529-15536; Kusuma,
B.
R.; Peterson, L. B.; Zhao, H.; Vielhauer, G.; Holzbeierlein, J.; Blagg, B. S.
J., Targeting
the Heat Shock Protein 90 Dimer with Dimeric Inhibitors. Journal of Medicinal
Chemistry 2011, 54 (18), 6234-6253.
[00119] The resulting noviosylated biaryl systems were exposed to
methanolic
ammonia to solvolyze the cyclic carbonate and give the desired novologues
(11a¨p) in
good to moderate yields.
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
CHO NaHCO3/BnBr CHO
Tf20, Et3N 401 CHO
1
CH3CN, rt, 75% DCM, 60%
HO OH Bn0 OH Bn0 OTf
1 4 5
CHO --. NO2
2a-p, Pd(PPh3)4
3. Bn0 ..x CH3NO2, NH40Ac
Bn0 1 X
K2CO3, DMF 1 vl
--- ...., 90-98%'
65-92% Ri rN3 Ri R3
6a-p R2 7a-p R2
R1, R2= H, R3= OH, X, Y = C
TBSCI, Imidd1---
.- 6m, R1, R2= H, R3= OTBS, X, Y = C
NHAc NHAc
1. LiAIH4, THE
2. Ac20, Et3N Bn0 ." X H2, Pd/C, Me0H Ho
X
_________ 1 ---0.
61-72% over 2 steps ..---Y. 69-81% ----Y.
Ri R3 Ri R3
8a-p R2 9a-p R2
Me0 NHAc
1.8, BF30Et2 4`YO \,00CCI3
2. Et3N, Me0H .s
55-88% =-)",(-)
_________ 1. HOõ,õ....õ...õ..--=,, 1 vl Me0 . 0 NH
OH ---- ..
R( "R --6---- 10
ha-p 0
R2
_____________ R1, R2= H, R3= OTBSõ X, Y = C
TBAF
________________________________________ I. 11M, Ri, R2= H,R3=0H X, Y=C
11a, Ri, R2, R3 = H, X, Y = C; 11b, R1, R3 = H, R2 = F, X, Y = C
11c, Ri, R2= H, R3 = F, X, Y = C; 11d, R2, R3 = H, Ri = CI, X, Y = C
11e, Ri, R3 = H, R2 = CI, X, Y = C; 11f, R1, R3 = H, R2 = CF3, X, Y = C
11g Ri, R2= H, R3 = CF3, X, Y = C; 11h, R2, R3= H, R1 = SMe, X, Y = C
11i, R2, R3 = H, R1 = OMe, X, V = C; 11j, R1, R3 = H, R2 = OMe, X, Y = C;
11k, R1, R3 = H, R2 = Me, X, Y = C; 111, Ri, R3 = H, R2 = CH2-morpholine, X, Y
= C
him, R1 R2= H, R3= OH X, Y = C; 11n, Ri= Hõ R2, R3= OCH20-, X, Y= C
11o, Ri, R2, R3 = H, X = N, Y = C; 11p, Ri, R2, R3 = H, X = C, Y --= N
Scheme 3. Synthesis of ethyl acetamide side chain containing novologues.
[00120] Compounds 41-43 are prepared in an analogous fashion by the
protocol
shown in Scheme 3.
26
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
OMe
Me0,X0 NHAc MeOX0 NHAc
Ha -.1 0 HO1O
OH OH OH
41 42
MeO.Y.0 NHAc
0
OH 43
1001211 In some embodiments, the disclosure provides a compound of
Formula
(I) wherein X2 together with X1 form a carbocyclic ring having 3 to 7 ring
members.
For example, two cyclohexene analogues 20a¨b were prepared to test the
hypothesis
regarding the region surrounding the flexible side chain (Scheme 4). Although
these
molecules contain the same linker length, these analogues contain a bulky
cyclohexane
tether between the biaryl ring system and the acetamide.
[00122] Synthesis of cyclohexene analogues 20a¨b began with the
previously
described phenol 4, which was protected as the methoxymethyl (MOM) ether 13
(Toda,
N. T., K.; Marumoto, S.; Takami, K.; On, M.; Yamada, N.; Koyama, K.; Naruto,
S.;
Abe, K.i; Yamazaki, R.; Hara, T.; Aoyagi, A.; Abe, Y.; Kaneko, T.; Kogen, H,
Monoenomycin: a simplified trienomycin A analog that manifests anticancer
activity.
Bioorganic & Medicinal Chemistry Letters, ACS ASAP) before the aldehyde of
which
was converted to nitrostyrene 14 under Henry conditions. Olson et al., 2011
Id. The
electron deficient nitrostyrene (14) was subjected to a Diels¨Alder
cycloaddition with
excess butadiene to give an enantiomeric mixture of cyclohexene derivative 15
in
excellent yield. Bryce, M. R.; Gardiner, J. M., Functionalised (+/-)-
cephalotaxine
analogues. Journal of the Chemical Society, Chemical Communications 1989,
(16),
1162-1164.
[00123] The nitro group of 15 was selectively reduced to the amine via
zinc dust
and acidic isopropanol, (Brandt, G. E. L.; Blagg, B. S. J., Monoenomycin: a
simplified
trienomycin A analog that manifests anticancer activity. ACS Medicinal
Chemistry
Letters, ACS ASAP; Pei, Z.; Li, X.; von Geldern, T. W.; Madar, D. J.;
Longenecker,
K.; Yong, H.; Lubben, T. H.; Stewart, K. D.; Zinker, B. A.; Backes, B. J.;
Judd, A. S.;
Mulhern, M.; Ballaron, S. J.; Stashko, M. A.; Mika, A. K.; Beno, D. W. A.;
Reinhart,
27
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
G. A.; Fryer, R. M.; Preusser, L. C.; Kempf-Grote, A. J.; Sham, H. L.;
Trevillyan, J.
M., Discovery of ((4R,5 S)-5-Amino-4-(2,4,5- trifluorophenyl)cyclohex-1-eny1)-
(3-
(trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl)methanone
(ABT-341), a Highly Potent, Selective, Orally Efficacious, and Safe Dipeptidyl
Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. Journal of
Medicinal
Chemistry 2006, 49 (22), 6439-6442) followed by acetylation to afford
acetamide 16 in
71% yield over two steps. In order to construct the biaryl ring system, the
MOM-ether
was cleaved to give the phenol, which was then converted to the corresponding
triflate,
17. A Suzuki reaction between 17 and 3-fluorophenylboronic acid or 3-
(trifluoromethyl) phenylboronic acid, yielded biaryl compounds 18a or 18b,
respectively. Finally, boron trifluoride etherate promoted removal of the
benzyl ether
(Andrieux, C. P.; Farriol, M.; Gallardo, I.; Marquet, J., Thermodynamics and
kinetics
of homolytic cleavage of carbon-oxygen bonds in radical anions obtained by
electrochemical reduction of alkyl aryl ethers. Journal of the Chemical
Society, Perkin
Transactions 2 2002, (5), 985-990) on compounds 18a¨b and gave phenols 19a¨b.
Lewis acid-catalyzed noviosylation of 19a¨b, with activated noviose carbonate
(10),
followed by methanolysis, afforded an inseperable mixture of diastereomeric
products,
20a¨b.
CHO
MOMCI, DIPEA CHO
CH3NO2, NH40Ac \ NO2 //
Bn0 OH DCM, rt, 84% Bn0 OMOM 84% Bn0 OMOM
toluene 120 C
2 95%
13 14
1. Zn dust, IN HCI 1. HCI, Me0H
2. Ac20, Et3N 2. Phenyl
triflimide 2b or 2f, Pd(PPh3)4
Et3N
Nv2 NHAc NHAc K2CO3, DMF
85%
Bn0 OMOM 71%, 2 steps Bn0 OMOM Bn0 OTf
15 16 17
HSEtSH, 1. 10, BF30Et2 Me04.-,-Yo
NHAc BF30Et2, NHAc 2 Et3N, Me0H
NHAc
Bn0 HO .
oH
18a, R = F, 89% 19a, R = F, 55%
20a, R = F, 35%
18b, R = CF3, 60% 19b, R = CF3, 86%
20b, R = CF3, 30%
Scheme 4. Synthesis of cyclohexene containing novologues.
28
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
[00124] In some embodiments, the disclosure provides compounds of Formula
(I) wherein X3 is CH2; in other words, wherein the noviose sugar substituent
is replaced
with a carbocyclic sugar analogue substituent.
[00125] In some embodiments, the disclosure provides compounds of Formula
Xi, ,NR'COR"
X2
I
no,.....------. .R8 R
X3 Z 1 r.3
I
R-4,-.. ,z1, R2
R- (CH)n r-c7 (IV)
(IV), Rb
wherein R', R", RI, R25 R35 R45 R55 R65 R75 R8, X, X15 X25 X35 Y, Z and Zi are
as defined
for a compound of Formula (I) above. In some embodiments, the disclosure
provides a -
compound of Formula (IV) wherein X3 is CH2.
[00126] For example, certain compounds are prepared by the synthetic
route
shown in Scheme 5.
OH OTs OTs
TsCI, Pyr, CHC13 0 C, lh
BnBr, NaH
ACN, RT
18 h
OH OH OBn
21 22
NHAc _("--->
Bn0 OTs 1,NHAc
HO ___________________________________________ 1.... Bn0-0--0
K2CO3, DMF, TBAI
18 h, reflux
F F
23 24
[00127] Scheme 5. Synthesis of carbocyclic sugar analogue compound 24.
[00128] The phenol core intermediate 23 in Scheme 5 can be prepared by
the
synthetic route shown in Scheme 6.
29
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
01H
H(CYB
Tf20, Et3N,
CHO Bn13r, NaHCO3 CHO CH2C12 CHO
HO OH
ACN, 8 Bn0 OH 0 C k I 0 C-rt
Bn0 OTf Pd(PPh3)4, K2CO3
DMF, reflux, 18 h
25 26
CHO CH3NO2, NO2 NH2
NH40Ac LiA1H4
BnOy Bn0 Bn0
50 C, 16 h
THF, 0 'C
27 28 29
NHAc NHAc
acetic anhydride Pd(OH)2, H2
TEA, rt, 3 h Bn0 Me0H, rt, 8 h HO
30 23
[00129] Scheme 6. Synthesis of phenol core intermediate 23.
[00130] In some embodiments, the disclosure provides compounds of Formula
(I) or Formula (IV) wherein X3 is CH2, Z is CH, and Zi is CH. In some
embodiments,
the disclosure provides compounds of Formula (I) or Formula (IV) wherein X3 is
CH2,
and Z ¨Z1 is ¨C=C-. For example, Scheme 7 shows a representative synthesis of
a
compound of Formula (I) or Formula (IV), where X3 is CH2 and or Z¨Z1 is ¨C=C-,
such as compound 36. For example, Scheme 7 shows a representative synthesis of
compounds of Formula (I) or Formula (IV), where X3 is CH2 and Z is CH, such as
compound 37.
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
MeSI, THF
mCPBA, DCM nBuLi
I' 33
rt, 3 h 0 -10 C-rt
31 32
65% 3 h, 44%
OH
HO-0--OH BnO¨C)--OH
OH Grubbs II, Bnl3r, NaH
34 35
33 DCM, reflux DMF, rt, on
2h
Bn0-0-0H
NHAc NHAc
DIAD, PPh3, THF
HO Bn0 ______________________________________ 0
0 C-rt, 4h
23 36
NHAc HO OH NHAc
II J 0s04, NMO
______________________________________ Bn0 0
¨0-0 THF, H20
rt, on, 80%
Bn0
36 37
[00131] Scheme 7. Synthesis of carbocyclic sugar analogues 36 and 37.
[00132]
In some embodiments, the disclosure provides a compound of Formula (I) or
Formula
(IV) wherein X3 is CH2 and R6 is alkyl. A representative synthetic route is
shown in
Scheme 8.
TsCl, Pyr
OH __________________________________________ OTs
0 C, to rt, quant.
38
)-0--0Ts
NHAc NHAc
38
HO 0
K2CO3, DMF, TBAI
23 ref lux
39
[00133] Scheme 8. Synthesis of carbocyclic compound 39.
31
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
Evaluation of Neuroprotective Efficacy
[00134] Upon synthesis of ethyl acetamide side chain novologues ha¨p that
contain various substitutions on the B-ring (hydrogen bond acceptors, hydrogen
bond
donors, hydrophobic groups, and a tertiary amine), their neuroprotective
efficacy
against glucose-induced toxicity of embryonic dorsal root ganglion (DRG)
sensory
neuron cultures was evaluated. As shown in Table 1, meta-substituted acetamide
novologues (11b, lie and 11f) showed significant protection against
glucotoxicity and
were comparable to that observed with KU-32. Although the corresponding ortho-
and
para- substituted (11c, lid and 11g) derivatives showed significant protection
against
glucose-induced cell death, they were modestly less effective than novologues
11b, lie
and llf. However in the case of analogues lli (ortho-OMe) and 11j (meta-OMe)
the
opposite trend was observed. Electronegative atoms at the meta-position (F,
Cl, CF3)
exhibited greater cytoprotective activity, which is believed to result from
favorable
interactions with Lys539 in the Hsp90 C-terminal binding pocket. Consistent
with this
hypothesis, increasing the size of the electronegative atom at the meta-
position (F to Cl
to CF3) resulted in a decrease in neuroprotective activity. Similarly, steric
bulk was
disfavored as well. Analogue llb (meta-F) was the most cytoprotective (95%+14)
compound evaluated.
[00135] Electronegative atoms at the ortho- or para-position on ring B
(11c, lid
and 11g) manifested activities comparable to the unsubstituted analogue (11a)
and
were less active than the corresponding meta-substituted analogues (11b, lie
and 11f).
Although novologues lid and hg manifested protection against neuronal
glucotoxicity, they were less effective than KU-32 and 11b. Compound (11m)
(para-
OH), with hydrogen-bond donor characteristics at the para position of the B-
ring, was
also somewhat, but not significantly less protective than the unsubstituted
analogue
(11a).
32
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
[00136] Table 1. Cell viability data of ethyl acetamide side chain
novologues.
Me0o NHAc
I A
HO'µµO 1 ' X
I B I
OH Ac ,r,,
R1 rx3
ila-q
R2
Entry R1 R2 R3 X Y % of cell
viability a
ha H H H C C 76% 11#
lib H F H C C 95% 144
lie H H F C C 75% 27#
lid Cl H H C C 71% 21#'*
lie H Cl H C C 90% 23#
llf H CF3 H C C 83% 16#
hg H H CF3 C C 74% 19#'*
11h SMe H H C C 83% 40#
111 OMe H H C C 92% 10#
11j H OMe H C C 78% 344
ilk H Me H C C 82% 304
111 H CH2-N- H C C 83% 26#
morpholine
him H H OH C C 67% 10*
lln H -OCH20- C C 83% 18#
ho H H H N C 61.% 7*
lip H H H C N 81% 124
'In the presence of 1 1.tM of each novologue + 20 mM excess glucose. Viability
in the
presence of 20mM excess glucose + DMSO was 54% 2 and 86% 2 in the presence
of glucose + 1 1AM KU-32. #, p<0.05 versus glucose + DMSO; * p<0.05 versus
glucose
+ KU-32 (n=6-24) per novologue.
33
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
1001371 On the other hand, hydrogen bond acceptors at the para-position
(11c
and 11g) protected against glucose-induced neuronal death but did not display
significantly increased protection compared to the novologue containing a para-
position hydrogen bond donor (11m).
1001381 Pyridine-containing analogues (110¨p) were also synthesized and
evaluated for neuroprotective activity. The 3-pyridine analogue (11o) was
unable to
protect against glucose-induce toxicity and was also significantly less
protective than
the corresponding 4-pyridine analogue, 11p, KU-32, and the unsubstituted
phenyl
analogue, ha. Although the 4-pyridine-containing analogue (11p) demonstrated a
modestly improved neuroprotective activity when compared to the simple phenyl
analogue 11a, this difference in efficacy was not significant.
[00139] Neuroprotective activity was also determined for the cyclohexene-
containing novologues (20a¨b) that contain the fluoro or trifluoromethane
substituent
at the meta-position of ring B. In general, cyclohexene-containing analogues
20a-b
were less efficacious than the corresponding derivatives that contain a
flexible side
chain (11b versus 20a, and llf versus 20b). Although not statistically
different,
novologue 20a (meta-F) exhibited slightly better cytoprotective activity than
analogue
20b (meta-CF 3), which follows the same trend observed for flexible acetamide-
containing compounds (11b versus 110. Although these data are inconsistent
with our
hypothesis that accommodation of the hydrophobic pocket would improve
efficacy, the
cyclohexene ring may exceed the space allowed in this binding cleft.
1001401 Table 2. Cell viability data of cyclohexene analogues.
Me04444.....X 111
0 NHAc
E:
HO\N
OH
20a-b R2
Entry R2 % of cell viability a
20a F 78% 18%#
20b CF3 69% 15% #'*
34
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
aIn the presence of liAM novologue + 20 mM excess glucose. Viability in the
presence
of 20mM excess glucose + DMSO was 54% 2 and 86% 2 in the presence of
glucose + 1 p,M KU-32. #, p<0.05 versus glucose + DMSO; * p<0.05 versus
glucose +
KU-32 (n=8) per novologue.
[00141] The data in Table 1 clearly support that the majority of
novologues
synthesized decrease neuronal toxicity induced by hyperglycemic stress.
Although
some of these compounds appear more effective than KU-32 at 1 iuM, the
differences
were relatively minor. Therefore, to further scrutinize their efficacy,
compounds
exhibiting high neuroprotective activity were further evaluated for
determination of
EC50 values. Since the difference in efficacy for novologues with meta-F and
meta-
CF3 substitutions on lib and llf were not significantly different from KU-32
or each
other at 11.1M, the EC50 values for these compounds were determined alongside
11h,
111, 11n, and llo. As shown in FIG. 4, EC50 values were significantly improved
upon
closer inspection and clear distinctions were obtained. Novologue lib
exhibited an
EC50 value (13.0 3.6 nM) that was approximately 14-fold lower than KU-32
(240.2
42.5 nM) or llf (187.7 43.5 nM). Similar results were also observed for
novologue
11n, which exhibited an EC50 value of 18.4 3.2 nM. In contrast, novologue
11h
which manifested similar efficacy to KU-32 at 1 p.M, exhibited an EC50 of 384
108
nM, approximately 1.6-fold greater than KU-32.
[00142] The data in FIG. 4 demonstrate that novologues llb and lln are
surprisingly more cytoprotective than the initial lead compound, KU-32. Since
it was
previously shown that the cytoprotective activity manifested by KU-32 requires
Hsp70,
the ability of lib and lln to induce Hsp70 was determined relative to KU-32.
Increasing concentrations of KU-32, lln, and lib were incubated with DRG
sensory
neurons for 24 hours before the cells were subjected to 4 hours of glucotoxic
stress.
Hsp70 levels were examined by performing immunoblot analysis with the cellular
lysates (FIG. 5). tin and lib induced Hsp70 levels at similar concentrations
(10 nM)
as those needed for neuroprotection. Although correlative, these data provide
a clear
link between neuroprotection and the ability of llb and lln to induce the heat
shock
response as exemplified by Hsp70 levels.
[00143] Through systematic replacement of substituents on the novologue B-
ring
(see Table 2), compound lib was identified as a neuroprotective agent that
surprisingly
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
exhibited ¨14-fold greater efficacy against glucose-induced toxicity than the
lead
compound, KU-32. The concentration of lib needed to manifest neuroprotective
activity correlated well with its ability to induce Hsp70 levels, and
therefore linking
cytoprotection to Hsp70 induction. When combined, these data demonstrate the
rationally-designed novologue scaffold provides a promising platform on which
diversification of the B-ring can lead to compounds that exhibit better
neuroprotective
activities.
[00144] In one embodiment, the disclosure provides a compound or
pharmaceutically acceptable salt according to Formula (I):
R24
R23 Xi NR'COR"
X2
X
0
R22
v R8
"3 R1
R4
Zi, R2
R5 (CH)n R7
R6
wherein
[00145] R1 is hydrogen, hydroxy, halo, trifluoroalkyl, alkyl, alkenyl,
alkynyl,
carbocyclic, heterocyclic, aryl, aralkyl, carboxyl, amido, amino, alkoxy,
halo,
trifluoromethyl, sulfanyl, sulfenyl, sulfonyl, or ether;
[00146] R2 is hydrogen, halo, hydroxy, trifluoromethyl, alkoxy, alkyl,
alkenyl,
alkynyl, carbocyclic, alkylcarbocyclic, alkylheterocyclic, heterocyclic, or
¨R9-0R1 ,
wherein R9 is a covalent bond or alkyl, and RI is hydrogen, alkyl, C-amido or
acyl; or
R2 together with R3 and the atoms to which they are attached form a
carbocyclic ring
with 5 to 7 ring members or a heterocyclic ring having 4 to 8 ring members
with at least
one heteroatom selected from oxygen or nitrogen;
[00147] R3 is hydrogen, hydroxy, halo, trifluoroalkyl, alkyl, alkoxy,
sulfanyl, or
11-
O-R -12 , wherein Ril is a covalent bond or alkyl, and R12 is alkyl, C-amido
or acyl;
or R3 together with R2 and the atoms to which they are attached form a
carbocyclic ring
with 5 to 7 ring members or a heterocyclic ring having 4 to 8 ring members
with at least
one heteroatom selected from oxygen or nitrogen;
36
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
[00148] R4 is hydrogen, hydroxy, alkyl, arylalkoxy, carboxyl, ¨R13-0-R14,
or ¨
R13-R15; and wherein R13 is a covalent bond or alkyl, and R14 is hydrogen, C-
amido or
acyl, and R15 is N-amido, -POR16R17 -S02R18, or sulfonamido, and wherein R16,
R17,
R18are independently alkoxy;
[00149] R5 is hydrogen, hydroxy, alkyl, arylalkoxy, alkenyl, alkynyl,
aryl, or
aralkyl;
[00150] R6 is hydrogen, hydroxy, sulfanyl, alkyl, alkenyl, alkynyl, aryl,
arylalkyl, alkoxy, aryloxy, arylalkoxy or a heterocyclic ring having 4 to 8
ring members
with at least one heteroatom selected from oxygen or nitrogen;
[00151] R7 is hydrogen, hydroxyl, arylalkoxy, alkyl, acyl, carboxyl or
absent;
[00152] R8 is hydrogen, hydroxyl, or arylalkoxy;
[00153] R22 is hydrogen, hydroxy, amino, amido, cyano, alkoxy, halogen,
trifluoroalkyl, alkyl,
[00154] alkenyl, alkynyl, ester, nitro, carboxyl, aralkyl, aryl,
carbocyclic,
heterocyclic, trifluoromethyl, sulfonyl, sulfanyl, sulfenyl, ether, R25-0R26,
or R25-
NR26; where R25 is a covalent bond or alkyl and R26 is a hydrogen, alkyl, C-
amido, or
acyl;
[00155] R23 is hydrogen, hydroxy, amino, amido, cyano, alkoxy, halogen,
trifluoroalkyl, alkyl,
[00156] alkenyl, alkynyl, ester, nitro, carboxyl, aralkyl, aryl,
carbocyclic,
heterocyclic, trifluoromethyl, sulfonyl, sulfanyl, sulfenyl, ether, R27-0R28,
or R27 ¨
NR28; where R27 is a covalent bond or alkyl and R28 is a hydrogen, alkyl, C-
amido, or
acyl; or R23 together with R24 and the atoms to which they are attached form a
carbocyclic ring with 5 to 7 ring members or a heterocyclic ring having 4 to 8
members
with at least one heteroatom selected from oxygen or nitrogen;
[00157] R24 is hydrogen, hydroxy, amino, amido, cyano, alkoxy, halogen,
trifluoroalkyl, alkyl, alkenyl, alkynyl, ester, nitro, carboxyl, aralkyl,
aryl, carbocyclic,
heterocyclic, trifluoromethyl, sulfonyl, sulfanyl, sulfenyl, ether, R29-0R30,
or R29 ¨
NR30; where R29 is a covalent bond or alkyl and R3 is a hydrogen, alkyl, C-
amido, or
acyl; or R24 together with R23 and the atoms to which they are attached form a
carbocyclic ring with 5 to 7 ring members or a heterocyclic ring having 4 to 8
members
with at least one heteroatom selected from oxygen or nitrogen;
37
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
[00158] X1 is ¨CHR19¨ , or -CR19=, and wherein R19 is selected from
hydrogen,
halo, alkyl, alkenyl, or alkynyl; or X2 together with X1 form a carbocyclic
ring having 3
to 7 ring members; or wherein X1-X2 is¨CfC-;
[00159] X2 is ¨CHR20¨ 5 or =CR20-, and wherein R2 is selected from
hydrogen,
halo, alkyl, alkenyl, or alkynyl; or X2 together with X1 form a carbocyclic
ring having 3
to 7 ring members; or wherein Xi-X2 is¨C=C-;
[00160] X3 is 0, or CH2;
[00161] X is =CR21¨, or =N¨, wherein R21 is hydrogen, halo,
trifluoromethyl,
alkyl, alkenyl, alkynyl, alkoxy, or hydroxy;
[00162] R' is H, or alkyl;
[00163] R" is alkyl, alkoxy, haloalkyl, alkylcycloalkyl or
alkylamidoalkyl;
[00164] Y is =CR3¨ or =N¨;
[00165] Z is CH, or Z ¨Z1 is ¨C=C-;
[00166] Z1 is CH, 0, S, N, or Z-Zi is ¨C=C-; and
[00167] n is 0, 1, 2, or 3.
[00168] In some embodiments, the disclosure provides compounds of Formula
(II):
Me04144...,X NHAc
0
(II)
X
HO\ b
OH
R3 Ri
R2
[00169] wherein RI, R2, R35 X and Y are defined as above.
[00170] In another embodiment, the disclosure provides a compound or salt
of
formula (II) wherein R1 is hydrogen, halo, hydroxy, trifluoroalkyl, alkoxy, or
sulfanyl;
[00171] R2 is hydrogen, halo, hydroxy, trifluoroalkyl, alkoxy, sulfanyl,
or alkyl,
or R2 together with R3 and the atoms to which they are attached form a
carbocyclic ring
with 5 to 7 ring members or a heterocyclic ring having 4 to 8 ring members
with at least
one heteroatom selected from oxygen or nitrogen;
[00172] R3 is hydrogen, halo, hydroxy, trifluoroalkyl, alkoxy, sulfanyl,
alkyl; or
R3 together with R2 and the atoms to which they are attached form a
carbocyclic ring
38
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
with 5 to 7 ring members or a heterocyclic ring having 4 to 8 ring members
with at least
one heteroatom selected from oxygen or nitrogen;
[00173] X is =CR21¨, or =N¨, wherein R21 is hydrogen, halo, or
trifluoromethyl;
and
[00174] Y is =CR3¨ or =N¨.
[00175] In some embodiments, the disclosure provides compounds of Formula
(III), wherein RI, R2, R3, R22, R23, R24, X and Y are defined as above.
R24
MeO R23 NHAc
¨
0
HO\ 0 X
R22
-05H Y\R
Ri 3
(III)
R2
[00176] In some embodiments, the disclosure provides a compound of
Formula
(III) wherein one of R22, R23, and R24 is not H.
[00177] In a specific embodiments, the neuroprotective compound is
selected
from:
[00178] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-yl)oxy)-[1,1'-bipheny1]-2-yflethypacetamide (11a);
[00179] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-ypoxy)-3'-fluoro-[1,1'-bipheny1]-2-ypethypacetamide (1 lb);
[00180] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-ypoxy)-4'-fluoro-{ 1,l'-biphenyl] -2-yflethypacetamide (1 1c);
[00181] N-(2-(2'-chloro-5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-yeoxy)-[1,1'-biphenyl]-2-ypethypacetamide (11d);
[00182] N-(2-(3'-chloro-5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-yl)oxy)-[1,11-biphenyl]-2-y1)ethyDacetamide (1 1
e);
[00183] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-ypoxy)-3'-(trifluoromethyl)41,1'-biphenyl]-2-ypethypacetamide (ii
f);
[00184] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-yl)oxy)-4'-(trifluoromethy1)41,1'-biphenyl]-2-yDethyl)acetamide
(11g);
39
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
[00185] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-ypoxy)-2'-(methylthio)-[1,1'-biphenyl]-2-yl)ethypacetamide (11h);
[00186] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-yl)oxy)-2'-methoxy-[1,11-bipheny1]-2-yDethypacetamide (11i);
[00187] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-yl)oxy)-3'-methoxy-[1,1'-bipheny1]-2-ypethyDacetamide (11j);
[00188] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-yl)oxy)-3'-methyl-[1,1'-bipheny1]-2-yDethyDacetamide (11k);
[00189] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-yl)oxy)-3'-(morpholinomethy1)41,1'-biphenyl]-2-y1)ethypacetamide
(111);
[00190] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-yl)oxy)-4'-hydroxy-[1,11-bipheny1]-2-ypethyDacetamide (11m);
[00191] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-yl)oxy)-4'-hydroxy-[1,1'-bipheny1]-2-yDethyl)acetamide (11m):
[00192] N-(2-(benzo[d][1,3]dioxo1-5-y1)-4-(((3R,4S,5R)-3,4-dihydroxy-5-
methoxy-6,6-dimethyltetrahydro-2H-pyran-2-y1)oxy)phenethyl)acetamide (11n):
[00193] N-(4-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-
2H-pyran-2-yl)oxy)-2-(pyridin-3-yl)phenethyl)acetamide (11o);
[00194] N-(4-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-
2H-pyran-2-yl)oxy)-2-(pyridin-4-yl)phenethyl)acetamide (11p);
[00195] N-(4'4(3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-
2H-pyran-2-yl)oxy)-3"-fluoro-1,2,3,6-tetrahydro-[1,1':2',1"-terpheny1]-2-
yl)acetamide
(20a);
[00196] N-(4'-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-
2H-pyran-2-yl)oxy)-3"-(trifluoromethyl)-1,2,3,6-tetrahydro-[1,1':21,1"-
terphenyl]-2-
ypacetamide (20b);
[00197] N-(2-(5-((4-(benzyloxy)cyclohexyl)oxy)-3'-fluoro-[1,1'-bipheny1]-
2-
ypethypacetamide (24);
[00198] N-(2-(5-((4-(benzyloxy)cyclohex-2-en-1-yl)oxy)-3'-fluoro-[1,1'-
biphenyl]-2-ypethypacetamide (36);
[00199] N-(2-(5-((4-(benzyloxy)-2,3-dihydroxycyclohexyl)oxy)-3'-fluoro-
[1,1'-
bipheny1]-2-ypethypacetamide (37);
[00200] N-(2-(54(4-(tert-butyl)cyclohexyl)oxy)-3'-fluoro-[1,1'-biphenyl]-
2-
ypethyDacetamide (39);
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
[00201] N-(2-(31-fluoro-5-04-(piperidin-4-yl)cyclohexyl)oxy)-[1,1'-
bipheny1]-2-
yOethypacetamide (40);
[00202] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-yl)oxy)-3'-fluoro-6-hydroxy-[1,11-biphenyl]-2-yDethyDacetamide
(41);
[00203] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-ypoxy)-3'-fluoro-3-methoxy-[1,1'-biphenyl]-2-y1)ethypacetamide
(42); and
[00204] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-
2H-pyran-2-yl)oxy)-3'-fluoro-4-methyl-[1,1'-biphenyl]-2-ypethypacetamide (43).
[00205] Several of the compounds of the present invention have been shown
to
inhibit Hsp90 in vitro. As such, it is contemplated that therapeutically
effective
amounts of the compounds of the present invention will be useful as
neuroprotective
agents that result in at least a 10% enhancement of cell viability compared to
control
over a given time period and under certain conditions, for example, such as
glucose-
induced toxicity in vitro or under a diabetic condition in vivo.
[00206] In the context of neuroprotection, it is contemplated that some
of the
compounds of the present invention may be used with other Hsp90 inhibitors
and/or
neuroprotective agents.
[00207] The following examples are provided to illustrate the present
invention
and are not intended to limit the scope thereof. Those skilled in the art will
readily
understand that known variations of the conditions and processes of the
following
preparative procedures can be used to prepare these compounds.
[00208] The present invention is directed to the use of therapeutically
effective
amount of one or more of the compounds disclosed herein to treat and/or
prevent a
neurodegenerative disorder such as diabetic peripheral neuropathy and/or to
provide
neuroprotection.
[00209] Compositions of the Present Invention
[00210] According to another aspect, the present invention provides a
pharmaceutical composition, which comprises a therapeutically-effective amount
of
one or more compounds of the present invention or a pharmaceutically-
acceptable salt,
ester or prodrug thereof, together with a pharmaceutically-acceptable diluent
or carrier.
The pharmaceutical compositions provide neuroprotection and used to treat
and/or
prevent neurodegenerative disorders.
[00211] The compositions may be formulated for any route of
administration, in
particular for oral, rectal, transdermal, subcutaneous, intravenous,
intramuscular, or
41
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
intranasal administration. The compositions may be formulated in any
conventional
form, for example, as tablets, capsules, caplets, solutions, suspensions,
dispersions,
syrups, sprays, gels, suppositories, patches, and emulsions.
[00212] Accordingly, the compounds of the present invention are useful in
the
treatment or alleviation of neurodegenerative disorders, such as Alzheimer's
disease,
Parkinson's disease, Lou Gehrig's disease, or multiple sclerosis, to name a
few, not to
mention central or peripheral nervous system damage, dysfunction, or
complications
involving same stemming from edema, injury, or trauma. Such damage,
dysfunction,
or complications may be characterized by an apparent neurological,
neurodegenerative,
physiological, psychological, or behavioral aberrations, the symptoms of which
can be
reduced by the administration of a therapeutically effective amount of the
compounds
of the present invention.
[00213] The following examples are provided for further illustration of
the
present invention, and do not limit the invention.
EXAMPLES
[00214] Example 1. Preparation of Embryonic Dorsal Root Ganglion (DRG)
Neuron Cultures.
[00215] DRG from embryonic day 15-18 Sprague Dawley rat pups were
harvested into Leibovitz's L15 medium (L15) and dissociated with 0.25% trypsin
for
30 min at 37 C. The ganglia were sedimented at 1,000 x g for 5 min,
resuspended in
growth media [phenol red free Neurobasal medium (Gibco, Grand Island, NY)
containing 25 mM glucose, 1X B-27 additive, 50 ng/ml NGF (Harlan Bioscience,
Indianapolis, IN), 4 mM glutamine, 100 U/mL penicillin and 100 [tg,/mL
streptomycin]
and triturated with a fire-polished glass pipette. The cells were cultured on
collagen-
coated (0.1 mg/mL collagen followed by overnight air drying in a laminar flow
hood)
black-walled 96-well plates (Corning Incorporated Corning, NY) at a seeding
density
of 2-3 x 104 cells per well. DRG neurons were re-fed the next day with fresh
growth
media containing 401,tM fluorodeoxyuridine and 10 I.A,M cytosine I3-D-
arabinoside
(both from Sigma Aldrich, St. Louis, MO) for 2 days to remove proliferating
cells.
Experiments were performed on DRG neurons on the third day in culture after
placing
the cells in fresh growth medium.
[00216] Example 2. Glucotoxicity Assay.
[00217] Immature DRG are susceptible to hyperglycemia-induced death.
Vincent, A. M.; Kato, K.; McLean, L. L.; Soules, M. E.; Feldman, E. L.,
Sensory
42
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
Neurons and Schwann Cells Respond to Oxidative Stress by Increasing
Antioxidant
Defense Mechanisms. Antioxid Redox Signal 2009, 11, 425-438. Therefore, an
additional 20 mM glucose was added to the growth medium of Example 1 (yielding
a
total of 45mM glucose) for 4 hours. Preliminary experiments found that 20 mM
excess
glucose for 4 lus was sufficient to induce a reproducible 40-50% loss in
neuronal
viability. As a result, the toxicity induced by the acute change in glucose
concentration
makes it a useful model for drug screening. Urban, M. J.; Li, C.; Yu, C.; Lu,
Y.; Krise,
J. M.; McIntosh, M. P.; Rajewski, R. A.; Blagg, B. S. J.; Dobrowsky, R. T.,
Inhibiting
Heat Shock Protein 90 Reverses Sensory Hypoalgesia in Diabetic Mice. ASN Neuro
2010, 2, e00040 DOI :189-199; Vincent, A. M.; Stevens, M. J.; Backus, C.;
McLean, L.
L.; Feldman, E. L., Cell culture modeling to test therapies against
hyperglycemia-
mediated oxidative stress and injury. Antioxid Redox Signal 2005, 7(11-12),
1494-506.
[00218] Given the short time frame that the neurons are grown in vitro,
they
are not pure neuronal cultures but instead, highly enriched. Importantly, the
contaminating SCs that remain in the culture are resistant to glucose-induced
death
as we and others have reported previously. Vincent, A. M.; Kato, K.; McLean,
L. L.;
Soules, M. E.; Feldman, E. L., Sensory Neurons and Schwann Cells Respond to
Oxidative Stress by Increasing Antioxidant Defense Mechanisms. Antioxid Redox
Signal 2009, 11, 425-438; Zhang, L.; Yu, C.; Vasquez, F. E.; Galeva, N.;
Onyango, I.;
Swerdlow, R. H.; Dobrowsky, R. T., Hyperglycemia alters the schwann cell
mitochondrial proteome and decreases coupled respiration in the absence of
superoxide
production. J Proteome Res 2010, 9 (1), 458-71.
[00219] Unfortunately, the use of highly purified cultures is problematic
since
the cells extend neurites and establish connections with each other, thus
becoming
resistant to hyperglycemia-induced death. Yu, C.; Rouen, S.; Dobrowsky, R. T.,
Hyperglycemia and downregulation of caveolin-1 enhance neuregulin-induced
demyelination. Glia 2008, 56, 877-887.
[00220] DRG neurons were incubated overnight with the test compounds in
the
presence of Neurobasal medium, 50 ng/ml NGF and antibiotics only. In order to
monitor the efficiency of the compounds in protecting DRG neurons against
glucotoxicity, Calcein AM (Invitrogen, Carlsbad, CA) was utilized to measure
cell
viability. Hydrolysis of calcein AM to a fluorescent product can only occur in
live cells.
Excess glucose was added to the cultures for 4 hrs and cell viability was
measured by
43
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
incubating the cells with 2 1AM calcein AM for 30 min in the dark at 37 C.
Fluorescence was then measured using a plate reader with excitation and
emission
wavelengths set to 485nm and 520nm, respectively. The arbitrary fluorescence
readings
were normalized to the total amount of protein from each respective well of
the
neuronal cultures. The protein concentrations in each well were determined
using the
DC protein assay (Bio-Rad). Significant differences in the efficacy of the
novologues
for increasing cell viability were determined using a Kruskal-Wallis non-
parametric
ANOVA and Dunn's post-test.
[00221] Example 3. Chemistry General-NMR.
[00222] 'I-INMR were recorded at 400 or 500 MHz (Bruker DRX-400 Bruker
with a H/C/P/F QNP gradient probe) spectrometer and BC NMR spectra were
recorded
at 125 MHz (Bruker DRX 500 with broadband, inverse triple resonance, and high
resolution magic angle spinning HR-MA probe spectrometer); chemical shifts are
reported in 6 (ppm) relative to the internal reference chloroform-d (CDC13,
7.27 ppm).
[00223] Example 4. Chemistry General-Mass Spectroscopy and HPLC.
[00224] FAB (HRMS) spectra were recorded with a LCT Premier (Waters
Corp.,
Milford, MA).
[00225] The purity, of all compounds was determined to be >95%as
determined
by 1H NMR and 13C NMR spectra, unless otherwise noted. The most active 5
compounds were verified for >95% purity by HPLC analyses. TLC was performed on
glass backed silica gel plates (Uniplate) with spots visualized by UV light.
All solvents
were reagent grade and, when necessary, were purified and dried by standard
methods.
Concentration of solutions after reactions and extractions involved the use of
a rotary
evaporator operating at reduced pressure.
[00226] Example 5. Synthesis of 5-(benzyloxy)-2-formylphenyl
trifluoromethanesulfonate (3): A solution of phenol 2 (11.2 g, mmol) in
anhydrous
DCM (245mL) was stirred at 0 C and triethylamine (10.2 mL, 73.5mmo1) was
added
followed by triflic anhydride (13.8 mL, 63.5 mmol) over 5 minutes. Upon
completion
the reaction was quenched by addition of water (50 mL), washed with saturated
aqueous NaC1 solution, dried (Na2SO4), filtered and concentrated. The residue
was
purified by column chromatography (SiO2, 4:1, Hex:Et0Ac) to afford triflate 3
as a
yellow oil (8.4g, 23.6 mmol, 48%). Immediately used in Suzuki coupling
reactions.
44
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
[00227] Example 6. General procedure for Suzuki coupling reaction of
triflate 3 and boronic acids 2a¨p:
[00228] 5-(benzyloxy)-[1,1'-biphenyl]-2-carbaldehyde (6a): Triflate 5
(0.246
g, 0.68 mmol), phenylboronic acid 2a (92 mg, 0.75 mmol),
tetrakis(triphenylphosphine)palladium(0) (70.4 mg, 0.068 mmol) and K2CO3
(0.169 g,
1.2 mmol) was dissolved in DMF (6.8 mL) under argon atmosphere in a sealed
tube.
The resulting reaction mixture was sealed and heated to reflux for 16 h. The
reaction
was cooled to RT, quenched with saturated sodium bicarbonate, extracted with
Et0Ac
(3 x 5 mL), washed with saturated aqueous sodium chloride, dried over
anhydrous
Na2SO4, filtered and concentrated. The crude product was purified by column
chromatography (SiO2, 3:1, Hex:Et0Ac) to afford 6a (0.16 g, 0.56 mmol, 82%) as
an
amorphous solid. 'H NMR (400 MHz, CDC13) 8 9.90 (s, 111), 8.08 (d, J= 8.7 Hz,
1H),
7.55 ¨7.34 (m, 10H), 7.11 (d, J= 8.7 Hz, 1H), 7.0 3 (d, J= 2.4 Hz, 1H), 5.19
(s, 2H);
13C NMR (100 MHz, CDC13) 8 191.2, 162.8, 148.6, 137.8, 136.0, 130.0, 128.8,
128.4,
127.6, 116.3, 114.7, 70.4; HRMS (FAB) m/z: [M + Na] for C20H1602Na, calcd,
311.1042; found, 311.1046.
[00229] 5-(benzyloxy)-3'-fluoro-[1,1'-bipheny11-2-carbaldehyde (6b):
Using
3-flourophenylboronic acid. 'H NMR (500 MHz, CDC13) 8 9.85 (d, J= 0.7 Hz, 1H),
8.03 (d, J= 8.7 Hz, 1H), 7.49 ¨ 7.33 (m, 6H), 7.20 ¨ 7.13 (m, 2H), 7.13 ¨7.08
(m, 2H),
7.03 (d, J= 2.5 Hz, 1H), 5.15 (s, 2H); 13C NMR (125 MHz, CDC13) 6 190.7,
162.9,
161.7, 147.2, 140.1, 136.0, 130.5, 129.0, 128.6, 127.8, 126.0, 117.1, 116.9,
116.4,
115.5, 115.1, 70.6; HRMS m/z: [M + Na] for C20Hi5FO2Na, calcd, 329.0948;
found,
329.0952.
[00230] 5-(benzyloxy)-4'-fluoro-[1,1'-biphenyl]-2-carbaldehyde (6c):
Using
4-Flourophenylboronic acid. 'H NMR (400 MHz, CDC13) 6 9.84 (s, 1H), 8.06 (dd,
J=
8.7, 1.0 Hz, 111), 7.49 ¨ 7.40 (m, 4H), 7.40 ¨ 7.32 (m, 3H), 7.21 ¨7.13 (m,
211), 7.12 ¨
7.06 (dd, J= 8.0, 2.5 Hz, 1H), 7.03 (d, J= 2.2 Hz, 1H), 5.17 (s, 2H); 13C NMR
(100
MHz, CDC13) 6 190.9, 162.8, 147.4, 136.0, 131.7, 131.6, 130.5, 128.8, 128.5,
127.7,
127.6, 116.5, 115.6, 115.4, 114.7, 70.4; HRMS m/z: [M + Nat] for C20Hi5F02Na,
calcd,
329.0948; found, 329.0944.
[00231] 5-(benzyloxy)-2'-chloro-[1,1'-biphenyl]-2-carbaldehyde (6d):
Using
2-Chlorophenylboronic acid. 'H NMR (500 MHz, CDC13) 6 9.70 (s, 1H), 8.08 (d,
J=
8.7 Hz, 111), 7.55 ¨7.49 (m, 1H), 7.49 ¨ 7.32 (m, 8H), 7.17 ¨ 7.12 (dd, J=
8.6, 2.5 Hz,
1H), 6.99 (d, J= 2.6 Hz, 1H), 5.16 (s, 211); 13C NMR (125 MHz, CDC13) 6 190.3,
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
162.9, 145.1, 136.8, 135.9, 133.5, 131.6, 130.0, 129.8, 129.6, 128.8, 128.4,
127.6,
127.6, 126.9, 116.7, 115.1, 70.4; FIRMS m/z: [M + Na] for C2oHi5C102Na, calcd,
345.0658; found, 345.0653.
[00232] 5-(benzy1oxy)-3'-chloro-[1,1'-bipheny11-2-carbaldehyde (6e):
Using
3-Chlorophenylboronic acid. 1H NMR (400 MHz, CDC13) 8 9.85 (s, 1H), 8.04 (d,
J=
8.7 Hz, 111), 7.49 ¨ 7.33 (m, 8H), 7.26 (m, 1H), 7.13 ¨7.07 (dd, J= 8.3, 2.8
Hz, 1H),
6.96 (d, J= 2.5 Hz, 111), 5.17 (s, 2H); 13C NMR (100 MHz, CDC13) 6 190.4,
162.8,
146.8, 139.7, 135.9, 134.5, 130.5, 129.8, 129.7, 128.8, 128.5, 128.4, 128.3,
127.6,
127.5, 116.3, 115.0, 70.4; HRMS m/z: [M + Cr] for C20Hi5C1202, calcd,
341.0505;
found, 341.0508.
[00233] 5-(benzyloxy)-3'-(trifluoromethy1)41,1'-bipheny11-2-carbaldehyde
(60: Using 3-(Trifluoromethyl)phenylboronic acid. 'H NMR (400 MHz, CDC13) 8
9.82
(s, 1H), 8.05 (m, 1H), 7.72 (m, 1H), 7.67 ¨ 7.64 (td, J= 1.6, 0.8 Hz, 1H),
7.64 ¨ 7.53
(m, 2H), 7.50 ¨ 7.35 (m, 5H), 7.15 ¨7.11 (dd, J= 8.7, 2.2 Hz, 111), 6.96 (d,
J= 2.5 Hz,
1H), 5.19 (s, 2H); 13C NMR (100 MHz, CDC13) 8 190.4, 163.0, 146.8, 138.8,
135.9,
133.4, 131.0, 130.9, 129.0, 129.0, 128.6, 127.8, 127.6, 126.6, 126.5, 125.2,
116.7,
115.2, 70.6; HRMS m/z: [M + Nat] for C211-115F302Na, calcd, 379.0922; found,
379.0926.
[00234] 5-(benzyloxy)-4'-(trifluoromethy1)41,1'-biphenyl]-2-carbaldehyde
(6g): Using 4-(Trifluoromethyl)phenylboronic acid. 'H NMR (400 MHz, CDC13) 8
9.84
(s, 111), 8.06 (d, J= 8.7 Hz, 111), 7.75 (d, J= 8.0 Hz, 2H), 7.55 ¨7.49 (m,
211), 7.49 ¨
7.34 (m, 6H), 7.17 ¨ 7.12 (dd, J= 9.1, 2.2 Hz, 111), 6.98 (d, J= 2.5 Hz, 1H),
5.19 (s,
2H); 13C NMR (100 MHz, CDC13) 6 190.2, 162.9, 146.7, 141.7, 135.9, 130.8,
130.3,
128.9, 128.6, 127.7, 127.5, 125.5, 125.4, 122.8, 116.6, 115.1, 70.5; HRMS m/z:
[M+
H+] for C2111i6F302, calcd, 357.1097; found, 357.1096.
[00235] 5-(benzy1oxy)-2'-(methylthio)-11,1'-bipheny1]-2-carbaldehyde
(6h):
Using 2-(Methylthio)phenylboronic acid. 'H NMR (400 MHz, CDC13) 6 9.62 (s,
1H),
8.05 (d, J= 8.7 Hz, 1H), 7.47 ¨ 7.32 (m, 611), 7.30 ¨ 7.23 (m, 2H), 7.24 ¨
7.20 (m, 1H),
7.13 ¨7.09 (m, 1H), 6.93 ¨6.90 (m, 1H), 5.17 (s, 211), 2.36 (d, J= 1.1 Hz,
3H); 13C
NMR (100 MHz, CDC13) 8 190.8, 163., 146.3, 138.4, 136.2, 136.1, 130.4, 129.5,
129.1,
128.8, 128.4, 127.8, 127.7, 124.7, 124.6, 116.4, 115.3, 70.4, 15.6; HRMS m/z:
[M+
H+] for C211-11802SNa, calcd, 357.0920; found, 357.0923.
[00236] 5-(benzyloxy)-2'-methoxy-11,1'-bipheny1]-2-carbaldehyde (6i):
Using
2-Methoxyphenylboronic acid. 'H NMR (500 MHz, CDC13) 6 9.73 (s, 111), 8.07 (d,
J=
46
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
8.7 Hz, 1H), 7.48 ¨ 7.39 (m, 5H), 7.37 (d, J-= 6.5 Hz, 1H), 7.32 ¨ 7.27 (m,
1H), 7.13 ¨
7.07 (m, 2H), 7.02 (d, J= 8.3 Hz, 1H), 6.98¨ 6.95 (dd, J= 2.4, 1.1 Hz, 1H),
5.15 (s,
2H), 3.75 (s, 3H); 13C NMR (125 MHz, CDC13) 8 191.5, 163.1, 156.6, 144.5,
136.2,
131.4, 130.1, 129.2, 128.8, 128.4, 127.9, 127.7, 126.8, 121.0, 116.9, 114.5,
110.8, 70.3,
55.5; HRMS m/z: [M + 11+] for C21141903, calcd, 319.1329; found, 319.1333.
[00237] 5-(benzyloxy)-3'-methoxy-[1,1'-bipheny1]-2-earbaldehyde (6j):
Using
3-Methoxyphenylboronic acid. 'H NMR (400 MHz, CDC13) 8 9.93 (s, 1H), 8.06 (d,
J=
9.0 Hz, 1H), 7.52¨ 7.35 (m, 6H), 7.10 (d, J= 8.6 Hz, 1H), 7.05 ¨6.93 (m, 4H),
5.20 (s,
2H), 3.89 (s, 3H); HRMS m/z: [M + Nat] for C211-11803Na, calcd, 341.1154;
found,
341.1150.
[00238] 5-(benzyloxy)-3'-methyl-[1,1'-bipheny1]-2-earbaldehyde (6k):
Using
3-Methylphenylboronic acid. 'H NMR (500 MHz, CDC13) 8 9.85 (d, J= 0.9 Hz, 1H),
8.03 (d, J= 8.6 Hz, 1H), 7.49 ¨ 7.39 (m, 3H), 7.39 ¨ 7.32 (m, 2H), 7.27 (d, J=
8.1 Hz,
1H), 7.22 ¨ 7.16 (m, 2H), 7.09 ¨ 7.05 (ddd, J= 8.8, 2.6, 0.9 Hz, 1H), 6.98 (d,
J= 2.5
Hz, 1H), 5.15 (s, 2H), 2.43 (s, 3H); 13C NMR (125 MHz, CDC13) 8 191.4, 162.8,
148.9,
138.3, 137.9, 136.2, 130.9, 130.1, 129.2, 128.9, 128.5, 128.5, 127.8, 127.3,
116.3,
114.8, 70.5, 21.7; HRMS m/z: [M + H+1 for C211-11802Na, calcd, 325.1205;
found,
325.1217.
[00239] 5-(benzyloxy)-3'-(morpholinomethy1)41,1'-biphenyl]-2-
carbaldehyde (61): Using 3-(4-Morpholinomethyl)phenylboronic acid pinacol
ester. 'H
NMR (400 MHz, CDC13) 8 9.87 (s, 1H), 8.83 (d, J= 8.7 Hz, 1H), 7.47 ¨ 7.31 (m,
7H),
7.32 ¨7.24 (m, 1H), 7.12¨ 7.04 (dd, J= 8.7, 2.5 Hz, 1H), 7.05 (d, J= 2.5 Hz,
1H),
5.17 (s, 2H), 3.79¨ 3.68 (t, J= 4.6 Hz, 4H), 3.56 (s, 3H), 2.49 (d, J= 6.5 Hz,
4H); 13C
NMR (100 MHz, CDC13) 8 191.0, 162.7, 148.5, 138.3, 137.8, 136.0, 130.7, 130.2,
129.1, 128.8, 128.4, 127.6, 127.6, 116.4, 114.5, 70.4, 67.1, 63.2, 53.7; HRMS
m/z: [M
+ Nal for C25H25NO3Na, calcd, 410.1726; found, 410.1730.
[00240] 5-(benzyloxy)-4'-hydroxy-[1,1'-bipheny1]-2-carbaldehyde (6m):
Used 4-
Hydroxyphenylboronic acid.
[00241] Partially purified biaryl phenol was treated with TBSC1 (1.2 eq.)
and
imidazole (3 eq.) in DCM and stirred for 2 h at RT. After reaction was
completed by
TLC, the resulting reaction mixture was concentrated. The crude product was
purified
by column chromatography (SiO2, 4:1, Hex:Et0Ac) to afford 6m (94%) as an
amorphous solid. 1H NMR (500 MHz, CDC13) 8 9.89 (s, 1H), 8.03 (d, J= 8.7 Hz,
1H),
7.52 ¨7.33 (m, 5H), 7.26 (dd, J= 6.6, 1.8 Hz, 2H), 7.05 (dd, J= 8.7, 2.3 Hz,
1H), 7.02
47
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
¨6.93 (m, 3H), 5.17 (s, 2H), 1.05 (s, 9H), 0.29 (s, 6H); 13C NMR (125 MHz,
CDC13) 8
191.2, 162.7, 156.0, 148.4, 136.1, 131.2, 130.6, 130.0, 128.7, 128.3, 127.6,
127.5,
120.0, 116.1, 114.3, 70.3, 25.7, 18.3, 4.3; ESI-HRMS m/z: [M + Nar for
C26H30Na03Si, calcd, 441.5899, found 441.5896.
[00242] 2-(benzo [d] 11,3]dioxo1-5-y1)-4-(benzyloxy)benzaldehyde (6n):
Using
3,4-(Methylenedioxy)phenylboronic acid. 11-INMR (500 MHz, CDC13) 8 9.90 (s,
1H),
8.08 (d, J= 8.7 Hz, 1H), 7.48 ¨7.39 (m, 4H), 7.39 ¨ 7.35 (m, 1H), 7.06 (d, J=
8.6 Hz,
1H), 6.97 (d, J= 2.5 Hz, 1H), 6.91 ¨6.86 (m, 2H), 6.83 ¨6.79 (m, 1H), 6.03 (s,
2H),
5.15 (s, 2H); 13C NMR (125 MHz, CDC13) 8 191.2, 162.8, 148.2, 147.9, 147.9,
136.1,
131.6, 130.2, 128.8, 128.4, 127.7, 127.6, 124.0, 116.2, 114.5, 110.3, 108.3,
101.5, 70.4;
HRMS (FAB) m/z: [M + Na] for C2IF11604Na, calcd, 355.0941; found, 355.0935.
[00243] 4-(benzyloxy)-2-(pyridin-3-yl)benzaldehyde (60): 11-INMR (400
MHz, CDC13) 8 9.79 (s, 1H), 8.65 (dd, 2H, J= 5.1, 8.3 Hz), 8.01 (d, 1H, J= 8.8
Hz),
7.67 (m, 1H), 7.48-7.26 (m, 6H), 7.09 (dd, 1H, J= 2.4, 8.7 Hz), 6.93 (d, 1H,
J= 2.4
Hz), 5.14 (s, 2H); 13C NMR (125 MHz, CDC13) 6 187.8, 165.3, 160.5, 135.8,
131.2,
129.0, 128.7, 127.8, 120.0, 109.5, 102.1, 91.0, 70.8; HRMS (FAB) m/z: [M + H]
for
C19Hi6NO2, calcd, 290.1181; found, 290.1177.
[00244] 4-(benzyloxy)-2-(pyridin-4-yl)benzaldehyde (6p): 1H NMR (500
MHz, CDC13) 8 9.82 (s, 1H), 8.67 (d, J= 5.9 Hz, 2H), 8.02 (d, J= 8.7 Hz, 1H),
7.49-
7.33 (m, 6H), 7.30 (d, J= 6.0 Hz, 1H), 7.15-7.10 (dd, J= 8.6, 2.6 Hz, 1H),
6.95 (d, J=
2.6 Hz, 1H), 5.15 (s, 2H); 13C NMR (125 MHz, CDC13) 8 189.7, 162.9, 149.8,
145.8,
145.2, 135.7, 131.0, 128.8, 128.5, 127.6, 127.1, 124.6, 116.3, 115.4, 70.5;
HRMS
(FAB) m/z: [M + Hl for C191-116NO2, calcd, 290.1181; found, 290.1183.
[00245] Example 7. General procedure for Henry Reaction of compounds
6a¨p:
[00246] (E)-5-(benzyloxy)-2-(2-nitroviny1)-1,1'-biphenyl (7a):
Nitromethane
(1.4 mL) was added to a mixture of aldehyde 6a (0.16g, 0.56mmo1) and ammonium
acetate (77mg, 1.0mmol) and heated to 50 C. Upon completion (-15-30 min), the
reaction mixture was cooled to RT and purified without work-up by column
chromatography (SiO2, 3:1, Hex:Et0Ac) to afford nitrostyrene 7a as a yellow
oil (182
mg, 0.55 mmol, 98%). 1H NMR (400 MHz, CDC13) 6 8.02 (d, J= 13.6 Hz, 1H), 7.64
(d, J= 9.5 Hz, 1H), 7.50 ¨ 7.35 (m, 10H), 7.31(d, J= 2.1 Hz, 2H), 7.04 (d, J=
2.5 Hz,
1H), 5.15 (s, 2H); 13C NMR (100 MHz, CDC13) 6 161.8, 146.1, 138.1, 136.4,
136.3,
48
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
135.5, 131.8 131.7, 129.9, 129.2, 128.8, 128.0, 121.3, 117.3, 116.3, 116.0,
115.6, 70.7;
HRMS (FAB) m/z: [M+Na] for C21E1181\103, calcd, 332.1281; found, 332.1290.
[00247] (E)-5-(benzyloxy)-3'-fluoro-2-(2-nitroviny1)-1,1'-biphenyl (7b):
1H
NMR (400 MHz, CDC13) 6 8.07 (d, J= 13.5 Hz, 111), 7.65 (d, J= 8.7 Hz, 1H),
7.49 ¨
7.35 (m, 7H), 7.20 ¨ 7.13 (ddd,J= 9.3, 7.9, 2.6 Hz, 111), 7.09¨ 7.03 (m, 211),
7.02 (d, J
= 2.8 Hz, 2H), 5.16 (s, 2H); 13C NMR (100 MHz, CDC13) 6 164.0, 161.5, 145.4,
141.4,
137,6, 136.1, 136.0, 130.5, 130.4, 129.6, 128.6, 127.7, 125.7, 121.0, 116.9,
116.6,
115.6, 115.4, 70.5; HRMS m/z: [M + H+] for C21HNFN03, calcd, 350.1187; found,
350.1185.
[00248] (E)-5-(benzyloxy)-4'-fluoro-2-(2-nitrovinyI)-1,1'-biphenyl (7c):
1H
NMR (400 MHz, CDC13) 6 8.08 (d, J= 13.6 Hz, 111), 7.64 (d, J= 8.7 Hz, 1H),
7.50 ¨
7.34 (m, 611), 7.32 ¨ 7.24 (m, 211), 7.23 ¨7.14 (t, J= 8.3 Hz, 211), 7.10 ¨
7.00 (m, 211),
5.17 (s, 2H); 13C NMR (100 MHz, CDC13) 6 161.5, 145.7, 137.8, 136.1, 136.0,
131.5,
131.4, 129.6, 128.9, 128.5, 127.7, 121.0, 117.0, 115.9, 115.7, 115.3, 70.4;
HRMS m/z:
[M + Nat] for C21H16FNO3Na, calcd, 372.1006; found, 372.1011.
[00249] (E)-5-(benzyloxy)-2'-chloro-2-(2-nitroviny1)-1,1'-biphenyl (7d):
1H
NMR (500 MHz, CDC13) 6 7.85 ¨ 7.75 (m, 111), 7.74 ¨ 7.66 (m, 1H), 7.55 (m,
1H),
7.53 ¨ 7.34 (m, 8H), 7.31 (d, J= 5.3 Hz, 111), 7.17 (d, J= 8.3 Hz, 111), 7.01
(t, J= 2.0
Hz, 1H), 5.20 ¨ 5.11 (m, 2H); 13C NMR (125 MHz, CDC13) 6 161.4, 143.8, 137.7,
137.0, 135.9, 133.2, 131.4, 130.0, 130.0, 129.3, 128.7, 128.3, 127.6, 127.1,
123.4,
121.5, 117.1, 115.6, 70.3; HRMS m/z: [M + H+] for C21Hi7C1NO3, calcd,
366.0892;
found, 366.0895.
[00250] 5-(benzyloxy)-3'-chloro-2-(2-nitroviny1)-1,1'-biphenyl (7e): 1H
NMR
(400 MHz, CDC13) 6 7.95 (d, J= 13.5 Hz, 111), 7.64 (d, J= 8.8 Hz, 1H), 7.50 ¨
7.36
(m, 8H), 7.33 (s, Hi), 7.18 (d, J= 7.0 Hz, 111), 7.09 ¨ 7.04 (m, 1H), 7.00 (d,
J= 2.6 Hz,
1H), 5.17 (s, 2H); 13C NMR (125 MHz, CDC13) 6 145.1, 141.1, 140.9, 137.4,
136.1,
134.7, 129.9, 129.6, 129.6, 129.5, 129.0, 128.8, 128.5, 128.4, 128,0, 127.6,
120.9,
116.9, 115.5, 109.9, 70.4; HRMS m/z: [M + Cr] for C2111i6C12NO3, calcd,
400.0513;
found, 400.0505.
[00251] (E)-5-(benzyloxy)-2-(2-nitroviny1)-3'-(trifluoromethyl)-1,1'-
biphenyl
(7f): IFINMR (400 MHz, CDC13) 6 7.90 (d, J= 13.5 Hz, 1H), 7.78 ¨ 7.70 (m,
111),
7.69 ¨ 7.55 (m, 3H), 7.51 ¨7.34 (m, 7H), 7.13 ¨7.05 (dd, J= 8.8, 2.6 Hz, 1H),
7.02 (d,
J= 2.6 Hz, 1H), 5.17 (s, 2H); 13C NMR (100 MHz, CDC13) 6 161.6, 155.7, 152.1,
145.1, 140.6, 140.0, 137.2, 136.4, 136.0, 133.2, 129.7, 129.3, 129.0, 128.6,
127.7,
49
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
121.0, 117.1, 115.8, 70.6; HRMS m/z: [M + H+] for C22H17F3NO3, calcd,
400.1161;
found, 400.1157.
[00252] (E)-5-(benzyloxy)-2-(2-nitroviny1)-4'-(trifluoromethyl)-1,1'-
biphenyl
(7g): Pushed through plug of SiO2. TS1-189: 1H NMR (400 MHz, CDC13) 8 7.98 ¨
7.90 (m, 111), 7.80 (d, J= 8.0 Hz, 2H), 7.68 (d, J= 8.8 Hz, 1H), 7.52 ¨7.37
(m, 8H),
7.11 (d, J= 8.8 Hz, 1H), 7.04 (s, 1H), 5.19 (s, 2H); 13C NMR (100 MHz, CDC13)
8
161.4, 147.8, 144.9, 144.3, 139.8, 138.6, 137.1, 136.4, 135.8, 133.5, 131.2,
129.5,
129.1, 128.8, 128.5, 127.6, 124.2, 120.8, 120.4, 117.0, 115.6, 70.4; HRMS m/z:
[M+
fl+] for C22Hi7F3NO3, calcd, 400.1155; found, 400.1151.
[00253] (E)-(5'-(benzyloxy)-2'-(2-nitroviny1)-[1,1'-biphenyl]-2-
y1)(methyl)sulfane (7h): 11-INMR (400 MHz, CDC13) 8 7.71 (d, J= 13.6 Hz, 1H),
7.62
(d, J= 8.6 Hz, 1H), 7.45 ¨ 7.31 (m, 7H), 7.31 ¨7.29 (m, 1H), 7.25 ¨7.19 (t, J=
7.2 Hz,
1H), 7.13 ¨6.99 (m, 2H), 6.95 (d, J= 2.8 Hz, 1H), 5.09 (s, 2H), 2.35 (s, 3H);
13C NMR
(100 MHz, CDC13) 8 161.5, 144.9, 138.0, 137.5, 137.2, 136.1, 135.7, 130.0,
129.4,
129.3, 128.8, 128.4, 127.7, 125.0, 124.9, 121.6, 117.0, 115.8, 70.3, 15.6;
HRMS m/z:
[M + K4] for C221119NO3SK, calcd, 416.0718; found, 416.0756.
[00254] (E)-5-(benzyloxy)-2'-methoxy-2-(2-nitroviny1)-1,1'-biphenyl (7i):
1H
NMR (500 MHz, CDC13) 8 7.86 (d, J= 13.8 Hz, 1H), 7.65 (d, J= 8.7 Hz, 1H), 7.57
¨
7.34 (m, 7H), 7.24 ¨ 7.17 (m, 111), 7.16 ¨ 6.99 (m, 4H), 5.15 (s, 2H), 3.74
(s, 3H); 13C
NMR (125 MHz, CDC13) 8 161.6, 156.4, 143.7, 138.8, 136.3, 135.3, 131.4, 130.4,
128.9, 128.4, 127.7, 122.0, 121.1, 117.5, 115.1, 111.4, 70.4, 55.6; HRMS m/z:
[M+
H+] for C221-119N04, calcd, 362.1387; found, 362.1389.
[00255] (E)-5-(benzyloxy)-3'-methoxy-2-(2-nitroviny1)-1,1'-biphenyl (7j):
1H
NMR (500 MHz, CDC13) 8 8.04 (d, J= 13.6 Hz, 1H), 7.62 (d, J= 9.5 Hz, 1H), 7.46
¨
7.37 (m, 6H), 7.07 ¨ 7.02 (m, 3H), 7.02 ¨6.97 (ddd, J= 8.2, 2.6, 0.9 Hz, 1H),
6.88 ¨
6.84 (m, 1H), 6.84 ¨ 6.80 (dd, J= 2.6, 1.6 Hz, 1H), 5.15 (s, 2H), 3.85 (s,
3H); 13C NMR
(125 MHz, CDC13) 8 161.5, 159.8, 146.8, 140.6, 138.2, 136.2, 135.9, 129.9,
129.5,
129.0, 128.6, 127.7, 122.3, 121.1, 116.8, 115.4, 115.4, 114.1, 70.5, 55.6;
HRMS m/z:
[M + Nat] for C221119NO4Na, 384.1212; found, 384.1218.
[00256] (E)-5-(benzyloxy)-3'-methy1-2-(2-nitroviny1)-1,1'-biphenyl (7k):
1H
NMR (500 MHz, CDC13) 8 8.01 (d, J= 13.6 Hz, 1H), 7.62 (m, 1H), 7.48 ¨ 7.39 (m,
7H), 7.39 ¨ 7.33 (t, J=7.7 Hz, 1H), 7.14¨ 7.07 (m, 2H), 7.05 ¨6.99 (m, 2H),
5.15 (s,
2H), 2.43 (s, 3H); 13C NMR (125 MHz, CDC13) 8 138.4, 135.8, 130.4, 129.5,
129.3,
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
128.9, 128.7, 128.5, 127.8, 127.8, 126.9, 121.1, 116.8, 115.3, 77.5, 77.4,
77.2, 77.0,
70.5 21.7; HRMS m/z: [M + Nal for C221119NO3Na1cd, 368.1263; found, 368.1257.
[00257] (E)-4-45'-(benzyloxy)-2'-(2-nitroviny1)-[1,1'-biphenyl]-3-
yl)methyl)morpholine (71): 1H NMR (400 MHz, CDC13) 5 7.98 (d, J= 13.6 Hz, 1H),
7.63 (d, 1= 9.5 Hz, 1H), 7.48 ¨ 7.33 (m, 8H), 7.33 (d, J= 1.7 Hz, 1H), 7.23
¨7.20 (dd,
J= 6.7, 1.8 Hz, 1H), 7.08 ¨ 6.99 (m, 2H), 5.15 (d, J= 1.6 Hz, 2H), 3.79 ¨ 3.67
(t, J=
4.1 Hz, 4H), 3.56 (s, 2H), 2.55 ¨2.40 (dd, J= 5.7, 3.4 Hz, 4H); 13C NMR (100
MHz,
CDC13) 5 161.5, 146.9, 139.2, 138.5, 138.1, 136.1, 135.8, 130.6, 129.5, 129.3,
128.9,
128.8, 128.5, 128.4, 127.7, 121.0, 116.9, 115.1, 70.4, 67.1, 63.3, 53.8; HRMS
m/z: [M
+ Hl for C26H27N204, calcd, 431.1971; found, 431.1974.
[00258] (E)-((5'-(benzyloxy)-2'-(2-nitroviny1)41,11-biphenyl]-4-
yDoxy)(tert-
butyl)dimethylsilane (7m): 1H NMR (400 MHz, CDC13) 5 8.03 (d, J= 13.7 Hz, 1H),
7.61 (d, J= 8.3 Hz, 1H), 7.49 ¨ 7.33 (m, 6H), 7.17 (d, J= 8.4 Hz, 2H), 7.02
(s, 2H),
6.95 (d, J= 8.5 Hz, 2H), 5.15 (s, 2H), 1.04 (s, 9H), 0.30 (s, 6H); 13C NMR
(100 MHz,
CDC13) 5 161.5, 156.2, 146.8, 138.5, 136.2, 135.8, 132.2, 131.0, 129.6, 128.9,
128.5,
127.7, 121.1, 120.4, 116.8, 115.0, 70.4, 25.9, 18.4, -4.1; HRMS (FAB) m/z: [M
+Nal
for C27H3INO4SiNa, calcd, 484.1914; found, 484.1936.
[00259] (E)-5-(5-(benzyloxy)-2-(2-nitrovinyl)phenyl)benzo [d] [1,3] dio
xo le
(7n): 1H NMR (400 MHz, CDC13) 5 8.03 (d, J= 13.6 Hz, 1H), 7.59 (d, J= 8.0 Hz,
1H),
7.50 ¨ 7.33 (m, 6H), 7.05 ¨6.98 (m, 2H), 6.92 ¨6.85 (m, 1H), 6.79 (s, 1H),
6.71(d, J-
7.9 Hz, 1H), 6.03 (s, 2H), 5.17 (s, 2H); 13C NMR (100 MHz, CDC13) 5 161.4,
148.0,
147.9, 146.5, 138.1, 136.1, 135.7, 132.9, 129.5, 128.8, 128.4, 127.6, 123.6,
121.0,
116.7, 115.0, 109.9, 108.5, 101.5, 70.3; HRMS (FAB) m/z: [M + Hl for
C221118N05,
calcd, 376.1185; found, 376.1160.
[00260] (E)-3-(5-(benzyloxy)-2-(2-nitrovinyl)phenyl)pyridine (7o): 1H NMR
(400 MHz, CDC13) 5 8.70 (dd, J= 4.8, 1.6 Hz, 1H), 8.59 (d, J= 1.6 Hz, 1H),
7.89 (d, J
= 13.5 Hz, 1H), 7.68 ¨ 7.60 (m, 2H), 7.47 ¨ 7.32 (m, 8H), 7.12 ¨ 7.06 (dd, J=
8.7, 2.5
Hz, 1H), 7.00 (d, J= 2.6 Hz, 1H), 5.15 (s, 2H); 13C NMR (100 MHz, CDC13) 5
161.5,
149.9, 149.6, 142.8, 136.9, 136.8, 136.3, 135.8, 134.8, 129.7, 128.8, 128.5,
127.6,
123.4, 121.1, 117.1, 115.8, 70.4; HRMS (FAB) m/z: [M + Na] for C20H17N203,
333.1239; found, 333.1234.
[00261] (E)-4-(5-(benzyloxy)-2-(2-nitrovinyl)phenyl)pyridine (7p): 1H NMR
(500 MHz, CDC13) 6 8.74 (dd, 2H, J= 1.6, 4.4 Hz), 7.91 (d, 1H, J= 13.6 Hz),
7.67 (d,
1H, J= 8.8 Hz), 7.48 (d, 1H, J= 13.4 Hz), 7.41 (m, 5H), 7.25 (dd, 2H, J= 1.6,
4.4 Hz),
51
7.11 (dd, 1H, 1= 2.6, 8.7 Hz), 7.01 (d, 1H, J= 2.5 Hz), 5.17 (s, 211); 13C NMR
(125
MHz, CDC13) 8 161.2, 150.2, 147.0, 143.7, 136.7, 136.6, 135.8, 128.9, 127.6,
124.5,
120.7, 116.8, 116.1, 70.6; ESI-HRMS m/z calculated for C20Hi7N203 [M +
333.1239, found 333.1249.
[00262] Example 8. General procedure for preparation of 8a-p from 7a-
p:
[00263] N-(2-(5-(benzyloxy)41,1'-bipbenyll-2-y1)ethy1)acetamide (8a):
Nitrostyrene 7a (182 mg, 0.55 mmol) in THF (0.7 mL) was added dropwise to a
solution of Lithiumaluminium hydride (42 mg, 1.12 mmol) in THF (2 mL) under
organ
atmosphere at RT. Upon completion (nearly immediately) the reaction was
quenched
by the addition of water (42 124 3M NaOH (42 lL), and water (84 'IL). The
resulted
FM
mixture was filtered through a plug of celite, washed with DCM, and dried over
K2CO3. Upon filtration the mixture was concentrated to oil and used without
further
purification. Acetic anhydride (58 4, 0.62 mmol) and triethylamine (93 1.1.L,
0.67
mmol) were added to a solution of the crude amine in DCM (5.6 mL) under an
organ
atmosphere at RT. After 3 h the reaction was quenched with saturated aqueous
ammonium chloride and extracted with DCM (3 x 10 mL); combined organic
fractions
were washed with saturated aqueous sodiumchloride, dried over Na2SO4, filtered
and
concentrated. The residue was purified by column chromatography (SiO2; 3:1,
Hex:Et0Ac) to afford acetamide 8a (0.12 g, 0.35 mmol, 64%). II-1 NMR (400 MHz,
CDC13) 8 7.50 -7.38 (m, 811), 7.38 - 7.30 (m, 211), 7.23 (d, J= 8.4 Hz, 111),
7.01 -
6.95 (dd, J= 8.4, 2.7 Hz, 1H), 6.93 (d, J= 2.7 Hz, 1H), 5.71 (br s, NH), 5.08
(s, 2H),
3.42 - 3.16 (q, J= 7.0 Hz, 211), 2.89 - 2.64 (t, J= 7.2 Hz, 211), 1.85 (s,
3H); 13C NMR
(100 MHz, CDC13) 8 170.2, 157.2, 143.4, 141.4, 137.0, 130.8, 129.1, 128.7,
128.6,
128.4, 128.0, 127.6, 127.2, 116.6, 114.2, 70.1, 40.7, 31.9, 23.2; HRMS m/z: [M
+ K41
for C23H23NO2K calcd, 384.1361; found, 384.1359.
[00264] N-(2-(5-(benzyloxy)-3'-fluoro-[1,1'-bipheny1]-2-
yl)ethyl)acetamide
(8b): 'H NMR (400 MHz, CDC13) 8 7.48 - 7.30 (m, 611), 7.24 -7.18 (d, J= 8.4
Hz,
1H), 7.12- 7.04 (m, 211), 7.04 - 6.92 (ddd, J= 18.6, 8.2, 2.5 Hz, 211), 6.85
(d, J= 2.7
Hz, 1H), 5.34 (br s, NH), 5.05 (s, 211), 3.32 - 3.21 (q, J= 6.4, 5.9 Hz, 211),
2.79 - 2.68
(t, J-= 7.1 Hz, 211), 1.86 (s, 311); 13C NMR (100 MHz, CDC13) 8170.3, 157.3,
143.7,
142.2, 136.9, 131.0, 130.1, 123.0, 128.8, 128.6, 128.2, 127.7, 125.0, 116.5,
116.4,
114.6, 114.4, 70,2, 40.8, 32.0, 23.3; HRMS m/z: [M + H-1 for C23H23FN02,
calcd,
364.1713; found, 364.1705.
52
CA 2866814 2019-06-20
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
[00265] N-(2-(5-(benzyloxy)-4'-fluoro-[1,1'-bipheny1]-2-ypethyl)acetamide
(8c): NMR (400 MHz, CDC13) 8 7.44 -7.31 (m, 6H), 7.27 -7.22 (dd, J= 8.4,
5.5
Hz, 1H), 7.21 -7.17 (d, J= 8.4 Hz, 111), 7.12 -7.05 (m, 3H), 6.96 - 6.91 (dd,
J= 8.3,
3.0 Hz, 1H), 5.83 (br s, NH), 5.05 (s, 2H), 3.33 - 3.15 (q, J= 6.7 Hz, 2H),
2.78 -2.66
(t, J= 7.2 Hz, 2H), 1.87 (s, 3H); 13C NMR (100 MHz, CDC13) ö 170.5, 157.3,
142.4,
137.0, 130.9, 130.8, 130.7, 128.7, 128.7, 128.2, 127.7, 116.8, 115.5, 115.3,
114.3, 70.2,
40.8, 32.0, 23.1; HRMS m/z: [M + Nat] for C23H22FNO2Na, calcd, 386.1527;
found,
386.1529.
[00266] N-(2-(5-(benzyloxy)-2'-chloro-[1,1`-bipheny1]-2-
yl)ethyl)acetamide
(8d): NMR (500 MHz, CDC13) 8 7.52 - 7.45 (m, 1H), 7.45 - 7.40 (m, 2H), 7.40 -
7.35 (m, 3H), 7.35 -7.29 (m, 3H), 7.25 -7.21 (m, 1H), 7.05 -6.95 (dd, J= 8.5,
2.8
Hz, 1H), 6.82 (d, J.-- 2.7 Hz, 1H), 5.93 (d, J= 5.4 Hz, 1H), 5.05 (s, 2H),
3.36 - 3.19
(ddq, J= 19.3, 13.0, 6.1 Hz, 2H), 2.67 - 2.49 (m, 2H), 1.93 (s, 3H); 13C NMR
(125
MHz, CDC13) 8 175.7, 171.0, 157.1, 140.4, 139.8, 136.9, 133.1, 131.3, 130.4,
129.6,
129.0, 128.6, 128.0, 127.6, 126.8, 116.4, 114.9, 70.1, 40.3, 31.8, 22.9; HRMS
m/z: [M
+ Hi for C23H23C1NO2, calcd, 380.1417; found, 380.1415.
[00267] N-(2-(5-(benzyloxy)-3'-chloro-[1,1'-bipheny1]-2-
yl)ethyl)acetamide
(8e): 'H NMR (500 MHz, CDC13) 8 7.47 - 7.28 (m, 8H), 7.25 -7.17 (m, 2H), 6.99 -
6.92 (dd, J= 8.5, 2.7 Hz, 1H), 6.84 (d, J= 2.8 Hz, 1H), 5.46 (br s, NH), 5.06
(s, 2H),
3.34- 3.25 (m, 2H), 2.83 -2.68 (t, J= 7.3 Hz, 2H), 2.03 (s, 3H); 13C NMR (125
MHz,
CDC13) 8 171.6, 157.5, 143.2, 142.1, 136.9, 134.3, 131.1, 129.9 129.3, 128.8,
128.3,
127.7, 127.6, 127.5, 116.7, 114.8, 70.3, 46.1, 41.3, 31.7, 22.5, 8.8; HRMS
m/z: [M +
Hi for C23H23C1NO2, calcd, 380.1412; found, 380.1414.
[00268] N-(2-(5-(benzyloxy)-3'-(trifluoromethyl)-11,1`-biphenyl]-2-
yl)ethyl)acetamide (80: 1H NMR (400 MHz, CDC13) 8 7.64 (d, J= 7.7 Hz, 1H),
7.59
- 7.54 (m, 2H), 7.55 -7.49 (t, J= 7.3 Hz, 1H), 7.47- 7.32 (m, 5H), 7.24 (d, J=
8.5 Hz,
1H), 7.01 -6.96 (dd, J= 8.5, 2.7 Hz, 1H), 6.87 (d, J= 2.7 Hz, 1H), 5.90 (br s,
NH),
5.06 (s, 2H), 3.34- 3.23 (q, J= 6.9 Hz, 2H), 2.79 -2.68 (t, J= 7.3 Hz, 2H),
1.99 (s,
3H); 13C NMR (100 MHz, CDC13) 8 170.7, 157.4, 142.2, 141.9, 136.9, 132.6,
131.1,
129.0, 128.8, 128.5, 128.2, 127.7, 124.2, 116.7, 114.8, 70.3, 40.8 31.9, 23.0;
HRMS
m/z: [M + H+] for C24H23F3NO2, calcd, 414.1676; found, 414.1681.
[00269] N-(2-(5-(benzyloxy)-4'-(trifluoromethyl)-[1,1'-bipheny1]-2-
yl)ethyl)acetamide (8g): 11-1NMR (400 MHz, CDC13) 8 7.66 (d, J= 8.1 Hz, 2H),
7.46
-7.23 (m, 8H), 6.99 - 6.94 (dd, J= 8.5, 2.7 Hz, 1H), 6.84 (d, J= 2.7 Hz, 1H),
6.03 (t, J
53
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
= 5.5 Hz, 1H), 5.06 (s, 2H), 3.33 -3.19 (dd, J 14.3, 6.4 Hz, 2H), 2.76 -2.68
(dd, J=
8.3, 6.6 Hz, 2H), 1.85 (s, 3H); 13C NMR (100 MHz, CDC13) 8 170.3, 157.1,
145.1,
141.8, 136.8, 130.9, 129.5, 129.1, 128.6, 128.6, 127.5, 125.6, 125.2, 125.2,
122.9,
116.4, 114.6, 70.1, 40.6, 31.9; HRMS m/z: [M + Nat] for C24H22F3NO2Na, calcd,
436.1495; found, 436.1489.
[00270] N-(2-(5-(benzyloxy)-2'-(methylthio)-[1,1'-bipheny1]-2-
yl)ethyl)acetamide (8h): 1H NMR (400 MHz, CDC13) 6 7.48 - 7.30 (m, 7H), 7.28 -
7.18 (m, 2H), 7.14 (s, 1H), 7.03 -6.98 (ddd, J= 8.5, 2.8, 1.0 Hz, 1H), 6.87 -
6.83 (m,
1H), 5.63 (br s, NH), 5.05 (s, 2H), 3.43 - 3.16 (ddt,J= 42.5, 13.3, 6.6 Hz,
2H), 2.66 -
2.52 (t, J= 6.7 Hz, 2H), 2.39 (d, J= 1.0 Hz, 3H), 1.84 (d, J= 1.0 Hz, 3H); 13C
NMR
(100 MHz, CDC13) 6 170.3, 157.3, 141.1, 139.1, 137.6, 137.0, 130.6, 129.8,
129.4,
128.7, 128.4, 128.1, 127.7, 124.5, 124.0, 116.5, 115.2, 70.2, 40.1, 31.7,
23.3, 15.2;
HRMS m/z: [M + Nat] for C24H25NO2SNa, calcd, 414.1504; found, 414.1509.
[00271] N-(2-(5-(benzyloxy)-2'-methoxy-[1,1'-bipheny1]-2-
yl)ethyl)acetamide
(Si): 1H NMR (400 MHz, CDC13) 6 7.47 -7.30 (m, 5H), 7.22 (d, J= 8.5 Hz, 1H),
7.17
-7.13 (dd, J= 7.4, 1.9 Hz, 1H), 7.07 - 6.95 (m, 4H), 6.85 (d, J= 2.7 Hz, 1H),
5.51 (br
s, NH), 5.07 (s, 2H), 3.77 (s, 3H), 3.44 - 3.18 (m, 2H), 2.68 - 2.56 (td, J=
6.8, 3.7 Hz,
2H), 1.86 (s, 3H); 13C NMR (125 MHz, CDC13) 6 170.0, 157.2, 156.4, 139.9,
137.1,
131.2, 130.1, 129.2, 128.7, 128.1, 127.8, 120.9, 116.8, 114.4, 111.2, 70.1,
55.8, 40.4,
31.9, 23.5; HRMS m/z: [M + H4-] for C24H26NO3, calcd, 376.1913; found,
376.1902.
[00272] N-(2-(5-(benzyloxy)-3'-methoxy-[1,1'-bipheny1]-2-
yl)ethyl)acetamide
(8j): 1H NMR (400 MHz, CDC13) 8 7.48 - 7.36 (m, 4H), 7.36 - 7.30 (m, 3H), 7.21
(d, J
= 8.4 Hz, 1H), 6.98 - 6.92 (m, 1H), 6.92 - 6.82 (m, 3H), 5.49 (br s, NH), 5.06
(s, 2H),
3.85 (s, 3H), 3.34 - 3.22 (q, J= 6.6, 6.2 Hz, 2H), 2.85 - 2.68 (t, J= 7.2 Hz,
2H), 1.85
(s, 3H); 13C NMR (100 MHz, CDC13) 6 170.1, 159.5, 157.2, 143.3, 142.9, 137.0,
130.8,
129.5, 128.7, 128.1, 128.1, 127.7, 121.6, 116.5, 114.9,114.3, 112.7, 70.17,
55.4, 40.8,
32.0, 23.3; HRMS m/z: [M + H+] for C24H25NO3Na, calcd, 398.1732; found,
398.1725.
[00273] N-(2-(5-(benzyloxy)-3'-methyl-[1,1'-bipheny1]-2-
yl)ethyl)acetamide
(8k): 'FT NMR (400 MHz, CDC13) 8 7.45 (m, 3H), 7.40 (m, 3H), 7.37 - 7.30 (q,
J=7.7,
7.1 Hz, 1H),7.21 (d, J= 1.4 Hz, 1H), 7.15 - 7.10 (m, 2H), 6.96 (d, J= 8.1 Hz,
1H),
6.90 (s, 1H), 5.51 (br s, NH), 5.08 (s, 2H), 3.34 - 3.24 (q, J= 6.5 Hz, 2H),
2.83 -2.71
(t, J= 7.0 Hz, 2H), 2.41 (s, 3H), 1.84 (s, 3H); 13C NMR (100 MHz, CDC13) 6
170.0,
157.2, 143.5, 141.4, 138.0, 137.0, 130.7, 129.9, 128.7, 128.7, 128.3, 128.1,
128.0,
54
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
127.6, 126.2, 116.5, 114.2, 70.1, 40.8, 31.9, 23.3, 21.6; ESI-HRMS m/z
calculated for
C24H25NO2Na [M + Na] 382.1777, found 382.1770.
[00274] N-(2-(5-(benzyloxy)-3'-(morpholinomethy1)41,1'-biphenyl]-2-
y1)ethyl)acetamide (81): 'H NMR (400 MHz, CDC13) 6 7.47 ¨ 7.30 (m, 7H), 7.28
(s,
1H), 7.24 ¨ 7.18 (m, 2H), 6.98 ¨ 6.93 (dd, J= 8.4, 2.8 Hz, 1H), 6.89 (d, J=
2.7 Hz,
1H), 5.40 (s, 1H), 5.05 (s, 2H), 3.75 ¨3.69 (t, J= 4.7 Hz, 4H), 3.55 (s, 2H),
3.36 ¨ 3.22
(q, J= 6.9 Hz, 2H), 2.80 ¨ 2.68 (t, J= 7.1 Hz, 2H), 2.47 (m, 4H), 1.85 (s,
3H); 13C
NMR (100 MHz, CDC13) 6 170.0, 157.3, 143.4, 141.5, 138.0, 137.1, 130.9, 123.0,
128.7, 128.7, 128.4, 128.2, 128.2, 128.0, 127.7, 116.8, 114.1, 70.2, 67.1,
63.5, 53.8,
40.6, 32.1, 23.4; HRMS m/z: [M + for C28H33N203, calcd, 445.2491; found,
445.2494.
[00275] N-(2-(5-(benzyloxy)-4'-((tert-butyldimethylsilyl)oxy)-11,1'-
bipheny1]-
2-yl)ethypacetamide (8m): 11-1 NMR (500 MHz, CDC13) 6 7.44 (d, J= 7.5 Hz, 3H),
7.42 ¨ 7.36 (dt, J= 10.5, 5.7 Hz, 3H), 7.36 ¨ 7.31 (m, 1H), 7.21 ¨7.14 (m,
3H), 6.94 ¨
6.86 (m, 2H), 5.08 (s, 2H), 3.34 ¨ 3.23 (q, J= 6.7 Hz, 2H), 2.75 (t, J= 7.1
Hz, 211),
1.74 (s, 3H), 1.97 (s, 9H), 0.25 (s, 6H); 13C NMR (125 MHz, CDC13) 6 169.9,
157.3,
155.0, 143.3, 137.2, 134.5, 130.8, 130.2, 128.7, 128.1, 127.7, 120.0, 116.8,
114.0, 70.2,
53.6, 40.7, 32.1, 25.8, 23.4, 18.4, -4.2; HRMS (FAB) m/z: [M + Nat] for
C29H371\103SiNa, calcd, 498.2440; found, 498.2447.
[00276] N-(2-(benzo[d][1,3]dioxo1-5-y1)-4-(benzyloxy)phenethyl)acetamide
(8n): 111 NMR (400 MHz, CDC13) 6 7.49 ¨ 7.36 (m, 5H), 7.34 (d, J= 4.4 Hz, 1H),
7.20
(d, J= 8.3 Hz, 1H), 6.96 ¨6.89 (dd, J= 8.4, 2.8 Hz, 1H), 6.90 ¨ 6.84 (m, 211),
6.81 ¨
6.73 (m, 1H), 6.00 (s, 2H), 5.69 ¨ 5.60 (t, J= 5.8 Hz, 1H), 5.06 (s, 2H),
3.42¨ 3.16 (m,
211), 2.93 ¨2.68 (t, J= 7.3 Hz, 214), 1.87 (s, 3H); 1-3C NMR (100 MHz, CDC13)
6 170.4,
157.2, 147.5, 146.8, 143.0, 137.0, 135.2, 130.8, 129.3, 128.8, 128.1, 127.6,
123.2,
122.4, 116.7, 114.1, 109.7, 108.3, 101.2, 70.1, 40.7, 31.9, 23.2; HRMS (FAB)
m/z: [M
+ Na] for C24H23NO4Na, 412.1519; found, 412.1524.
[00277] N-(4-(benzyloxy)-2-(pyridin-3-yl)phenethyl)acetamide (80): 'H NMR
(400 MHz, CDC13) 6 8.69 ¨8.52 (dd, J= 18.2, 4.0 Hz, 2H), 7.71 ¨7.63 (dt,J=
7.8, 2.0
Hz, 1H), 7.49 ¨ 7.31 (m, 7H), 7.06 ¨ 6.97 (dd, J= 8.5, 2.8 Hz, 1H), 6.84 (d,
J= 2.8 Hz,
111), 5.06 (s, 2H), 3.36¨ 3.20 (q, J= 6.5 Hz, 2H), 2.78 ¨2.67 (dd, J¨ 8.1, 6.6
Hz, 2H),
1.90 (s, 3H); 13C NMR (125 MHz, CDC13) 6 170.1, 157.5, 149.6, 148.5, 139.5,
136.9,
131.2, 129.0, 128.8, 128.3, 127.7, 123.5, 116.9, 115.0, 70.3, 40.7, 32.2,
23.5; HRMS
(FAB) m/z: [M + H+] for C22H23N202, calcd, 347.1759; found, 347.1754.
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
[00278] N-(4-(benzyloxy)-2-(pyridin-4-yl)phenethyl)acetamide (8p): 11-
1NMR
(400 MHz, CDC13) 8 8.66 (d, J= 5.1 Hz, 2H), 7.46 ¨ 7.39 (m, 5H), 7.36 (s, 1H),
7.30
(s, 2H), 7.06¨ 7.01 (m, 1H), 6.84 (d, J= 2.7 Hz, 1H), 5.94 (d, J= 4.8 Hz, 1H),
5.09 (s,
2H), 3.35 ¨3.23 (dd, J= 14.5, 6.4 Hz, 2H), 2.74 (t, J= 7.5 Hz, 2H), 1.90 (s,
3H); 13C
NMR (100 MHz, CDC13) 8 171.4, 158.1, 156.3, 137.2, 132.3, 132.2, 130.8, 128.7,
128.5, 129.7, 127.5, 117.9, 106.2, 103.0, 69.9, 41.1, 29.7, 29.6, 23.1; HRMS
(FAB)
m/z: [M + Na] for C22H22N202Na, calcd, 369.1579; found, 369.1573.
[00279] Example 9. General hydrogenolysis procedure for compounds 8a-p.
[00280] N-(2-(5-hydroxy-[1,1'-bipheny11-2-ypethyl)acetamide (9a):
Palladium
on carbon (10%, 5 mg) was added to 8a (120 mg, 0.35 mmol) in degassed Me0H
(3.5
mL) and the solution was placed under an atmosphere of H2. After 12 h, the
solution
was diluted with DCM and filtered through Celite. The eluent was concentrated
to
afford a yellow solid, which was purified by column chromatography (SiO2,
100:5,
DCM:Me0H) to afford phenol 9a (64 mg, 0.25mmo1, 79%) as a pale yellow
amorphous solid. 111NMR (400 MHz, CDC13) 8 7.25 ¨7.14 (m, 5H), 7.11 ¨7.05 (m,
1H), 6.90 (d, J= 8.3 Hz, 1H), 6.64 (d, J= 8.3 Hz, 1H), 6.59 (d, J= 2.5 Hz,
1H), 5.61 (t,
J= 5.5 Hz, 1H), 3.12¨ 3.02 (m, 2H), 2.55 (t, J= 7.1 Hz, 2H), 1.66 (s, 3H); 13C
NMR
(100 MHz, CDC13) 8 171.2, 155.2, 143.4, 141.6, 130.8, 129.1, 128.4, 127.2,
127.2,
117.4, 115.0, 41.1, 31.8, 23.2; HRMS m/z: [M + Nat] for C161-117NO2Na, calcd,
278.1151; found, 278.1155.
[00281] N-(2-(3'-fluoro-5-hydroxy-[1,1'-biphenyl]-2-ypethypacetamide
(9b):
11-1 NMR (500 MHz, Me0D) 8 7.88 (s, 1H), 7.39 (d, J= 7.5 Hz, 1H), 7.16 ¨ 6.99
(m,
4H), 6.77 (d, J= 8.1 Hz, 1H), 6.62 (d, J= 2.6 Hz, 1H), 3.15 (t, J= 6.6 Hz,
2H), 2.66 (t,
J= 7.4 Hz, 2H), 1.80 (s, 3H); 13C NMR (125 MHz, Me0D) 8 173.1, 164.8, 162.9,
156.7, 145.5, 143.3, 132.0, 131.0, 128.3, 126.1, 117.6, 115.9, 114.7, 41.8,
32.8, 22.5;
HRMS m/z: [M + Na] for Ci6Hi6FNO2Na, calcd, 296.1063; found, 296.1059.
[00282] N-(2-(4'-fluoro-5-hydroxy-[1,1'-biphenyl]-2-ypethypacetamide
(9c):
11-1NMR (400 MHz, Me0D) 8 7.26 ¨ 7.20 (m, 2H), 7.11 ¨7.03 (m, 3H), 6.71 (dd,
J=
8.3, 2.5 Hz, 111), 6.56 (d, J= 2.5 Hz, 1H), 3.07 (t, J= 7.6 Hz, 2H), 2.60 (t,
J= 7.6 Hz,
2H), 1.78 (s, 311); 13C NMR (100 MHz, Me0D) 8 173.0, 156.7, 143.5, 139.2,
131.9,
131.9, 131.8, 128.5, 117.8, 116.0, 115.8, 115.7, 41.8, 32.9, 22.5; HRMS m/z:
[M +
for CI6H16FNO2Na, calcd, 296.1063; found, 296.1065.
[00283] N-(2-(2'-chloro-5-hydroxy-[1,1'-biphenyl]-2-yl)ethyl)acetamide
(9d):
11-1NMR (400 MHz, CDC13) 8 8.37 (br s, OH), 7.45 ¨ 7.39 (m, 1H), 7.32 ¨ 7.24
(m,
56
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
2H), 7.21 ¨7.15 (m, 1H), 7.09 (d, J= 8.3 Hz, 1H), 6.85 (dd, J= 8.3, 2.5 Hz,
1H), 6.68
(d, J= 2.6 Hz, 1H), 5.62 (s, 1H), 3.40 ¨ 3.14 (m, 2H), 2.63 ¨2.44 (dd, J=7.1,
5.1 Hz,
2H), 1.86 (s, 3H); 13C NMR (125 MHz, CDC13) 8 171.1, 155.1, 140.5, 140.0,
133.2,
131.4, 130.5, 129.7, 129.0, 127.7, 126.9, 117.3, 115.7, 40.5,31.8, 23.3; HRMS
m/z: [M
+ Hl for Ci6Hi7C1NO2, 290.0948; found, 290.0941.
[00284] N-(2-(3'-chloro-5-hydroxy-[1,1'-bipheny1]-2-yl)ethyl)acetamide
(9e):
'H NMR (500 MHz, CDC13) 8 7.40-7.09 (m, 5H), 6.83 ¨6.76 (dq, J= 8.1, 4.9, 3.8
Hz,
1H), 6.76 ¨6.67 (dd, J= 18.3, 2.7 Hz, 1H), 3.34 ¨ 3.23 (p, J= 6.6 Hz, 2H),
2.77 ¨ 2.64
(dt, J= 14.3, 7.2 Hz, 2H), 1.76 (s, 3H); 13C NMR (125 MHz, CDC13) 6 170.8,
154.9,
143.6, 141.6, 131.0, 130,9, 129.7, 129.2, 128.5, 127.5, 117.4, 115.5, 115.0,
41.0, 32.0,
23.4; HRMS m/z: [M + Nal for C16H16C1NO2Na, calcd, 312.0762; found, 312.0788.
[00285] N-(2-(5-hydroxy-3'-(trifluoromethy1)41,1'-biphenyl]-2-
yl)ethyl)acetamide (9f): 1FINMR (400 MHz, CDC13) 8 7.64 ¨ 7.39 (m, 4H), 7.07
(s,
1H), 6.82 (s, 1H), 6.73 (s, 1H), 6.00 (s, 1H), 3.34 ¨3.18 (q, J= 6.8 Hz, 2H),
2.66 (t, J=
7.0 Hz, 2H), 1.87 (s, 3H); 13C NMR (100 MHz, CDC13) 6 171.3, 155.4, 142.4,
141.8,
132.6, 131.0, 130.8, 128.9, 126.9, 125.8, 125.8, 124.0, 117.3, 115.6, 60.7,
41.0, 21.2;
HRMS m/z: [M + Na] for Ci7H16F3NO2Na, calcd, 346.1031; found, 346.1040.
[00286] N-(2-(5-hydroxy-4'-(trifluoromethyl)-[1,1'-bipheny1]-2-
ypethypacetamide (9g): 114 NMR (400 MHz, CDC13) 6 7.54 (d, 2H, J= 8.0 Hz),
7.31
(d, 2H, J= 8.0 Hz), 7.03 (d, 1H, J= 8.3 Hz), 6.72 (dd, 1H, J= 2.5, 8.3 Hz),
6.59 (d,
1H, J= 2.5 Hz), 4.09 (br s, 2H), 3.10 (t, J= 7.5 Hz, 2H), 2.56 (t, 2H, J= 7.5
Hz), 1.76
(s, 3H); 13C NMR (100 MHz, CDC13) 8 170.5, 155.1, 146.3, 141.7, 130.8, 129.5,
127.1,
125.1 (q, J= 4.2 Hz), 116.9, 116.5, 115.3, 45.6, 40.6, 23.0; HRMS m/z: [M + 1-
11 for
Ci7H16F3NO2Na, calcd, 346.1031; found, 346.1025.
[00287] N-(2-(5-hydroxy-2'-(methylthio)-[1,1'-bipheny1]-2-
yl)ethyl)acetamide (9h): 'H NMR (500 MHz, CDC13) 8 7.40 ¨ 7.34 (m, 1H), 7.25 ¨
7.14 (m, 3H), 7.12 ¨ 7.07 (m, 1H), 6.86 ¨ 6.82 (dd, J= 8.4, 2.7 Hz, 1H), 6.68
(d, J=
2.7 Hz, 1H), 5.51 (br s, NH), 3.42¨ 3.16 (m, 2H), 2.55 (t, J= 6.8 Hz, 2H),
2.37 (s, 3H),
1.85 (s, 3H); 13C NMR (125 MHz, CDC13) 6 170.5, 154.5, 141.2, 139.1, 137.6,
130.7,
123.0, 128.8, 128.5, 124.6, 124.0, 117.3, 115.6, 40.2, 31.6, 23.4, 15.2; HRMS
m/z: [M
+ Nat] for CI7H19NO2SNa, calcd, 324.1034; found, 324.1035.
[00288] N-(2-(5-hydroxy-2'-methoxy-[1,1'-bipheny1]-2-ypethyl)acetamide
(91): 11-1NMR (400 MHz, CDC13) 8 7.52 (br s, OH), 7.41 ¨7.31 (m, 1H), 7.14 ¨
7.07
(dd, J= 8.4, 6.4 Hz, 1H), 7.05 ¨6.94 (m, 3H), 6.83 ¨6.76 (dd, J= 8.3, 2.7 Hz,
1H),
57
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
6.70 (d, J= 2.7 Hz, 1H), 5.55 (s, 1H), 3.76 (s, 3H), 3.41 -3.17 (ddt, J= 34.4,
13.1, 6.5
Hz, 2H), 2.57 (t, J= 6.9 Hz, 2H), 1.85 (s, 3H); 13C NMR (125 MHz, CDC13) 6
171.0,
156.4, 155.1, 139.9, 131.3, 130.5, 130.1, 129.1, 128.5, 121.0,117.7, 115.2,
111.4, 55.9,
40.7, 31.7, 23.3; HRMS m/z: [M + Na] for Ci7Hi9NO3Na, calcd, 308.1263; found,
308.1264.
[00289] N-(2-(5-hydroxy-3'-methoxy-[1,1'-bipheny11-2-ypethypacetamide
(9j): 'H NMR (400 MHz, CDC13) 6 7.83 (br s, OH), 7.30 - 7.24 (m, 1H), 7.06 (d,
J=
8.2 Hz, 1H), 6.90 - 6.70 (m, 5H), 5.59 (t, J= 5.7 Hz, 1H), 3.79 (s, 3H), 3.33 -
3.19 (q,
J= 6.9 Hz, 2H), 2.69 (t, J= 7.1 Hz, 2H), 1.85 (s, 3H); 13C NMR (100 MHz,
CDC13) 6
171.1, 159.4, 155.1, 143.3, 143.0, 130.9, 129.5, 127.3, 121.7, 117.2, 115.1,
115.0,
112.6, 55.4, 41.1, 31.8, 23.3; HRMS m/z: [M + Hi for Ci7H20NO3, calcd,
286.1443;
found, 286.1436.
[00290] N-(2-(5-hydroxy-3'-methyl-[1,1'-bipheny1]-2-yl)ethyl)acetamide
(9k): 'H NMR (400 MHz, CDC13) 6 7.50 (br s, OH), 7.30 -7.24 (m, 1H), 7.15 (d,
J=
7.6 Hz, 1H), 7.09 -7.03 (m, 3H), 6.80 (d, J= 7.6 Hz, 1H), 6.73 (s, 1H), 5.53
(br s,
NH), 3.31 -3.21 (q, J= 6.7 Hz, 2H), 2.71 (t, J= 7.0 Hz, 2H), 2.37 (s, 3H),
1.85 (s,
3H); 13C NMR (1001 MHz, CDC13) 6 170.9, 155.0, 143.6, 141.6, 138.1, 130.8,
1230.0,
128.3, 128.0, 127.4, 126.3, 117.4, 114.9, 41.1, 31.8, 23.3, 21.7; HRMS m/z: [M
+
for Ci7Hi9NO2Na, calcd, 292.1308; found, 292.1314.
[00291] N-(2-(5-hydroxy-3'-(morpholinomethyl)-[1,1'-bipheny1]-2-
yl)ethyl)acetamide (91): 'H NMR (500 MHz, CDC13) 6 7.36 - 7.23 (m, 4H), 7.16
(d, J
= 7.2 Hz, 1H), 7.07 (d, J= 8.2 Hz, 1H), 6.74 -6.69 (dd, J= 8.2, 2.7 Hz, 1H),
6.62 (d, J
= 2.6 Hz, 1H), 5.50 (br s, NH), 3.74 (m, 4H), 3.53 (s, 3H), 3.29 - 3.20 (q, J=
6.7 Hz,
2H), 2.69 (t, J= 7.0 Hz, 2H), 2.49 (t, J= 4.8 Hz, 4H), 1.87 (s, 3H); 13C NMR
(125
MHz, CDC13) 6 170.5, 155.0, 143.4, 141.7, 130.9, 130.2, 128.4, 128.2, 117.5,
115.0,
66.9, 63.4, 53.8, 40.8, 32.0, 23.4; HRMS m/z: [M + Hi for C211-127N203, calcd,
355.2022; found, 355.2024.
[00292] N-(2-(4'-((tert-butyldimethylsilypoxy)-5-hydroxy-11,1'-bipheny1]-
2-
yl)ethyl)acetamide (9m): 'H NMR (500 MHz, CDC13) 6 7.16 - 7.10 (d, J= 6.7 Hz,
2H), 7.10 - 7.06 (d, J= 8.2 Hz, 1H), 7.00 (br s, OH), 6.91 -6.84 (d, J= 8.4
Hz, 2H),
6.79 - 6.72 (m, 2H), 5.38 (s, 1H), 3.34 - 3.21 (q, J= 6.6 Hz, 2H), 2.78 - 2.64
(t, J= 6.9
Hz, 2H), 1.93 - 1.81 (s, 3H), 1.00 (s, 9H), 0.24 (s, 6H); 13C NMR (125 MHz,
CDC13) 6
170.7, 155.0, 154.9, 143.3, 134.6, 130.9, 130.3, 127.8, 120.0, 117.5, 114.7,
41.0, 32.0,
58
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
26.0,23.4, 18.4, -4.1; HRMS (FAB) m/z: [M + Na] for C22H3INO3SiNa, calcd,
408.1965; found, 408.1960.
[00293] N-(2-(benzo[d][1,3]dioxo1-5-y1)-4-hydroxyphenethyl)acetamide
(9n):
111NMR (500 MHz, CDC13) 5 8.00 (br s, OH), 7.08 - 6.98 (d, J= 8.3 Hz, 1H),
6.81 -
6.73 (m, 2H), 6.73 -6.68 (m, 2H), 6.68 - 6.64 (dd, .1= 7.9, 1.7 Hz, 1H), 5.97-
5.92 (s,
2H), 5.70 - 5.63 (t, J= 5.7 Hz, 1H), 3.29 -3.21 (td, J= 7.1, 5.6 Hz, 2H), 2.75
-2.63 (t,
.1= 7.2 Hz, 2H), 1.89- 1.81 (s, 3H); 13C NMR (125 MHz, CDC13) 5 171.1, 155.1,
147.5, 146.8, 143.0, 135.4, 130.8, 127.4, 122.4, 117.5, 114.9, 109.8, 108.3,
101.2, 41.1,
31.9, 23.3; HRMS (FAB) m/z: [M + Na] for Ci7Hi7NO4Na, calcd, 322.1050; found,
322.1022.
[00294] N-(4-hydroxy-2-(pyridin-3-yl)phenethypacetamide (9o): 1H NMR
(400 MHz, CDC13) 5 8.54 (s, 2H), 7.72 (d, J= 7.9 Hz, 1H), 7.42 - 7.34 (dd, J=
8.0, 4.8
Hz, 1H), 7.14 (d, J= 8.4 Hz, 1H), 6.90 - 6.84 (dd, J= 8.3, 2.7 Hz, 1H), 6.73
(d, .1=2.7
Hz, 1H), 5.82 (t, J= 5.9 Hz, 2H), 3.33 - 3.19 (q, J= 6.8 Hz, 2H), 2.69 (t, J=
7.2 Hz,
2H), 1.85 (s, 3H); 13C NMR (100 MHz, CDC13) 5 170.7, 156.1, 149.1,
147.7,138.8,
138.0, 131.4, 127.3, 123.7, 117.5, 116.4, 100.2, 40.9, 32.0, 23.4; HRMS (FAB)
m/z: [M
+ Hl for C15Hi7N202, calcd, 257.1290; found, 257.1297.
[00295] N-(4-hydroxy-2-(pyridin-4-yl)phenethyl)acetamide (9p): 1H NMR
(400 MHz, CDC13) 5 8.69 - 8.60 (m, 2H), 7.25 (d, J= 1.5 Hz, 2H), 7.17 (d, J=
8.4 Hz,
1H), 6.90- 6.83 (dd, J= 8.4, 2.7 Hz, 1H), 6.70 (d, J= 2.7 Hz, 1H), 6.02 (br s,
OH),
5.47 (s, 1H), 3.33 -3.24 (q, J= 7.0 Hz, 2H), 2.71 (t, J= 7.4 Hz, 2H), 1.90 (s,
3H); 13C
NMR (125 MHz, CDC13) 5 173.0, 157.1, 152.8, 149.7, 149.6, 141.3, 132.4, 128.0,
126.2, 117.2, 117.1, 116.9, 41.8, 32.8, 22.5; HRMS (FAB) m/z: [M + Nal for
Ci5Hi6N202Na, calcd, 279.1104; found, 279.1109.
[00296] Example 10. General procedure for activated Noviose carbamate
coupling and followed by methanolysis of compounds 9a-p:
[00297] Borontrifluoride etherate (6.2 pL, 0.05 mmol) was added to 9a-p
(0.25
mmol) and activated noviose (0.2 mmol) in 2.5 mL anhydrous DCM. After stirring
at
RT for 2 h, triethylamine (150 tiL) was added and the solvent was
concentrated. The
residue was partially purified via column chromatography (SiO2, 100:8
DCM:acetone)
to give noviose coupled product as a colorless foam, which was used directly
for next
step. Triethylamine (0.22 mL, 10%) was added to the cyclic carbonate (100 mg,
0.22
mmol) in Me0H (2.2 mL). After 12 h, the solvent was concentrated and the
residue
was purified via column chromatography (SiO2, 10:1, DCM:Acetone) to afford
59
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
inseparable diastereomers ha-p (see following experimental section for
diastereoselectivities) as a colorless amorphous solids.
[00298] N-(2-(5-(a3R,48,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-ypoxy)-[1,1'-bipheny11-2-ypethypacetamide
(11a): Colorless amorphous solid (63% yield over 2 steps); IFINMR (500 MHz,
CDC13) 6 7.41 -7.28 (m, 311), 7.28 - 7.18 (dt, J= 5.9, 3.2 Hz, 2H), 7.13 (m,
1H), 6.97
(m, 1H), 6.92 -6.78 (dd, J= 7.6, 2.7 Hz, 1H), 5.55 - 5.47 (dd, J= 7.7, 2.7 Hz,
1H),
5.39 (m, 1H), 4.14 (m, 21-1), 3.58 -3.46 (m, 3H), 3.34 - 3.15 (m, 4H), 3.03
(d, J= 5.5
Hz, 1H), 2.77 -2.65 (m, 2H), 1.84 - 1.76 (m, 311), 1.31 (d, J= 4.9 Hz, 3H),
1.21 - 1.10
(m, 311); 13C NMR (125 MHz, CDC13) 6 170.3, 155.4, 143.5, 141.4, 130.8, 129.5,
129.2, 128.5, 127.4, 118.2, 115.2, 98.1, 84.5, 78.4, 71.5, 68.8, 62.0, 40.8,
32.1, 29.2,
23.4, 23.1; HRMS m/z: [M + H+] for C24H32N06, calcd, 430.2224; found,
430.2227.
[00299] N-(2-(5-(43R,48,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-ypoxy)-3'-fluoro-[1,1'-biphenyl]-2-
ypethyl)acetamide (11b): Colorless amorphous solid (51% yield over 2 steps);
11-1
NMR (500 MHz, CDC13) 6 7.39 (dd, 1H, J= 7.9, 13.9 Hz), 7.22 (d, 1H, J= 8.5
Hz),
7.07 (dd, 211, J= 7.5, 10.5 Hz), 7.02 (dd, 1H, J= 2.8, 8.4 Hz), 6.99 (m, 111),
6.91 (d,
1H, J= 2.7 Hz), 5.34 (d, 1H, J= 1.3 Hz), 5.28 (s, 1H), 4.20 (d, 1H, J= 2.2
Hz), 3.80
(m, 1H), 3.63 (s, 3H), 3.30 (d, 1H), 3.28 (m, 211), 2.75 (t, 2H, J= 7.2 Hz),
2.63 (m, 2H,
J= 15.9 Hz), 1.87 (s, 311), 1.41 (s, 311), 1.28 (s, 3H); 13C NMR (125 MHz,
CDC13) 6
169.9, 163.5-161.6 (d, J= 251 Hz) 155.0, 143.2 (d, J= 7.8 Hz), 142.1 (d, J=
1.8 Hz),
130.9, 130.1, 130.0 (d, J= 8.8 Hz), 124.8 (d, J= 2.8 Hz), 118.0, 116.0 (d, J=
8.8 Hz),
115.4, 114.3 (d, J= 21.6 Hz), 93.8, 84.2, 76.0, 71.3, 71.1, 62.0, 40.4, 32.0,
28.6, 23.3,
18.5; HRMS m/z: [M + 11+] for C24113IFN06, calcd, 448.2180; found, 448.2174.
This
material was determined to be 95.6% pure (retention time = 6.401) by HPLC
(Phenomenex Luna C-18, 5 pm, 10 x 250 mm column eluting with 30% CH3CN, 70%
1120, flow rate 5.0 mL/min).
[00300] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-ypoxy)-4'-fluoro-[1,1'-biphenyl]-2-
ypethyl)acetamide (11c): Colorless amorphous solid (57% yield over 2 steps);
II-1
NMR (500 MHz, CDC13) 6 7.25 (dd, 2H, J= 5.4, 8.6 Hz), 7.18 (d, 111, J= 8.5
Hz),
7.10 (t, 2H, J= 8.7 Hz), 7.01 (dd, 1H, J= 2.7, 8.5 Hz), 6.87 (d, 1H, J = 2.7
Hz), 5.54
(d, 1H, J= 2.2 Hz), 5.37 (t, 1H, J = 5.2 Hz), 4.20 (dd, 1H, J= 3.3, 9.1 Hz),
4.15 (m,
1H), 3.59 (s, 3H), 3.33 (d, 111,J= 9.1 Hz), 3.26 (q, 2H, J = 6.9 Hz), 2.97 (s,
1H), 2.81
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
(s, 1H), 2.72 (t, 2H, J = 7.3), 1.87 (s, 3H), 1.36 (s, 3H), 1.22 (s, 3H); 13C
NMR (125
MHz, CDC13) 8 170.2, 163.2-161.3 (d, J= 250 Hz), 155.3, 142.3, 137.2 (d, J=
3.2 Hz),
130.8, 130.8, 130.7, 129.5, 118.1, 115.4, 115.3, 115.3, 97.9, 84.4, 78.3,
71.4, 68.7,
62.0, 40.6, 32.1, 29.1, 23.4, 23.1; HRMS m/z: [M + Na] for C241130FN06, calcd,
470.1955; found, 470.1958.
[00301] N-(2-(2'-ehloro-5-(43R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-y0oxy)41,1'-biphenyl]-2-y0ethy0acetamide
(11d): Colorless amorphous solid (62% yield over 2 steps); 'H NMR (500 MHz,
CDC13) 67.46 (m, 1H), 7.31 (m, 2H), 7.21 (m, 2H), 7.03 (m, 1H), 6.86 (dd, 1H,
J=
= 2.7, 13.2 Hz), 5.55 (m, 1H), 5.42 (s, 1H), 4.20 (dt, 1H, J= 3.0, 9.1 Hz),
4.14 (m, 1H),
3.59 (s, 3H), 3.33 (dd, 1H, J= 2.5, 9.1 Hz), 3.26 (ddt, 2H, J= 4.8, 6.8, 9.3
Hz), 3.11 (s,
1H), 2.93 (s, 1H), 2.58 (tq, 2H, J= 7.1, 14.2 Hz), 1.86 (s, 3H), 1.35 (d, 3H,
J= 2.4 Hz),
1.20 (t, 3H, J= 5.8 Hz); 13C NMR (125 MHz, CDC13) 6170.2, 155.2, 140.6, 140.5,
139.8, 133.4, 131.4, 130.5, 129.8, 126.9, 118.1, 117.9, 116.05, 97.9, 84.5,
78.4, 71.5,
71.4, 68.7, 62.1, 62.0, 40.2, 40.2, 32.1, 32.1, 29.3, 29.2, 23.5, 23.1, 23.0;
HRMS m/z:
[M + Nat] for C24H30C1NO6Na, 486.1659; found, 486.1652.
[00302] N-(2-(3'-chloro-5-(43R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-211-pyran-2-y0oxy)-[1,1'-bipheny11-2-y0ethyl)acetamide
(11e): Colorless amorphous solid (55% yield over 2 steps); 'H NMR (500 MHz,
CDC13) 67.35 (m, 2H), 7.28 (m, 1H), 7.18 (m, 2H), 7.03 (dd, 1H, J= 2.7, 8.5
Hz), 6.87
(d, 1H, J= 2.7 Hz), 5.55 (t, 1H, J= 2.5 Hz), 5.34 (m, 1H), 4.21 (dd, 11-1, J=
3.1, 9.1
Hz), 4.16 (m, 1H), 3.60 (s, 3H), 3.34 (dd, 1H, J= 1.9, 9.1 Hz), 3.28 (m, 2H),
2.75 (dt,
4H, J= 7.3, 14.5 Hz), 1.88 (s, 3H), 1.37 (s, 3H), 1.22 (s, 3H); '3C NMR (125
MHz,
CDC13) 6 170.1, 155.4, 143.5, 142.0, 134.3, 131.0, 130.9, 129.8, 129.4, 128.5,
127.6,
127.4, 118.2, 115.7, 97.9, 84.6, 78.4, 71.5, 68.7, 62.1, 40.8, 32.1, 29.2,
23.6, 23.1;
HRMS m/z: [M + Na] for C24H30C1NO6Na, ealcd, 486.1659; found, 486.1642.
[00303] N-(2-(5-(03R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-211-pyran-2-y0oxy)-3'-(trifluoromethy041,1'-biphenyl]-2-
y0ethyDacetamide (110: Colorless amorphous solid (52% yield over 2 steps); 'H
NMR (500 MHz, CDC13) 6 7.64 (d, 1H, J= 7.7 Hz), 7.55 (t, 2H, J= 7.6 Hz), 7.49
(m,
1H), 7.23 (d, 1H, J= 8.5 Hz), 7.06 (dd, 1H, J= 2.7, 8.4 Hz), 6.89 (d, 1H, J=
2.7 Hz),
5.56 (d, 111, J= 2.2 Hz), 5.31 (s, 111), 4.19 (m, 2H), 3.60 (s, 3H), 3.34 (d,
1H, J= 9.1
Hz), 3.29 (dd, 2H, J= 7.0, 13.3 Hz), 2.72 (t, 2H, J= 7.3 Hz), 2.69 (s, 1H),
2.64 (s, 1H),
1.87 (s, 3H), 1.37 (s, 311), 1.22 (s, 3H); 13C NMR (125 MHz, CDC13) 8 170.1,
155.4,
61
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
142.1, 141.9, 132.6, 131.0, 130.7 (q, J= 31.5 Hz), 129.4, 129.0, 125.9 (q, J=
3.6, 7.2
Hz), 125.3, 124.2 (q, J-= 3.6, 7.2 Hz), 123.1, 118.0, 115.8, 97.9, 84.4, 77.4,
71.4, 68.7,
62.0, 40.6, 32.1, 29.8, 29.2, 23.4, 23.0; HRMS m/z: [M + Na] for
C25H30F3NO6Na,
520.1923; found, 520.1932. This material was determined to be 97.2% pure
(retention
time --- 7.631) by HPLC (Phenomenex Luna C-18, 5 gm, 10 x 250 mm column
eluting
with 30% CH3CN, 70% H20, flow rate 5.0 mL/min).
[00304] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-211-pyran-2-ypoxy)-4'-(trifluoromethy1)41,1'-bipheny11-2-
ypethypacetamide (11g): Colorless amorphous solid (49% yield over 2 steps); 11-
1
NMR (400 MHz, CDC13) 8 7.70 (d, J.= 7.6 Hz, 2H), 7.43 (d, J= 7.9 Hz, 2H), 7.24
(d, J
= 8.4 Hz, 1H), 7.09 ¨ 7.03 (dd, J= 8.6, 2.7 Hz, 1H), 6.90 (d, J= 2.7 Hz, 1H),
5.55 (d, J
= 2.3 Hz, 1H), 5.33 (m, 1H), 4.26 ¨ 4.11 (m, 2H), 3.60 (s, 3H), 3.36 ¨ 3.25
(m, 3H),
2.74 (t, J= 7.4 Hz, 2H), 2.56 (br s, 20H), 1.88 (s, 3H), 1.37 (s, 3H), 1.22
(s, 3H); 13C
NMR (125 MHz, Me0D) 6 173.1, 156.8, 146.9, 143.2, 132.1, 130.9, 130.7, 130.5,
130.2, 126.3, 126.2, 124.7, 118.5, 116.8, 100.1, 85.3, 79.5, 72.8, 69.5, 62.1,
41.7, 32.9,
29.2, 23.6, 22.5; HRMS m/z: [M + Na] for C25H30F3NO6Na, 520.1923; found,
520.1934.
[00305] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-ypoxy)-2'-(methylthio)-[1,1'-bipheny1]-2-
ypethypacetamide (11h): Colorless amorphous solid (63% yield over 2 steps); 11-
1
NMR (400 MHz, CDC13) 8 7.36 (t, 1H, J= 7.0 Hz), 7.27 (m, 3H), 7.09 (m, 1H),
7.01
(m, 1H), 6.87 (s, 1H), 5.64 (s, 1H), 5.54 (m, 1H), 4.16 (m, 2H), 3.32 (d, 2H,
J= 8.8
Hz), 3.27 (m, 2H), 3.06 (s, 1H), 2.56 (t, 2H, J= 6.2 Hz), 2.36 (d, 3H, J= 7.6
Hz), 1.83
(s, 3H), 1.33 (s, 3H), 1.20 (s, 3H); 13C NMR (100 MHz, CDC13) 8 170.3, 155.1,
155.0,
141.0, 138.9, 130.5, 130.1, 129.8, 128.4, 124.6, 124.2, 118.3, 116.2, 115.9,
97.9, 84.5,
78.3, 71.5, 68.7, 62.0, 53.6, 40.1, 31.7, 29.3, 23.3, 15.3, 15.2; HRMS m/z: [M
+ Na]
for C25H33NO6SNa, calcd, 498.1926; found, 498.1925. This material was
determined to
be 95% pure (retention time = 7.465) by HPLC (Phenomenex Luna C-18, 5 um, 10 x
250 mm column eluting with 30% CH3CN, 70% H20, flow rate 5.0 mL/min).
[00306] N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-yl)oxy)-2'-methoxy-[1,1'-bipheny11-2-
ypethypacetamide (11i): Colorless amorphous solid (41% yield over 2 steps); 11-
1
NMR (500 MHz, CDC13) 8 7.36 (ddd, 1H, J= 1.8, 7.6, 8.2 Hz), 7.18 (d, 1H, J=
8.3
Hz), 7.12 (t, 1H, J= 5.8 Hz), 7.02 (m, 3H), 6.87 (dd, 1H, J= 2.3, 11.3 Hz),
5.54 (s,
62
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
1H), 5.39 (s, 1H), 4.21 (dt, 1H, J= 3.3, 9.0 Hz), 4.15 (m, 1H), 3.77 (d, 3H,
J= 6.9 Hz),
3.60 (s, 3H), 3.33 (d, 1H, J= 8.7 Hz), 3.29 (m, 2H), 2.73 (s, 1H), 2.66 (s,
1H), 2.60 (dd,
2H, J= 6.5, 12.8 Hz), 1.84 (s, 3H), 1.37 (s, 3H), 1.24 (s, 3H); 13C NMR (125
MHz,
CDC13) 6 170.0, 156.4, 155.2, 139.9, 131.2, 130.8, 130.2, 130.0, 129.2, 120.9,
118.6,
118.3, 115.7, 115.2, 111.4, 111.2, 98.0, 97.9, 84.5, 78.2, 71.4, 68.7, 62.0,
55.9, 55.9,
40.3, 31.9, 30.2, 29.3, 29.2, 23.4, 23.1; HRMS m/z: [M + HI for C25H34N07,
calcd,
460.2335; found, 460.2336. This material was determined to be 96.1% pure
(retention
time = 5.057) by HPLC (Phenomenex Luna C-18, 5 gm, 10 x 250 mm column eluting
with 30% CH3CN, 70% H20, flow rate 5.0 mL/min).
[00307] N-(2-(5-0(3R,48,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-y0oxy)-3'-methoxy-[1,1'-biphenyl]-2-
ypethyl)acetamide (11j): Colorless amorphous solid (53% yield over 2 steps);
1H
NMR (400 MHz, CDC13) 8 7.31 (t, J= 7.9 Hz, 1H), 7.17 (d, J= 8.5 Hz, 1H), 7.02
¨
6.96 (dd, J= 8.5, 2.7 Hz, 1H), 6.92 ¨6.83 (m, 4H), 6.81 (d, J= 1.5 Hz, 2H),
5.54 (d, J
= 2.2 Hz, 1H), 5.45 (s, 1H), 4.25 ¨4.16 (dd, J= 9.1, 3.2 Hz, 1H), 4.17 ¨ 4.10
(dd, J=
3.3, 2.2 Hz, 1H), 3.82 (s, 3H), 3.58 (s, 3H), 3.39 ¨ 3.20 (m, 3H), 3.24 (br s,
OH), 2.97
(br s, OH), 2.75 (t, J= 7.1 Hz, 2H), 1.85 (s, 3H), 1.35 (s, 3H), 1.20 (s, 3H);
13C NMR
(125 MHz, CDCI3) 8 170.4, 159.5, 155.3, 143.3, 142.8, 130.8, 129.5, 129.5,
121.7,
118.0, 115.3, 115.1, 112.7, 98.1, 84.5, 78.4, 71.5, 68.7, 62.0, 55.4, 40.9,
32.0, 29.1,
23.4, 23.1; HRMS m/z: [M + H ] for C25H34N07, calcd, 460.2335; found,
460.2322.
[00308] N-(2-(5-(43R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-211-pyran-2-ypoxy)-3'-methy1-11,1'-bipheny1]-2-
ypethyl)acetamide (11k): Colorless amorphous solid (44% yield over 2 steps);
1H
NMR (400 MHz, CDC13) 6 7.32 ¨ 7.27 (m, 1H), 7.16 (d, J= 6.6 Hz, 2H), 7.10 ¨
7.04
(m, 2H), 6.99 (d, J= 8.5 Hz, 1H), 6.88 (s, 1H), 5.55 (s, 1H), 5.41 (s, 1H),
4.25 ¨4.08
(m, 2H), 3.57 (s, 3H), 3.37¨ 3.20 (m, 5H), 2.75 (t, J= 7.0 Hz, 2H), 2.39 (s,
3H), 1.83
(s, 3H), 1.35 (s, 3H), 1.20 (s, 3H); 13C NMR (100 MHz, CDC13) 8 170.4, 155.3,
143.6,
141.3, 138.1, 130.8, 130.0, 129.5, 128.3, 128.1, 126.3, 118.1, 115.1, 98.1,
84.5, 78.4,
71.5, 68.7, 62.0, 40.9, 32.0, 29.2, 23.4, 23.1, 21.7; HRMS m/z: [M + H+] for
C25H33NO6Na, calcd, 466.2206; found, 466.2203.
[00309] N-(2-(5-0(3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-211-pyran-2-yl)oxy)-3'-(morpholinomethyl)-[1,1'-bipheny1]-2-
yl)ethyl)acetamide (111): Colorless amorphous solid (47% yield over 2 steps);
1H
NMR (500 MHz, CDC13) 6 7.41 ¨ 7.29 (m, 2H), 7.27 (m, 1H), 7.19 (d, J= 8.1 Hz,
2H),
63
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
7.04 ¨ 6.99 (dd, J= 8.5, 2.7 Hz, 1H), 6.91 (d, J= 2.7 Hz, 1H), 5.55 (d, J= 2.4
Hz, 1H),
5.35 (s, 1H), 4.26 ¨ 4.18 (dd, J= 9.0, 3.3 Hz, 1H), 4.15 (t, J= 2.8 Hz, 1H),
3.72 (t, J=
4.7 Hz, 4H), 3.59 (s, 3H), 3.56 (s, 2H), 3.34 (d, J= 9.0 Hz, 1H), 3.30 ¨ 3.21
(q, J= 6.7
Hz, 2H), 2.75 (t, J= 7.1 Hz, 2H), 2.58¨ 2.41 (m, 6H), 1.85 (s, 3H), 1.36 (s,
3H), 1.23
(s, 3H); 13C NMR (125 MHz, CDC13) 6 155.4, 143.4, 141.5, 137.8, 130.9, 130.1,
129.6,
128.5, 128.3, 128.2, 118.2, 115.3, 98.1, 84.6, 78.4, 71.5, 68.8, 67.1, 63.5,
62.0, 53.8,
40.7, 32.2, 29.2, 23.5, 23.2; HRMS (FAB) m/z: [M + Na] for C29H40N207Na,
calcd,
551.2728; found, 551.2734.
[00310] N-(2-(5-(43R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-ypoxy)-4'-hydroxy-[1,1'-bipheny11-2-
yl)ethypacetamide (11m):
[00311] After cyclic carbonate hydrolysis following the same procedure as
compound lla¨p, the crude TBS protected compound was dissolved in THF (2 mL)
and tertrabutylammonium fluoride (1.5 eq.) was added dropwise at 0 C under
argon
atmosphere. After 1 h the reaction was quenched with water and extracted with
Et0Ac
(3 x 10 mL); combined organic fractions were washed with saturated aqueous
sodium
chloride, dried over anhydrous Na2SO4, filtered and concentrated. The residue
was
purified by column chromatography (SiO2; 10:1, DCM:acetone) to afford
acetamide
llm as a amorphous solid (40% yield over 3 steps). 1H NMR (500 MHz, Me0D) 6
7.20 (d, J= 8.4 Hz, 111), 7.15 ¨7.08 (d, J= 8.4 Hz, 2H), 6.96 (dd, J= 8.4, 2.6
Hz, 1H),
6.85 ¨6.79 (m, 3H), 5.45 (d, J= 2.4 Hz, 1H), 4.12 (dd, J= 9.3, 3.3 Hz, 1H),
3.96 (t, J=
2.8 Hz, 1H), 3.59 (s, 3H), 3.21 (d, J= 9.3, Hz, 1H), 3.16 (dd, J= 8.5, 6.5 Hz,
2H), 2.70
(dd, J= 8.5, 6.5 Hz, 2H), 1.84 (s, 3H), 1.32 (s, 3H), 1.18 (s, 3H); 13C NMR
(125 MHz,
Me0D) 6 173.1, 157.7, 156.6, 144.7, 134.0, 131.7, 131.2, 131.1, 118.9, 116.0,
115.7,
100.1, 85.4, 79.4, 72.8, 69.5, 62.1, 41.8, 33.0, 29.2, 23.6, 22.5; HRMS (FAB)
m/z: [M +
Na] for C24H3INO7Na, calcd, 468.1998; found, 468.1999.
[00312] N-(2-(benzo[d][1,31dioxo1-5-y1)-4-(((3R,4S,5R)-3,4-dihydroxy-5-
methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)phenethypacetamide (11n):
Colorless amorphous solid (51% yield over 2 steps); 1H NMR (500 MHz, CDC13) 6
7.15 (d, J= 8.5 Hz, 1H), 7.00 ¨ 6.96 (dd, J= 8.5, 2.7 Hz, 1H), 6.88 (d, J= 2.6
Hz, 1H),
6.84 (d, J= 7.9 Hz, 1H), 6.76 (d, J= 1.6 Hz, 1H), 6.74 ¨ 6.69 (m, 1H), 6.01
(s, 2H),
5.54 (d, J= 2.4 Hz, 1H), 5.40 (s, 1H), 4.21 (dd, J= 9.1, 3.3 Hz, 1H), 4.14 (t,
J= 2.7 Hz,
2H), 3.58 (s, 3H), 3.33 (d, J= 9.1 Hz, 1H), 3.30 ¨ 3.23 (q, J= 6.9 Hz, 2H),
3.11 (br s,
OH), 2.92 (br s, OH), 2.74 (t, J= 7.2 Hz, 2H), 1.86 (s, 3H), 1.34 (s, 3H),
1.20 (s, 3H);
64
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
13C NMR (125 MHz, CDC13) 8 170.2, 155.4, 147.7, 147.0, 143.1, 135.3, 130.8,
129.7,
122.6, 118.3, 115.2, 109.9, 108.4, 101.3, 98.1, 84.6, 78.4, 71.5, 68.8, 62.0,
40.8, 32.1,
29.2, 23.4, 23.2; FIRMS (FAB) m/z: [M + Nat] for C25H3INO8Na, calcd, 496.1947;
found, 496.1940. This material was determined to be 98.4% pure (retention time
=
4.384) by HPLC (Phenomenex Luna C-18, 5 gm, 10 x 250 mm column eluting with
40% CH3CN, 60% H20, flow rate 5.0 mL/min).
[00313] N-(4-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-yl)oxy)-2-(pyridin-3-yl)phenethyl)acetamide
(110): Colorless amorphous solid (37% yield over 2 steps); IFI NMR (500 MHz,
CDC13) 8 8.55 (d, J= 3.9 Hz, 1H), 8.49 (s, 1H), 7.60 (m, 1H), 7.35 (dd, J=
7.8, 4.5 Hz,
1H), 7.20 (d, J= 8.5 Hz, 1H), 7.05 ¨ 6.99 (dd, J= 8.4, 2.7 Hz, 1H), 6.85 (d,
J= 2.6 Hz,
1H), 5.52 (d, J= 2.4 Hz, 1H), 5.36 (s, 1H), 4.14 (dd, J= 3.4, 9.1 Hz, 1H),
4.10 (t, J=
2.7 Hz, 1H), 3.59 (s, 3H), 3.31 (d, J= 9.0 Hz, 1H), 3.27 ¨3.20 (m, 2H), 2.68
(t, J= 7.3
Hz, 2H), 1.86 (s, 3H), 1.33 (s, 3H), 1.17 (s, 3H); 13C NMR (125 MHz, CDC13) 8
170.2,
155.5, 149.8, 148.7, 139.5, 136.8, 131.1, 131.0, 130.6, 129.8, 123.4, 118.3,
118.2,
116.1, 98.0, 84.5, 78.5, 71.4, 68.7, 62.1, 40.7, 32.2, 29.2, 23.5, 23.1; HRMS
(FAB) m/z:
[M + Na] for C23H31N206, calcd, 431.2182; found, 431.2194.
[00314] N-(4-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-yl)oxy)-2-(pyridin-4-yl)phenethypacetamide
(11p): Colorless amorphous solid (42% yield over 2 steps); 1H NMR (400 MHz,
CDC13) 8 8.73 ¨8.63 (dd, J= 5.7, 3.9 Hz, 2H), 7.27 ¨ 7.23 (m, 3H), 7.11 ¨7.03
(m,
1H), 6.86 (t, J= 2.8 Hz, 1H), 5.55 (d, J= 2.3 Hz, 1H), 5.41 ¨ 5.31 (m, 2H),
4.26 ¨4.13
(m, 2H), 4.05 (d, J= 6.9 Hz, 1H), 3.61 (s, 3H), 3.36¨ 3.25 (m, 2H), 2.78 ¨2.71
(dd, J
= 8.3, 6.8 Hz, 2H), 1.90 (s, 3H), 1.39 (s, 3H), 1.24 (s, 3H); 13C NMR (125
MHz,
CDC13) 8 170.1, 155.5, 149.8, 140.5, 131.4, 129.1, 124.4, 117.9, 116.3, 98.0,
94.1,
84.5, 71.5, 71.4, 68.7, 62.1, 40.7, 32.2, 29.2, 28.8, 23.5, 23.1, 18.7; HRMS
(FAB) m/z:
[M + Nal for C23H30N206Na, calcd, 453.2001; found, 453.1972.
[00315] Example 11. (Z)-4-(benzyloxy)-2-(methoxymethoxy)-1-(2-
nitrovinyl)benzene (14): Nitromethane (11.5 mL) was added to a mixture of
aldehyde
13 (1.24g, 4.6 mmol) and ammonium acetate (0.63 g, 8.2 mmol) and heated to 50
C.
Upon completion (20 mm), the reaction mixture was cooled to RT and purified
without
work-up by column chromatography (5i02, 4:1, Hex:Et0Ac) to afford nitrostyrene
14
as a clear, colorless oil (1.22 g, 3.87 mmol, 84%). 'H NMR (400 MHz, CDC13) 8
8.17
(d, J= 13.4 Hz, 111), 7.80 (d, J= 13.6 Hz, 1H), 7.50¨ 7.32 (m, 6H), 6.88 (d,
J= 2.5
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
Hz, 114), 6.67 (m, 1H), 5.30 (s, 211), 5.12 (s, 214), 3.52 (s, 3H); 13C NMR
(100 MHz,
CDC13) 8 163.4, 159.0, 136.1, 136.0, 135.6, 133.5, 128.8, 128.5, 127.7, 127.7,
113.0,
108.6, 102.2, 94.7, 70.5, 56.6; HRMS (FAB) m/z: [M + Nat] for C17Hi7NO5Na,
calcd,
338.1004; found, 338.1007.
[00316] Example 12. 4'-(benzyloxy)-2'-(methoxymethoxy)-2-nitro-1,2,3,6-
tetrahydro-1,1'-biphenyl (15): Nitrostyrene 14 (0.65 g, 2.06 mmol) was
dissolved in
toluene (0.6 mL)in a 2 mL sealed tube and cooled to -78 C. Butadiene was
bubbled into
the solution to double the volume and then the tube was sealed and heated to
reflux for
48 h. To prevent bumping of the butadiene gas, the tube was cooled again to -
78 C and
used directly in purification by column chromatography (SiO2; 3:1, Hex:Et0Ac)
to
afford cyclohexene 15 (0.72 g, 1.96 mmol, 95%). 1H NMR (500 MHz, CDC13) 8 7.40
(m, 4H), 7.36 - 7.28 (m, 1H), 7.06 (d, J= 8.4 Hz, 1H), 6.80 (d, J= 2.4 Hz,
1H), 6.56
(dd, J= 8.4, 2.5 Hz, 1H), 5.86 - 5.77 (m, 111), 5.71 (ddd, J= 9.8, 5.1, 2.3
Hz, 1H), 5.27
- 5.20 (m, 1H), 5.20 (s, 2H), 5.00 (s, 211), 3.70 (dt, J= 17.0, 8.7 Hz, 1H),
3.49 (s, J=
12.7 Hz, 3H), 2.84 - 2.74 (m, 1H), 2.71 (ddd, J= 13.2, 8.4, 1.5 Hz, 1H), 2.45
(m, 2H);
13C NMR (125 MHz, CDC13) 8 159.2, 156.1, 136.9, 129.3, 128.6, 127.0, 122.5,
120.9,
107.8, 120.6, 94.6, 85.6, 70.1, 31.5, 31.3, 29.7.
[00317] Example 13. N-(4'-(benzyloxy)-2'-(methoxymethoxy)-1,2,3,6-
tetrahydro-[1,1'-bipheny11-2-ypacetamide (16): Nitro compound 13 (0.23 g, 0.62
mmol) was dissolved in isopropanol (12.4 mL) and aqeous 1M HC1 (6.2 mL). Zinc
dust
(811 mg, 12.4 mmol) was added and the mixture was stirred vigorously for 1.5
hat
50 C. After cooling to room temperature, saturated NaHCO3 (8 mL) was added and
the
resulting mixture was stirred for an additional 20 mm. The solids were removed
by
filtration and the remaining solution was extracted with DCM (3 x 20 mL). The
organic
layers were combined and washed with saturated aqueous sodium chloride
solution,
dried (Na2SO4) and concentrated to afford amine as clear, colorless oil (0.20
g, 0.59
mmol, 95%).
[00318] Acetic anhydride (62 4, 0.65 mmol) and triethylamine (95 1AL,
0.68
mmol) were added to a solution of the amine (0.62 mmol) in DCM (6.2 mL) under
an
atmosphere at RT. After 3 h the reaction was quenched with saturated aqueous
ammonium chloride and extracted with DCM (3 x 10 mL); combined organic
fractions
were washed with Brine, dried (Na2SO4), filtered and concentrated. The residue
was
purified by column chromatography (SiO2; 3:1, Hex:Et0Ac) to afford acetamide
16
(0.17 g, 0.46 mmol, 74%). 1H NMR (500 MHz, CDC13) 8 7.42 (d, J= 7.8 Hz, 2H),
7.39
66
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
-7.33 (t, J= 7.2 Hz, 2H), 7.33 -7.28 (m, 1H), 7.12 (d, J= 8.5 Hz, 1H), 6.77
(s, 1H),
6.63 (d, J= 8.5 Hz, 1H), 5.90 (d, J= 8.4 Hz, 111), 5.71 (d, J= 36.2 Hz, 2H),
5.17 (s,
2H), 5.02 (s, 2H), 4.36 - 4.23 (dtd, J= 13.8, 10.4, 9.9, 7.2 Hz, 1H), 3.50 (s,
3H), 3.31 -
3.22 (dd, J= 18.6, 7.9 Hz, 1H), 2.59 (d, J= 17.3 Hz, 1H), 2.33 (s, 2H), 2.02-
1.93 (m,
1H), 1.74 (s, 3H); 13C NMR (125 MHz, CDC13) 6 169.8, 158.3, 156.1, 136.9,
128.5,
128.3, 127.9, 127.6, 126.7, 125.0, 124.4, 108.0, 102.9, 95.6, 70.0, 56.2,
48.8, 37.4,
33.0, 32.6, 23.1; HRMS (FAB) m/z: [M + Nal for C23H27NO4Na, calcd, 404.1832;
found, 404.1827.
[00319] Example 14. N-(4'-(benzyloxy)-2'-hydroxy-1,2,3,6-tetrahydro-[1,1'-
bipheny11-2-yl)acetamide : Catalytic amount of conc. HC1 (few drops) was added
to
MOM protected phenol 16 (0.27 g, 0.71 mmol) in methanol (7.1 mL) and stirred
vigorously at 50 C for overnight. Upon completion the reaction mixture was
concentrated and was purified by column chromatography (SiO2; 5:100, MeOH:DCM)
to afford phenol (0.19 g, 0.58 mmol, 81%). 'H NMR (400 MHz, CDC13) 6 8.86 (s,
1H),
7.41 -7.25 (m, 5H), 7.01 (d, J= 8.5 Hz, 1H), 6.73 (d, J= 2.4 Hz, 1H), 6.48 (d,
J= 6.0
Hz, 1H), 5.73 (m, 1H), 5.65 (m, 1H), 4.96 (s, 2H), 4.26 (m, 1H), 3.42 (m, 1H),
2.55 -
2.12 (m, 4H), 1.98 (s, 3H); 13C NMR (100 MHz, CDC13) 6 173.2, 158.3, 155.4,
136.9,
128.5, 128.0, 127.9, 127.6, 127.0, 123.9, 121.1, 107.2, 103.4, 69.9, 51.9,
50.0, 36.6,
31.6, 21.0; HRMS (FAB) m/z: [M + Nat] for C211-123NO3Na, calcd, 360.1576;
found,
360.1571.
[00320] Example 15. 2'-acetamido-4-(benzyloxy)-1',2',3',6'-tetrahydro-
[1,1'-
bipheny11-2-y1 trifluaromethanesulfonate (17): A solution of phenol (0.19 g,
0.58
mmol) in anhydrous DCM (5.8 mL) was stirred at 0 C and triethylamine (0.12
mL,
0.87 mmol) was added followed by N-phenyl-bis(trifluoromethanesulfonimide)
(0.31 g,
0.87 mmol). Upon completion the reaction was quenched by addition of water (50
mL),
washed with saturated aqueous NaCl solution, dried (Na2SO4), filtered and
concentrated. The residue was purified by column chromatography (SiO2, 3:1,
Hex:Et0Ac) to afford triflate 17 as a clear, yellow oil (0.23 g, 0.49 mmol,
85%). 1H
NMR (400 MHz, CDC13) 6 7.45 -7.31 (m, 6H), 7.00 (d, .1= 11.2 Hz, 1H), 6.84 (d,
J-
2.4 Hz, 1H), 5.70 (m, 2H), 5.60 (d, J= 9.3 Hz, 1H), 5.04 (s, 2H), 4.53 -4.38
(dt, J=
15.2, 10.2 Hz, 1H), 3.18 - 3.03 (td, J= 11.2, 5.2 Hz, 1H), 2.63 -2.50 (dd, J=
16.2, 4.2
Hz, 1H), 2.42 - 2.32 (m, 1H), 2.28 - 2.15 (m, 1H), 2.11 - 1.97 (t, J= 14.5 Hz,
1H),
1.71 (s, 3H); 13C NMR (100 MHz, CDC13) 6 169.7, 158.2, 147.6, 136.0, 129.9,
128.8,
128.5, 128.1, 127.7, 126.1, 125.4, 115.8, 108.2, 70.7, 48.3, 38.5, 34.8, 33.7,
23.2;
67
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
HRMS (FAB) m/z: [M + Nal for C22H22F3NO5SNa, calcd, 492.106318; found,
492.1067.
[00321] Example 16. N-(4'-(benzyloxy)-3"-fluoro-1,2,3,6-tetrahydro-
11,1%2',1"-terpheny1]-2-ypacetamide (18a): Followed same Suzuki coupling
procedure as described above for 6a-p. NMR (400 MHz, CDC13) 8 7.47 - 7.30 (m,
7H), 7.13 -7.05 (t, J= 8.9 Hz, 1H), 7.05 -7.00 (t, J= 7.2 Hz, 2H), 6.97 (d, J=
10.9
Hz, 1H), 6.80 (d, J= 2.7 Hz, 1H), 5.72 - 5.53 (m, 2H), 5.06 (s, 2H), 4.91 (d,
J= 8.7
Hz, 1H), 4.36 - 4.24 (m, 1H), 2.90 - 2.75 (dd, J= 19.2, 8.2 Hz, 1H), 2.59 -
2.45 (dt, J
= 16.3, 4.4 Hz, 1H), 2.36 (m, 2H), 1.75 (s, 3H); 13C NMR (100 MHz, CDC13) 8
169.3,
156.8, 143.9, 142.3, 137.0, 132.6, 130.2, 130.2, 128.8, 128.5, 128.2, 127.8,
126.7,
125.2, 125.0, 116.4, 116.2, 116.0, 115.2, 114.5, 114.3, 70.2, 49.4, 40.5,
35.3, 33.4,
23.5; HRMS (FAB) m/z: [M + Na] for C27H26FNO2Na, calcd, 438.1840; found,
438.1818.
[00322] N-(4'-(benzyloxy)-3"-(trifluoromethyl)-1,2,3,6-tetrahydro-
[1,1%2',1"-terpheny11-2-ypacetamide (18b): Followed same Suzuki coupling
procedure as described above for 6a-p. 'H NMR (400 MHz, CDC13) 8 7.73 - 7.30
(m,
10H), 7.05 (d, J= 8.7 Hz, 1H), 6.85 (s, 1H), 5.66 (m, 2H), 5.16 (d, J= 8.5 Hz,
1H),
5.08 (s, 2H), 4.43 -4.29 (m, 1H), 2.90 - 2.74 (q, J = 10.0, 9.0 Hz, 1H), 2.50
(d, J=
17.7 Hz, 1H), 2.40 -2.28 (dd, J= 6.9, 3.9 Hz, 2H), 1.75 (s, 3H); 13C NMR (101
MHz,
CDC13) 8 169.7, 156.9, 142.4, 141.9, 136.9, 132.6, 131.1, 130.8, 129.1, 128.7,
128.6,
128.2, 127.7, 126.6, 126.0, 125.9, 125.0, 124.3, 124.2, 116.3, 115.3, 70.2,
49.4, 40.6,
35.2, 33.1, 23.4; HRMS (FAB) m/z: [M + Nal for C28H26F3NO2Na, calcd, 488.1813;
found, 488.1812.
[00323] Example 17. N-(3"-fluoro-4'-hydroxy-1,2,3,6-tetrahydro-[1,1%2',1"-
terpheny1]-2-ypacetamide (19a): 1,2-Ethanedithiol (0.22 mL, 2.66 mmol) and
BF30Et2 (0.176 mL, 1.4 mmol) were added to benzyl ether 18a (64 mg, 0.14 mmol)
in
DCM (1.8 mL). After 8 h, reaction mixture was concentrated and purified by
column
chromatography (SiO2, 10:100, MeOH:DCM) to afford phenol 19a as an amorphous
solid (45 mg, 0.12 mmol, 86%) 1H NMR (500 MHz, CDC13) 8 8.98 (s, 1H), 7.40 -
7.34
(q, J= 7.1, 6.2 Hz, 1H), 7.27 (d, J- 7.6 Hz, 1H), 7.10 - 7.01 (m, 2H), 6.96
(d, J= 9.4
Hz, 111), 6.84 - 6.79 (dd, J = 8.5, 2.6 Hz, 1H), 6.68 (d, J = 2.6 Hz, 1H),
5.73 -5.52 (m,
2H), 4.51 -4.38 (dt, J= 9.9, 5.0 Hz, 1H), 2.88 - 2.77 (q, J= 9.5, 7.9 Hz, 1H),
2.43 (d,
J= 17.3 Hz, 1H), 2.34 (m, 2H), 2.18 (s, 1H), 1.77 (s, 3H); 13C NMR (125 MHz,
CDC13) 8 170.5, 163.6-161.7 (d, J = 244.0 Hz), 155.2, 144.2 (d, J= 7.6 Hz),
142.3,
68
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
130.8, 130.1 (d, J= 8.4 Hz), 128.2, 127.0,125.0 (d, J= 2.2 Hz), 124.7, 116.5,
116.3 (d,
J= 20.3 Hz), 115.9, 114.2 (d, J= 20.3 Hz, 49.6, 40.8, 35.5, 33.5, 23.2; HRMS
(FAB)
m/z: [M + Na +] for C211-125FNO2Na, 348.1376; found, 348.1379.
[00324] N-(4'-hydroxy-3"-(trifluoromethyl)-1,2,3,6-tetrahydro-[1,1%2',1"-
terpheny1]-2-yl)acetamide (196): Followed same procedure as for 19a.1HNMR (400
MHz, CDC13) 8 9.20 (s, 1H), 7.66- 7.56 (m, 4H), 7.29 (d, J= 8.5 Hz, 1H), 6.82 -
6.72
(d, J= 10.5 Hz, 1H), 6.65 (s, 1H), 5.65 (m, 1H), 5.54 (m, 1H), 5.21 (d, J= 9.7
Hz, 2H),
4.56 - 4.33 (m, 1H), 2.76 - 2.61 (m, 1H), 2.46 - 2.24 (m, 3H), 1.75 (s, 3H);
13C NMR
(100 MHz, CDC13) 8 170.5, 155.3, 142.7, 142.0, 132.6, 130.8, 130 (q, J= 32.5
Hz),
128.8, 128.4, 126.9, 126.0 (m), 124.7, 124.0 (m), 116.7, 116.0, 49.6, 40.9,
35.6, 33.5,
23.2; HRMS (FAB) m/z: [M + Nat] for C2,1H20F3NO2Na, calcd, 398.1344; found,
398.1346.
[00325] Example 18. N-(4'-(((3R,48,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-yl)oxy)-3"-fluoro-1,2,3,6-tetrahydro-[1,1%2',1"-
terpheny1]-2-yl)acetamide (20a): Followed same noviose coupling procedure as
described above for lla-p to afford 20a as a inseparable mixture of
diastereomers. 11-1
NMR (500 MHz, CDC13) ö 7.32 (ddd, 1H, J= 6.0, 7.9, 13.9 Hz), 7.22 (dd, 1H, J=
2.8,
8.7 Hz), 7.00 (m, 2H), 6.94 (d, 1H, J= 7.6 Hz), 6.87 (m, 1H), 6.77 (dd, 1H, J=
2.7, 8.7
Hz), 5.59 (m, 1H), 5.52 (m, 1H), 5.49 (d, 1/2H, J= 2.4 Hz), 5.45 (d, 1/2H, J=
2.4 Hz),
4.81 (dd, 1H, J= 2.5, 8.8 Hz), 4.21 (m, 1H), 4.12 (m, 1H), 4.07 (m, 1H), 3.52
(s, 3H),
3.25 (dd, 1H, J= 0.9, 9.0 Hz), 2.89 (br s, 1H), 2.76 (m, 1H), 2.67 (s, 1H),
2.26 (m, 2H),
1.69 (m, 1H), 1.65 (s, 3/2H), 1.64 (s, 3/2H), 1.29 (s, 3/2H), 1.28 (s, 3/2H),
1.13 (s,
3/2H), 1.12 (s, 3/2H); 13C NMR (125 MHz, CDC13) ö 169.4, 169.4, 163.7-161.7
(d, J=
249.0 Hz), 154.9, 154.7, 143.0 (dd, J= 1.7, 8.5 Hz), 142.2 (d, J= 1.7 Hz),
133.4, 133.3,
130.2 (dd, J= 1.7, 8.5 Hz), 128.4 (d, J= 5.0Hz), 126.6 (d, J= 3.2 Hz), 125.1
(d, J.= 3.6
Hz), 125.0 (m), 117.2, 116.9, 116.6, 116.3 (dd, J= 13.4, 20.9 Hz), 116.2,
114.3 (dd, J=
1.5, 20.9 Hz), 98.0, 97.7, 84.5, 84.4, 78.3, 78.3, 77.4, 71.5, 71.4, 68.8,
62.0, 61.9, 49.6,
49.6, 40.5, 40.5, 35.2, 35.1, 33.4, 29.2, 23.6, 23.5, 23.2, 23.1; HRMS (FAB)
m/z: [M +
Na+] for C28H34FNO6Na, 522.2262; found, 522.2267.
[00326] N-(4'-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-
dimethyltetrahydro-2H-pyran-2-yl)oxy)-3"-(trifluoromethyl)-1,2,3,6-tetrahydro-
[1,1':2',1"-terphenyl]-2-y1)acetamide (206): Followed same noviose coupling
procedure as described above for lla-p to afford 20b as a inseparable mixture
of
diastereomers. NMR (500 MHz, CDC13) ö 7.65 (d, 1H, J= 8.2 Hz), 7.56 (t, 1H, J=
69
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
7.7 Hz), 7.49 (s, 1H), 7.45 (d, 1H, J= 7.6 Hz), 7.32 (dd, 1H, J= 3.0, 8.7 Hz),
7.08 (td,
1H, J= 2.7, 8.6 Hz), 6.85 (dd, 1H, J= 2.7, 8.5 Hz), 5.65 (m, 1H), 5.59 (m,
1H), 5.57 (d,
1/2H, J= 2.4 Hz), 5.53 (d, 1/2H, J= 2.3 Hz), 4.90 (t, 1H, J= 8.2 Hz), 4.30 (m,
1H),
4.19 (dd, 1H, J= 4.3, 8.2 Hz), 4.14 (m, 1H), 3.59 (s, 3/2H), 3.59 (s, 3/2H),
3.33 (d, 1H,
J= 9.0 Hz), 3.17 (s, 1H), 2.95 (s, 1H), 2.76 (m, 1H), 2.49 (m, 1H), 2.33 (m,
1H), 1.74
(m, 1H), 1.73 (s, 3/2H), 1.72 (s, 3/2H), 1.36 (s, 3/2H), 1.35 (s, 3/2H), 1.21
(s, 3/2H),
1.20 (s, 3/2H); NMR (100 MHz, CDC13) 8 169.4, 169.4, 155.0, 154.8, 142.3,
141.8,
133.4, 133.3, 132.8, 132.6, 131.8 (dq, J= 2.2, 32.5 Hz), 129.1, 128.6, 126.5,
125.9 (q, J
= 3.2, 7.0 Hz), 125.0, 124.2, 117.6, 117.0, 116.8, 98.1, 97.8, 84.5, 84.4,
78.4, 78.3,
71.3, 71.3, 68.7, 68.7, 61.9, 61.9, 49.4, 49.3, 40.5, 40.5, 35.1, 35.0, 33.1,
29.0, 29.0,
23.4, 23.4, 23.1, 23.0; HRMS (FAB) ,n/z: [M + Na] for C29H34F3NO6Na, Calcd,
572.2230; found, 572.2227.
[00327] Example 19. Synthesis of carbocyclic analogue N-(2-(5-((4-
(benzyloxy)cyclohexyl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)acetamide
(24):
[00328] 4-hydroxycyclohexyl 4-methylbenzenesulfonate (21):
[00329] To a solution of pyridine (4 g, 0.025 mol) in CHC13(25 mL) was
added
Cyclohexanediol (2.5 g, 0.021 mol) at room temperature. This was then cooled
to 0 C,
and tosyl chloride (4.1 g, 0.021) added to the mixture. The reaction was
stirred for 16 h
under argon at room temperature. Upon completion of the reaction from TLC, the
reaction mixture was poured into dilute HC1, and the solid precipitate
collected by
filtration, washed with water and dried (Na.2SO4).
[00330] 4-(benzyloxy)cyclohexyl 4-methylbenzenesulfonate (22):
[00331] To a solution of 21 (0.5 mg, 1.8 mmol) in acetonitrile (3 mL) was
added
sodium hydride (0.11 g, 2.7 mmol) at 0 C. A solution of benzyl bromide (0.48
mL, 2
mmol) in acetonitrile (2 mL) was then added to the mixture dropwise, under an
argon
atmosphere. The reaction was stirred for 16 h at room temperature. Upon
completion,
distilled water (10 mL) was added to the mixture and the organic layer
extracted into
ethyl acetate. The organic layers were combined, dried and concentrated to
give a crude
mixture that was purified by column chromatography (Silica gel, 10% -20 %
Et0Ac in
hexane) to give 22(300 mg) as a white solid.
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
[00332] N-(2-(5-44-(benzyloxy)cyclohexyl)oxy)-3'-fluoro-[1,1'-bipheny1]-2-
ypethypacetamide (24):
[00333] To a solution of phenol 23 (45 mg, 0.16 mmol) in DMF (1 mL) was
added potassium carbonate (30 mg, 0.19 mmol) and stirred at room temperature
for 30
min, after which 22 (75 mg, 0.19 mmol) and TBAI (7 mg, 0.016 mmol) were added
to
the solution, and heated to reflux overnight. Upon completion, distilled water
(5 mL)
was added to the mixture and the organic layer extracted into ethyl acetate.
After
removal of the solvent on a rotor evaporator, the crude mixture was purified
by column
chromatography (Silica gel, 40% Et0Ac in hexane) to give 24 (8 mg) as a white
solid.
[00334] Synthesis of phenol core intermediate 23.
[00335] 4-(benzyloxy)-2-hydroxybenzaldehyde (25):
[00336] 2,4-dihydroxybenzaldehyde (10 g, 0.072 mol) was dissolved in
acetonitrile (83 mL). To this solution was added NaHCO3 (9.1 g, 0.10 mol) and
stirred
for 5 min. Benzyl bromide (12.9 mL, 0.10 mol) was added in under an argon
atmosphere. The reaction was heated to reflux for 16 h. After cooling to room
temperature, the reaction was quenched by addition of distilled water, and the
organic
layer extracted into dichloromethane (3 x 50 mL), and organic layers combined,
washed with water and brine, dried (Na2SO4) and concentrated. The crude
mixture was
purified by column chromatography (Silica gel, 10% -20 % Et0Ac in hexane) to
give
25 in 65% yield.
[00337] 5-(benzyloxy)-2-formylphenyl trifluoromethanesulfonate (26):
[00338] A solution of 25 (1.1 g, 4.9 mmol) in freshly distilled
dichloromethane
(10 mL) was stirred at 0 C. Triethylamine (1.02 mL, 7.35 mmol) was added to
this
solution followed by triflic anhydride (1.38 mL, 6.35 mmol) over 5 min. Upon
completion of the reaction from TLC, the reaction was quenched by addition of
distilled water and extracted into dichloromethane (3 x 10 mL). The organic
layers
were combined and dried (Na2SO4). After removal of the solvent on a rotor
evaporator,
the crude brown mixture was purified by column chromatography (Silica gel, 10%
Et0Ac in hexane) to give 26 in 55% yield.
71
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
[00339] 5-(benzyloxy)-3'-fluoro-[1,1'-bipheny1]-2-carbaldehyde (27):
[00340] A solution of 26 (246 mg, 0.68 mmol), boronic acid (92 mg, 0.75
mmol), Pd(PPh3)4(70.4 mg, 0.068 mmol) and K2CO3 (0.169 g, 1.2 mmol) in
anhydrous
DMF (7 mL) in a sealed tube, was degassed with argon for 10 minutes at room
temperature. After this, the reaction mixture was heated to reflux for 16 h.
Upon
completion of the reaction from TLC, the reaction was cooled to room
temperature and
quenched by addition of saturated NaHCO3 and extracted into ethyl acetate (3 x
5 mL).
The organic layers were combined and washed with brine, dried (Na2SO4), and
concentrated. The crude brown mixture was purified by column chromatography
(Silica
gel, 20% Et0Ac in hexane) to give the desired product.
[00341] (E)-5-(benzyloxy)-3'-fluoro-2-(2-nitroviny1)-1,1'-biphenyl (28):
[00342] 0.37 g, 1.2 mmol of 7 was added to a flask containing 3.3 mL
nitromethane. Ammonium acetate (1.8 g, 2.2 mmol) was added to the solution and
the
resulting mixture stirred at 50 C until the reaction was complete as evidenced
by the
disappearance of starting material on TLC. The reaction mixture was then
cooled to
room temperature and purified by silica gel column chromatography using 3:1
hexane:Et0Ac mixture as eluent, giving the desired product in 93% yield.
[00343] 2-(5-(benzyloxy)-3'-fluoro-[1,1'-bipheny11-2-yl)ethanamine (29):
[00344] Nitrostyrene 28 (400 mg, 1.1 mmol) in freshly distilled THF (2
mL) was
added dropwise to a solution of LiA1H4 (87 mg, 2.2 mmol), at 0 C under an
argon
atmosphere. Upon completion of the reaction (from TLC) the reaction was
quenched by
addition of water (45 [IL), 3M NaOH (45 lit), and an additional 80111 water,
and 20
mL Et0Ac. The resulting mixture was stirred at room temperature for 1 h,
filtered
through a plug of celite, washed with Et0Ac, dried (Na2SO4) and concentrated
to a
crude brown mixture, which was purified by column chromatography (Silica gel,
10%
Me0H in DCM) to give the desired product.
[00345] N-(2-(5-(benzyloxy)-3'-fluoro-[1,1'-bipheny1]-2-
yl)ethyl)acetamide
(30):
[00346] 80 mg, 0.25 mmol of 29 was added to a 25 mL oven-dried flask
containing 5 mL freshly distilled DCM, under argon atmosphere. Acetic
anhydride (21
L, 0.22 mmol) and triethyl amine (35 11.L) were then added to the solution and
the
resultant mixture stirred at room temperature for 3 h. The reaction mixture
was then
72
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
quenched by addition of saturated ammonium chloride, and extracted into DCM.
The
combined organic layers were dried (Na2SO4) and concentrated to a crude
mixture,
which was purified by column chromatography (Silica gel, 3:1 hexane:Et0Ac) to
give
the desired product.
[00347] N-(2-(3'-fluoro-5-hydroxy-[1,1'-biphenyl]-2-yDethyDacetamide
(23):
[00348] 400 mg of 10 was added to a 10 mL round bottom flask containing
methanol, and 10 mol% Pd(OH)2 was added to the flask. This was subjected to
degassing using a hydrogen balloon attached, for 10 min, and then left
stirring at room
temperature under a hydrogen atmosphere for 8 h. The reaction was filtered,
and
concentrated to give pure product 23 that was used without further
purification.
[00349] Example 20. Synthesis of carbocyclie analogues N-(2-(54(4-
(benzyloxy)cyclohex-2-en-1-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-
2y1)ethyl)acetamide
(36), and N-(2-(5-44-(benzyloxy)-2,3-dihydroxycyclohexyl)oxy)-3'-fluoro-[1,1'-
biphenyl]-2y1)ethypacetamide (37):
[00350] 1,2-di(oxiran-2-yl)ethane (32):
[00351] To a solution of 1,5-hexadiene (5 g, 0.12 mol) in freshly
distilled DCM
(100 mL) at 0 C was added mCPBA. (12.5 g, 0.146 mol, 70% by wt.) The
suspension
was stirred at room temperature for 2h. The reaction was washed with saturated
NaHCO3 solution, (4 x 80 mL) followed by brine. (100 mL) The organic layers
were
then dried (Na2SO4) and concentrated. The residue was purified by flash column
chromatography using 5-20% Et0Ac/hex as eluent, to give the desired product in
65%
yield.
[00352] 1,6-Heptadiene-3,5-diol (33):
[00353] To a stirred solution of tri-methylsulfonium iodide (6.12 g, 30
mmol) in
dry THF (50 mL) at -10 C was added drop-wise butyllithium (14 mL, 2.5 M in
hexane). The reaction mixture was stirred at -10 C for 30 min, and a solution
of
diepoxide 32 (570 mg, 5 mmol) in dry THF (5 mL) was added. The reaction
mixture
was allowed to warm to room temperature, and the white suspension was stirred
overnight. The mixture was treated with a saturated aqueous NH4C1 solution (15
mL),
extracted with CH2C12 (3 x 10 mL), dried over Na2SO4, and concentrated. The
crude
product was purified on silica gel(pentane/ether 50/50) to yield the compound
33 (360
mg, 45% yield)
73
CA 02866814 2014-09-09
WO 2013/119985 PCT/US2013/025387
[00354] cyclohex-2-ene-1,4-diol (34):
[00355] To a stirred solution of 33 (190 mg, 1.3 mmol) in DCM (0.1M) was
added Grubbs Catalyst, 2nd Generation. (22 mg, 0.026 mmol) The reaction
mixture was
heated to reflux for 2 h and was then concentrated under vacuum. The crude
product
was purified by column chromatography on silica gel with 50-100% Et0Ac/hex to
yield the desired compound.
[00356] 4-(benzyloxy)cyclohex-2-en-1-ol (35):
[00357] To a solution of 34 (79 mg, 0.69 mmol) in DMF (1 mL) was added
sodium hydride (14 mg, 0.62 mmol) at 0 C. Benzyl bromide (73 p,L, 0.62 mmol)
was
added to the mixture dropwise, under an argon atmosphere. The reaction was
stirred for
16 h at room temperature. Upon completion, distilled water (3 mL) was added to
the
mixture and the organic layer extracted into ethyl acetate. The organic layers
were
combined, dried and concentrated to give a crude mixture that was purified by
column
chromatography (Silica gel, 10% -20% Et0Ac in hexane) to give 35 as an oil.
[00358] N-(2-(5-04-(benzyloxy)cyclohex-2-en-1-yl)oxy)-3'-lluoro-[1,1'-
biphenyll]-2y1)ethyl)acetamide (36):
[00359] To a solution of 35 (70 mg, 0.34 mmol) in freshly distilled THF
(3 mL)
at 0 C was added triphenyl phosphine (180 mg, 0.68 mmol) and 23 (90 mg, 0.34
mmol). DIAD (0.135 mL, 0.68 mmol) was added to the mixture dropwise. The
reaction
was warmed to room temperature and stirred for 4 h. The reaction mixture was
treated
with saturated aqueous NaHCO3 solution (2 mL), washed with water, followed by
brine, dried over Na2SO4, and concentrated to give a crude mixture that was
purified by
column chromatography (30% 50% Et0Ac in hexane) to give 36 as an oil.
[00360] N-(2-(54(4-(benzyloxy)-2,3-dihydroxycyclohexyl)oxy)-3'-fluoro-
[1,1'-biphenyl]-2y1)ethypacetamide (37):
[00361] To a solution of 36 (15 mg, 0.032 mmol) in a mixture of THF/H20,
(1:1,
1 mL) was added catalytic amount of 0s04 (0.0032 mmol) and NMO. (5.7 mg, 0.048
mmol) The resulting solution was stirred at room temperature overnight. THF
was
evaporated and the residue extracted with Et0Ac. The organic layer was washed
with
saturated NaHCO3 followed by saturated NH4C1, dried, (Na2SO4) concentrated and
purified (50% -100% Et0Ac in hexane) to give 37.
74
CA 02866814 2014-09-09
WO 2013/119985
PCT/US2013/025387
[00362] Example 21. Synthesis of carbocyclic analogue N-(2-(54(4-(tert-
butyl)cyclohexyl)oxy)-3cfluoro41,1%bipheny11-2-yDethyl) acetamide (39):
[00363] 4-(tert-butyl)cyclohexyl 4-methylbenzenesulfonate (38):
[00364] 4-(tert-butyl)cyclohexan-1 -ol (500 mg, 3 mmol) was dissolved in
pyridine (50 mL) and stirred at room temperature for 30 min. Tosyl chloride
(915 mg,
4.79 mmol) was added to the reaction mixture and allowed to stir overnight.
The
reaction was quenched by addition of water (50 mL) and extracted with ether.
(3 x 20
mL) washed with saturated CuSO4,water, saturated aqueous NaHCO3, water, and
dried,
(Na2SO4) concentrated and purified (10% Et0Ac in hexane) to give 38 as a white
solid.
[00365] N-(2-(5-44-(tert-butyl)cyclohexyl)oxy)-3'-fluoro-[1,1'-biphenyl]-
2-
yl)ethyl) acetamide (39):
[00366] To a solution of 38 (50 mg, 0.16 mmol) in anhydrous DMF (2 mL)
was
added K2CO3, (24 mg) 38 (44 mg, 0.16 mmol) and TBAI (6 mg). The solution
mixture
was heated to 80 C for 4 days. Upon completion, distilled water (4 mL) was
added to
the mixture and the organic layer extracted into ethyl acetate. After removal
of the
solvent on a rotor evaporator, the crude mixture was purified by column
chromatography (50% Et0Ac in hexane) to give 39.
[00367] From the foregoing it will be seen that this invention is one
well adapted
to attain all ends and objectives herein-above set forth, together with the
other
advantages which are obvious and which are inherent to the invention. Since
many
possible embodiments may be made of the invention without departing from the
scope
thereof, it is to be understood that all matters herein set forth or shown in
the
accompanying drawings are to be interpreted as illustrative, and not in a
limiting sense.
While specific embodiments have been shown and discussed, various
modifications
may of course be made, and the invention is not limited to the specific forms
or
arrangement of parts and steps described herein, except insofar as such
limitations are
included in the following claims. Further, it will be understood that certain
features and
subcombinations are of utility and may be employed without reference to other
features
and subcombinations. This is contemplated by and is within the scope of the
claims.